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1 Summary 
 
The two homologous proteins Megakaryoblastic Leukemia 1 and 2 (MKL1 and MKL2 or 
MRTF-A and MRTF-B) are transcriptional coactivators of the transcription factor serum 
response factor (SRF) that are essential for fundamental biological processes like cell 
migration, cell proliferation, cell differentiation as well as actin cytoskeleton organization. 
Depletion of MKL1/2 was shown to reduce the proliferative, migratory and invasive capacity 
of HuH7 hepatocellular carcinoma (HCC) cells and also in vivo the HCC tumor growth of 
nude mice in a xenograft model was significantly reduced due to the systematic treatment of 
polyethylenimine (PEI)-complexed siRNA directed against MKL1 and MKL2 by inducing 
oncogene-induced senescence. 
A DNA microarray analysis of MKL1/2 depleted HuH7 cells versus HuH7 control cells 
revealed several novel MKL1/2 dependent target genes that were potential mediators of the 
MKL1/2 dependent induction of oncogene-induced senescence. In this context, we identified 
the transmembrane protein myoferlin (MYOF) as a novel MKL1/2 and SRF dependent target 
gene responsible for the effects of MKL1/2 on the characteristics of tumor cells. We could 
show that depletion of MYOF in HCC cells resulted in reduced cell proliferation and cell 
invasion as well as the sustained activation and phosphorylation of the epidermal growth 
factor receptor (EGFR). As a consequence, the loss of MYOF also activated the 
Ras/Raf/MEK/ERK signaling pathway and finally ended up in senescence induction, revealed 
by β-galactosidase staining and the increased expression of the senescence messaging 
secretome factors CXCL10 and TNFSF10. In this work, we additionally provided evidence 
that the mRNA and protein expression of MYOF was increased in vivo in the premalignant 
nodule tissue and even stronger increased in the tumor tissue of mice conditionally 
expressing SRF-VP16 in hepatocytes in comparison to the non-tumorous control tissue 
showing no MYOF expression. Furthermore, we could confirm the results obtained in vitro in 
HCC cell lines also ex vivo in liver tumor cells derived from SRF-VP16 expressing mice and 
figured out that MYOF depletion also leads to the oncogene-induced senescence response 
by activating the EGFR and the Ras/Raf/MEK/ERK pathway. 
In conclusion, in this thesis we pointed out that MYOF is a novel MKL1/2 dependent target 
gene that mediates the tumor inhibiting properties of an MKL1/2 knockdown by the induction 
of oncogene-induced senescence. This way, MYOF serves as a promising therapeutical 
target for HCC patients by a senescence inducing strategy. 
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2 Introduction 
	  
2.1 The transcription factor Serum Response Factor (SRF) 
 
2.1.1 Structure and biological functions 
	  
Transcription factors are proteins that bind to DNA sequences and thereby control gene 
expression in response to intra- and extracellular signals. Well coordinated transcription 
requires transcription factors acting alone or in concert with coregulators, like coactivators or 
corepressors. The highly conserved Serum Response Factor (SRF) is a ubiquitously 
expressed transcription factor that belongs to the family of MADS-box proteins. The MADS-
box itself, named after its founding members MCM1, Agamous, Deficiens and SRF, is a 
conserved structure motif in the DNA binding domain being characteristic for all proteins of 
the MADS-box family (Pellegrini et al., 1995). Since the N-terminus of the MADS-box is 
responsible for the specific DNA binding of SRF to the Serum Response Element (SRE) of 
target genes, the C-terminus enables the dimerization of two SRF monomers (Treisman, 
1986 and Shore & Sharrocks, 1995). A schematic structure of the SRF protein containing the 
MADS-box and the transcription activation domain (TAD) is shown in Fig. 1. 
	  
Figure 1: Schematic structure of human SRF. Shown are the MADS-box domain and the transcription 
activation domain (TAD) of the transcription factor SRF (Niu et al., 2007). 
 
For control of transcription and induced expression of SRF dependent target genes SRF 
binds the DNA at the SRE or also named CArG box with the conserved palindromic 
CC(A/T)6GG consensus sequence that is found in many promoter regions of known SRF 
target genes (Treisman, 1986). This DNA consensus sequence is recognized by SRF and 
subsequently bound by an SRF homodimer (Treisman, 1986 and Sun et al., 2006). Recently, 
160 different target genes directly regulated by SRF are found (Pipes et al., 2006). A majority 
of these target genes are so called immediate early genes (IEG) due to their rapid 
transcriptional activation by stimulation with serum or growth factors within only few minutes 
(Winkles, 1998). SRF regulates via its target genes essential biological processes in the cell, 
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like actin cytoskeleton organization, cell proliferation, migration and differentiation 
(Knoll & Nordheim, 2009 and Olson & Nordheim, 2010). Already well characterized and 
established SRF target genes are c-fos (Shaw et al., 1989), the connective tissue growth 
factor (CTGF) (Muehlich et al., 2007), integrin alpha-5 (Itga5) (Leitner et al., 2011 and 
Muehlich et al., 2012) and Transgelin (TAGLN/SM22) (Olson & Nordheim, 2010). 
	  
2.1.2 Signaling pathways of SRF activation 
 
The induction of SRF activity occurs by two independent but in parallel proceeding signaling 
pathways involving the Ras/MAPK/TCF cascade as well as the Rho/actin signaling pathway 
(Fig. 2).  
	  
Figure 2: Model of SRF activation by two different pathways. SRF becomes activated upon serum stimulation 
resulting in activation of the Rho or Ras signaling pathway (Clark and Graves, 2014). 
 
First, the ternary complex factor (TCF) dependent signaling pathway is activated by 
extracellular stimuli, like serum, lysophosphatidic acid (LPA) or growth factors. The 
subsequent activation of the small GTPase Ras then leads to phosphorylation and therefore 
activation of the mitogen activated protein kinases (MAPK). As a consequence, the TCFs 
were phosphorylated by the three MAPK subfamilies extracellular signal regulated kinase 
(ERK), c-Jun N-terminal kinase (JNK) and p38 (Whitmarsh et al., 1997). The activated TCFs 
consisting of Elk-1, SAP-1 and SAP-2/Net that all belong to a subgroup of the Ets family of 
transcription factors recognize and bind an Ets Binding Site (EBS) in proximity to a CArG box 
(Janknecht & Nordheim, 1993, Treisman, 1994 and Treisman, 1995). This way, TCFs bind 
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SRF and act as transcriptional coactivators for induction of target gene expression. The 
activation of SRF by the TCF-dependent signaling pathway is shown in Fig. 3. 
	  
Figure 3: Model of the TCF-dependent SRF activation. TCFs were phosphorylated by the Ras/Raf/MAPK 
pathway and then activate SRF to trigger target gene expression (Posern & Treisman, 2006). 
	  
Second, the TCF-independent signaling pathway is also activated by extracellular stimuli, like 
serum, LPA or growth factors. This stimulation leads to activation of RhoA, a member of the 
Rho family of small GTPases resulting in altered actin dynamics (Hill et al., 1995 and 
Wang & Olson, 2004). In more detail, RhoA leads to an enhanced polymerization of 
unpolymerized globular G-actin monomers into the formation of polymerized filamentous F-
actin. The decrease of G-actin in the cytoplasm delivers the transcriptional coactivator 
Megakaryoblastic Leukemia 1 (MKL1/MRTF-A) from bound G-actin resulting in nuclear 
translocation of MKL1. MKL1 itself subsequently binds SRF and activates it leading to target 
gene expression (Miralles et al., 2003 and Muehlich et al., 2008). This pathway shown in 
Fig. 4 regulates the activity of SRF and target gene induction also by the phosphorylation 
status of MKL1 in the nucleus. After phosphorylation of MKL1 by ERK1/2 G-actin binds to 
MKL1 that in consequence leads to nuclear export of MKL1 and therefore prevents activation 
of SRF and target genes (Muehlich et al., 2008). 
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Figure 4: Model of SRF activation by MKL1 regulation. Activation of RhoA leads to an increased formation of 
F-actin and a decrease of G-actin that shuttles MKL1 into the nucleus where it binds and activates SRF. Inhibition 
of target gene expression is achieved by phosphorylation of MKL1 by ERK1/2 and the subsequent nuclear export 
of the phosphorylated MKL1 bound to G-actin (Muehlich et al., 2008). 
 
 
2.2 The transcriptional coactivators Megakaryoblastic Leukemia 1 and 2 (MKL1        
and MKL2)  
 
 
2.2.1 Structure and biological functions 
 
The two proteins Megakaryoblastic Leukemia 1 and 2 (MKL1 and MKL2) are transcriptional 
coactivators of the transcription factor serum response factor (SRF). Before identifying them 
myocardin that is specifically expressed in cardiac and smooth muscle cells was initially 
discovered by performing a screening to find cardiac-specific genes and thus, myocardin was 
described as transcriptional coactivator of SRF (Wang et al., 2001). Later in 2002, MKL1 and 
MKL2 were identified in mammalian species and due to its function as myocardin analoga 
they were also called myocardin related transcription factors A and B (MRTF-A/B) (Wang et 
al., 2002). In contrast to the cell type specific expression of myocardin, MKL1 and MKL2 are 
ubiquitously expressed proteins acting as transcriptional coactivators in a variety of different 
tissues (Du et al., 2004). As shown in Fig. 5 the functional domains within the proteins of the 
MRTF family, the cardiac and the smooth muscle isoform of myocardin, MRTF-A (MKL1) and 
MRTF-B (MKL2), are homologous and evolutionary conserved (Pipes et al., 2006 and 
Olson & Nordheim, 2010). 
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Figure 5:  Homology of the functional domains within the proteins of the myocardin family. The structures 
and different domains of the two myocardin isoforms, MRTF-A (MKL1) and MRTF-B (MKL2) as well as the 
number of amino acids are shown (Olson & Nordheim, 2010). 
 
 
Sharing the same functional regions in all proteins of the myocardin family (Fig. 5), the 
different domains will be described closer in the following exemplified for the MKL1 protein 
shown in Fig. 6. The RPEL domain located at the N-terminus of the protein consists of three 
distinct RPEL motifs and is named after its amino acid sequence of Arg-Pro-X-X-X-Glu-Leu 
(Miralles et al., 2003). This sequence in the proteins of the MRTF family serves as binding 
domain for monomeric G-actin thus maintaining MKL1 in unstimulated cells in the cytoplasm 
(Miralles et al., 2003 and Posern et al., 2004). The association of the transcriptional 
coactivators and their transcription factor SRF occurs at the basic region (B) and the 
glutamine-rich region (Q) (Wang et al., 2001 and Muehlich et al., 2008). Another important 
domain for the myocardin family is the SAP domain, named after SAF-A/B, Acinus and Pias, 
that is relevant for the interaction with other transcription factors (Pipes et al., 2006). It is 
suggested that the SAP domain is also involved in the regulation of apoptosis as well as 
chromosomal dynamics and DNA metabolism (Aravind & Koonin, 2000 and Wang et al., 
2001). The conserved leucine zipper domain (LZ) mediates the homo- and 
heterodimerization of the members of the myocardin family (Wang et al., 2001 and Miralles 
et al., 2003). At the C-terminus myocardin and the MRTFs contain the transcriptional 
activation domain (TAD) that is required for the stimulation and activation of SRF activity 
(Cen at al., 2003). 
 
	  
 
Figure 6: Schematic representation of the MKL1 structure. Shown are the RPEL domain, the basic region (B), 
the glutamine-rich region (Q) as well as the SAP domain and a leucine zipper region (LZ) of MKL1. 
 
Looking at the biological function of MKL1 and MKL2 in the cell, both proteins function, as 
previously described, as transcriptional coactivators of SRF and activate by association with 
SRF in the nucleus target genes involved in essential biological processes, like cell growth or 
MKL1 
B RPEL Q SAP LZ TAD 
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cell differentiation (Pipes et al., 2006). This way, they act in an interface between two 
essential signaling pathways, the MAPK and the RhoA pathway, that are involved in 
tumorigenesis, described by a RhoA overexpression that was found in different tumors 
(Kohno et al., 2006). Another important role of MKL1 is its requirement for skeletal muscle 
differentiation and muscle growth (Selvaraj & Prywes, 2003). As much as known about the 
physiological and cellular processes MKL1 is involved in, the role of MKL1 and MKL2 in 
embryogenesis and development was also investigated by a great number of MKL1 and/or 
MKL2 knockout mice studies. Since a knockout of MKL1 mostly revealed viable and fertile 
mice, the female MKL1 knockout mice failed to nurse their offspring due to defects in the 
mammary gland epithelial cell differentiation affecting the milk ejection (Li et al., 2006 and 
Sun et al., 2006a). Further studies also showed that depletion of MKL1 in a small number of 
mice resulted in dead MKL1 null embryos because of cardiac abnormalities (Sun et al., 
2006a). Another important outcome is that the megakaryocyte maturation and platelet 
formation is affected by a parallel knockout of both MKL1 and MKL2 and also of MKL1 alone 
displaying a reduced number of platelets and also a decreased amount of mature 
megakaryocytes (Cheng et al., 2009 and Smith et al., 2012). However, MKL2 depletion in 
mice always led to embryonic lethality due to cardiovascular effects and defects in the 
smooth muscle differentiation suggesting a crucial role for MKL2 in the development of mice 
(Oh et al., 2005). Medjkane et al. (2009) pointed out that the presence of MKL1 and MKL2 is 
necessary for tumor cell invasion and metastasis, because depletion of MKL1/2 in human 
breast carcinoma and mouse melanoma cells using specific siRNA eliminated cell adhesion, 
motility and invasion. In a more recent study of Hampl and colleagues MKL1 displayed also 
migratory as well as proliferative effects in hepatocellular carcinoma (HCC) cells monitored 
by several cell-based assays (Hampl et al., 2013). In further studies a very important result 
was obtained from HCC xenograft models in which human liver carcinoma cells were 
transplanted into nude mice and the developed tumors were treated with polyethylenimine 
(PEI)-complexed control or MKL1+2 siRNA. This depletion of MKL1 and MKL2 inhibited the 
tumor growth suggesting a role of evading tumorigenesis by MKL1 and MKL2 knockdown 
(Hampl et al., 2013).  
 
 
 
 
 
 
 
2 Introduction	  
	   	  
	  
     15 
	  
	   	  
2.2.2 The novel MKL1 binding partner Filamin A (FLNa) 
 
In a recent study of Kircher and colleagues Filamin A (FLNa), a protein of the filamin family, 
was found to interact with MKL1 and to act as novel MKL1 binding partner (Kircher et al., 
2015). The FLNa protein is a homodimer consisting of two large subunits, which form a V-
shaped structure (van der Flier & Sonnenberg, 2001) since at each of the monomers an actin 
binding domain is located at the N-terminus (Gorlin et al., 1990). Whereas Filamins in 
general are actin-binding proteins that are essential for crosslinking of actin filaments and 
also for linking actin filaments to proteins localized in the cell membrane, FLNa specifically is 
the most potent protein among the filamin family for actin filament crosslinking underlined by 
the fact that only one FLNa homodimer per actin filament is sufficient for induction of actin-
based gelation, the ability of FLNa for efficiently gathering actin filaments into a three-
dimensional gel in vitro by crosslinking actin filaments (Hartwig et al., 1980; Bennett et al., 
1984 and Ito et al., 1992). Since FLNa is a multifunctional protein acting on a variety of 
different proteins and therefore signaling complexes, the most noteworthy features of cells 
expressing FLNa are the providing of cell stability as well as the possibility of cell motility 
(Stossel et al., 2001 and Small et al., 2002). Confirming these properties, M2 cells lacking 
FLNa expression show an unstable surface and are not able to undergo locomotion 
(Cunningham et al., 1992 and Dai & Sheetz, 1999). M2 cells also display so-called blebs, a 
phenomenon that arises because the cell cortex is unable to withstand hydrostatic pressure 
within the cell and results from a weakened actin structure, because the blebs contain 
predominantly monomeric G-actin and not filamentous F-actin (Cunningham, 1995).  There is 
also an increasing evidence for FLNa to be directly involved in cell signaling and transducing 
gene expression via an interaction of FLNa and its targets (Stossel et al., 2001). Referring to 
this, the filamins bind a variety of different molecules and thus 20 binding partners are known 
so far (Stossel et al., 2001). Several studies provide evidence that FLNa has an important 
role in the nucleus by directly interacting with transcription factors and nuclear proteins, like 
FOXC1 and proteins of the SMAD family as well as with the tumor suppressor BRCA1/2 
(Sasaki et al., 2001; Yuan et al., 2001 and Berry et al., 2005). Due to its association with the 
RNA polymerase I FLNa is able to suppress the ribosomal RNA (rRNA) transcription (Deng 
et al., 2012). FLNa is also known to bind to Rho GTPases and their cofactors involved in the 
regulation of actin assembly and to play an important role in signal transduction by 
transducing stress signals to the actin cytoskeleton (Glogauer et al., 1998 and Bishop & Hall, 
2000). Additionally, Kircher et al. found FLNa to directly interact with the transcriptional 
coactivator MKL1 in different cell lines proved by immunoprecipitation and showed the novel 
MKL1-FLNa complex by immunofluorescence (Kircher et al., 2015). Some functional studies 
also revealed a positive effect for FLNa presence on target gene expression and promoter 
activity, thus suggesting a role for FLNa in the activation of SRF by MKL1 as shown in Fig. 7. 
2 Introduction	  
	   	  
	  
     16 
	  
	   	  
Therefore, in the following the extended model of SRF and target gene activation described 
under 2.1.2 and the localization of MKL1 will be specified. Generally, the subcellular 
localization and the transcriptional activity of MKL1 is regulated by Rho/actin signaling 
whereas the actin sensitivity of SRF is mediated by the MKLs (Miralles et al., 2003). In 
unstimulated cells, like in NIH 3T3 fibroblasts, MKL1 is located in the cytoplasm and exists in 
a repressive complex bound to monomeric G-actin (Miralles et al., 2003 and Posern et al., 
2004). After stimulation with serum or LPA, the G-actin monomers polymerize into 
filamentous F-actin resulting in the release of MKL1 from the G-actin-MKL1 complex and 
therefore in a translocation and accumulation of MKL1 in the nucleus where it can bind SRF 
and induce target gene expression (Miralles et al., 2003 and Vartiainen et al., 2007). Baarlink 
and his group additionally showed that the nuclear actin polymerization triggered by serum 
stimulation enhances SRF activation mediated by released MKL1, whereas another result of 
cell stimulation is the ERK1/2 dependent phosphorylation of MKL1 at serine 454 that serves 
as a stimulus for MKL1-G-actin binding (Muehlich et al., 2008 and Baarlink et al., 2013). 
Besides the existing repressive complex of MKL1 and G-actin also an activating MKL1-FLNa 
complex exists (Fig. 7) in which the bound FLNa impairs the MKL1 phosphorylation and 
enhances the formation of F-actin resulting in active SRF and further target gene expression 
(Kircher et al., 2015). 
	  
	  
 
Figure 7: Model of the activating MKL1-FLNa complex. MKL1 is in a repressive state bound to G-actin (left) or 
in an activating state bound to FLNa (right) thereby impairing MKL1 phosphorylation and enhancing formation of 
F-actin (Kircher et al., 2015).  
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2.3 The novel MKL target gene myoferlin 
 
2.3.1 Structure and biological functions 
 
Myoferlin, abbreviated MYOF and also named Fer-1-like protein 3 (FER1L3), is a protein of 
the evolutionary conserved ferlin family of proteins. The first discovered member of the ferlin 
family is represented by dysferlin, a protein that was identified in patients with Miyoshi 
myopathy and limb girdle muscular dystrophy type 2B arising from diverse mutations in the 
dysferlin gene (Liu et al., 1998 and Weiler et al., 1999). A database and BLAST searching 
with the dysferlin sequence revealed a novel protein that was called myoferlin due to its high 
homology over nearly the whole length of the dysferlin gene and its strong preferential 
expression in cardiac and skeletal muscles (Davis et al., 2000). All proteins of the ferlin 
family, consisting of dysferlin, myoferlin, fer-1 and otoferlin, share a very similar structure and 
nearly the same functional domains. In Fig. 8 the schematic structure of MYOF with its 
essential domains is shown and described in greater detail in the following. Based on its 
structural properties and its single-pass transmembrane domain (TM), MYOF was 
characterized as type II transmembrane protein with an intracellular N-terminus and a C-
terminal membrane-spanning domain (Davis et al., 2000). The large cytoplasmic domain 
consists of six C2 domains (A-F) that are known for playing a role in signal transduction and 
in the capability of Ca2+, phospholipid and lipid bilayer binding and thus especially for 
involvement in calcium-mediated membrane fusion or membrane repair (Davletov & Sudhof, 
1993). Another important domain of MYOF is the SH3 domain specifically recognizing prolin-
rich amino acid regions and therefore interacting with tyrosine kinases and adaptor proteins 
and participating in signaling pathways (Yu et al., 1992). 
 
Figure 8: Schematic representation of the MYOF structure. The C2, SH3 and transmembrane (TM) domains 
of MYOF are shown.  
 
Since the expression of MYOF was restricted to cardiac and skeletal muscle cells at the 
beginning of its discovery, several novel studies substantiate a broader MYOF expression 
also in other cell tissues and cell types, like endothelial and breast cancer cells (Bernatchez 
et al., 2007 and Eisenberg et al., 2011). Within the cell, it was shown that MYOF was 
MYOF 
B A C SH3 TM E D F 
C2 domains 
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associated with the plasma membrane as well as with the nuclear membrane (Davis et al., 
2000). On a cellular level, a potential modifying function of MYOF for muscular dystrophy and 
cardiomyopathy was assessed in two different mouse models with muscular dystrophy 
(Davis et al., 2000). Doherty and colleagues demonstrated convincingly a requirement of 
MYOF for normal myoblast fusion (Doherty et al., 2005). Therefore, they generated MYOF 
null mice exhibiting no alteration in fertility, viability and longevity but still showing a 
significantly smaller body mass compared to the wildtype control mice. Concerning the 
myoblasts, visible effects of MYOF loss were detected, namely the MYOF null mice revealed 
smaller muscles with strongly reduced mean myofiber size and MYOF null mice muscles 
additionally failed to regenerate completely after injury than wildtype mice did (Doherty et al., 
2005). This data confirmed a crucial role for MYOF in the maturation of myotubes and also in 
the further formation of large myotubes arising from the myoblast fusion to multinucleate 
myotubes. Another fundamental impact of MYOF is its influence on the stability and function 
of diverse receptor tyrosine kinases. Thus, silencing of MYOF in vascular endothelial cells 
was shown to result in instability and also rapid degradation of the vascular endothelial 
growth factor receptor 2 (VEGFR-2) (Bernatchez at al., 2007). Demonbreun and colleagues 
demonstrated a decline in insulin growth factor 1 receptor (IGFR) and a receptor 
accumulation in vesicles upon MYOF knockdown, whereas Yu and colleagues also reported 
an effect of MYOF on the angiogenic tyrosine kinase receptor (Tie-2) (Demonbreun et al., 
2010 and Yu et al., 2011). Beside these important cellular characteristics, MYOF takes also 
part in a variety of essential cellular processes, such as endocytosis, membrane repair and 
vesicular transport (Bernatchez et al., 2009 and Sharma et al., 2010). 
 
 
2.3.2 MYOF and its role in cancer 
 
Regarding the Human Protein Atlas and the publications of the last years, a strong MYOF 
expression in different cancer types, like breast, ovarian and liver cancer for example, was 
observed (Adam et al., 2003; Labhart et al., 2005 and Ponten et al., 2008). Beyond the direct 
effect of MYOF on cancer cells by its strong upregulation it is indispensible to give a deeper 
insight into the association of MYOF and cancer and thus to additionally have a look at the 
more indirect involvement of MYOF by showing its cancer cell specific attributes. One very 
important characteristic of cancer cells is their invasive capacity that is affected by MYOF 
expression compellingly demonstrated by Eisenberg et al. (2011). They used the breast 
cancer cell line MDA-MB 231 and compared the invasive behavior of control cells and cells 
with a stable lentiviral-based knockdown of MYOF achieving the result that the MYOF 
depleted cells revealed a strongly reduced invasivity compared to the control cells 
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(Eisenberg et al., 2011). Thus, MYOF seems to play an important role in promoting the 
invasive behavior of cancer cells. The MDA-MB 231 breast cancer cells likewise exhibited a 
more epithelial-like morphology upon MYOF depletion than the fibroblastic shape and more 
mesenchymal appearance of the control cells, referring to a mesenchymal-epithelial 
transition (MET) in accordance to the known epithelial-mesenchymal transition (EMT) known 
as characteristic for tumor cells (Li et al., 2012). A good correlation between the visible 
morphologic shift and the downregulation of the corresponding EMT markers, like fibronectin 
and vimentin, as well as the upregulation of the epithelial marker E-cadherin at the molecular 
level in MYOF knockdown cells was shown (Li et al., 2012). In addition, silencing of MYOF 
via intratumoral injections of MYOF siRNA decreased the tumor growth of mouse Lewis Lung 
carcinoma (LLC) cells in vivo (Leung et al., 2013). There was also evidence for MYOF 
dependent regulation of cell proliferation because depletion of MYOF decreased the 
proliferation rate of the LCC tumors in vivo as well as in vitro in cultured LCC cells (Leung et 
al., 2013). Recently in 2013, MYOF was initially characterized as a specific, negative 
regulator of the epidermal growth factor receptor (EGFR) in human breast cancer cells 
(Turtoi et al., 2013). In the absence of myoferlin, the EGFR gets activated due to a block of 
the phosphorylated EGFR degradation and therefore activates the EGFR signaling pathway 
leading to inhibition of migration of the breast cancer cells (Turtoi et al., 2013). Concluding, 
MYOF is strongly overexpressed in a variety of different cancer cell lines and plays an 
important role in mediating cancer cell specific properties. Thus, it seems very indispensable 
and promising to investigate the underlying mechanisms of MYOF acting on tumorigenesis 
and MYOF itself serves as a potential therapeutic target to prevent cancer development and 
progression. 
 
 
2.4 Senescence 
 
2.4.1 Hallmarks of cancer  
 
More than 100 different types of cancers exist and the developed tumors can be found in a 
plenty of specific organs, giving rise to the need of a better understanding of the process of 
tumorigenesis and the progressive transformation of normal cells into tumorigenic cells. In 
contrast to somatic cells, cancer cells display a multitude of alterations on the histological 
level visible under the microscope as well as on the cellular level. This way, cancer cells 
often have an enlarged and irregular shaped nucleus or actually multiple nuclei accompanied 
by smaller amounts of cytoplasm and the nucleoli are more prominent 
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(Hanahan & Weinberg, 2000 and Baba & Câtoi, 2007). Besides the morphological changes, 
a malignant cell is amongst others characterized by prolonged proliferation, uncontrolled 
mitotic divisions, a tissue invasive and metastatic behavior and also an acceleration of the 
cell cycle due to circumventing the cell cycle restriction points (Hanahan & Weinberg, 2000 
and Baba & Câtoi, 2007). For a better understanding and classification of cancer cells and 
the process of a malignant cell transformation, Hanahan and Weinberg defined a variety of 
distinct capabilities that tumorigenic cells acquire as the six hallmarks of cancer shown in Fig. 
9 (Hanahan & Weinberg, 2000). In 2011, they expanded their model by two further 
hallmarks, the reprogramming of energy metabolism and the evading of immune destruction 
of transforming cells (Hanahan & Weinberg, 2011). These principals shared by all cancers 
impressingly demonstrate that cells develop several tumor evasion strategies that are 
circumvented by tumor cells resulting in metastatic cancer. The fact that tumor development 
occurs relatively rare in a human lifespan compared to the enormous number of cells in the 
human body, suggests also for very effective cancer evading strategies. One very prominent 
mechanism is the apoptosis pathway, a naturally occurring programmed cell death that 
influences the malignant phenotype (Wyllie et al., 1980 and Lowe & Lin, 2000). Due to the 
complexity of tumor diseases and their development, even more programs for bypassing 
tumorigenesis have to exist. In contrast to apoptosis, the non-apoptotic form of programmed 
cell death is represented by cellular senescence, a mechanism of cell cycle arrest described 
in greater detail in the following chapter (Wynford-Thomas, 1999). 
 
	  	  	  	  	  	  	  	  	  	   	  
Figure 9: Hallmarks of cancer. The six acquired features of cancer cells are shown (Hanahan & Weinberg, 
2000). 
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2.4.2 Cellular senescence 
 
The word senescence goes back to senex, the latin origin that means “old man” or “old age” 
and therefore is used interchangeably with ageing. In this context, the term cellular 
senescence was initially described in 1961 by Hayflick and Moorhead pointing out that 
normal somatic cells have a limited ability to proliferate in culture and thus a finite number of 
replicative cycles (Hayflick & Moorhead, 1961 and Hayflick, 1964). The so-called Hayflick 
limit therefore says that normal mitotic cells undergo only approximately 50 cell divisions 
before they become senescent and die. Among the limited life span of human cells, three 
phases of cell growth in a cell’s life are described. Phase one is characterized as the primary 
culture, whereas phase two is defined as the period of proliferation and exponential 
replication of the subcultivated cells. At least, cells reach phase three specified by decreased 
cell growth and cell division and remain in this senescent state until they die 
(Hayflick & Moorhead, 1961). Hayflick and colleagues also showed that the non-dividing cells 
remained viable and metabolically active, but failed to proliferate (Hayflick & Moorhead, 
1961). The initially discovered underlying molecular mechanism of cellular senescence was 
the phenomenon of telomere shortening explaining the ceased division of cells in culture 
(Harley et al., 1990 and Harley, 1991). As depicted in Fig. 10, telomeres, the characteristic 
repetitive DNA sequences at the end of chromosomes, were shortened with each cell 
doubling resulting in the loss of telomeric DNA and a threshold telomere length causing 
senescence, by this reason also termed replicative senescence. This replication end problem 
naturally occurs due to the inability of the DNA polymerase to replicate the lagging strand of 
the DNA in the 3’ to 5’ direction (Harley et al., 1990 and D’Adda di Fagagna et al., 2004). The 
telomere shortening can be efficiently circumvented by the enzyme named telomerase 
exhibiting a reverse transcriptase activity that was discovered for the first time in 1985 
(Greider & Blackburn, 1985; Greider & Blackburn, 1987 and Lingner et al., 1997). 
Telomerases are predominantly active in highly proliferative cells, like stem cells or germline 
cells and a majority of cancer cells, since they are not or only modestly expressed in most 
normal somatic cells explaining why the telomerase activity in these cells is only low (Wright 
et al., 1996 and Shay & Bacchetti, 1997). The cellular function of the telomerase is the 
elongation of the telomers by de novo synthesis of telomeric DNA and its addition directly to 
the chromosome ends counteracting the telomere shortening and senescence induction 
(Greider & Blackburn, 1987 and Collins & Mitchell, 2002). Mechanistically, an RNA 
component associated with the reverse transcription subunit of the telomerase serves as 
template for the extending of the telomeric DNA strand (D’Adda di Fagagna et al., 2004). In 
1998, Bodnar and colleagues introduced a telomerase into normal human epithelial cells and 
fibroblasts and provided evidence for the concept of antagonizing reduction of telomere 
length and entering senescence by telomerase activity displayed by an extension of life-span 
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in the telomerase expressing cells due to telomere lengthening (Bodnar et al., 1998). The 
regulation of telomere shortening and telomere elongation depending on the telomerase 
activity and the resulting fate of different cell types is illustrated in Fig. 10. 
 
	  
 
Figure 10: Telomerase-dependent cellular senescence. Telomeres (pink) are located at the end of each 
chromosome (blue) in order to protect them. Since germline cells and many cancer cells express a telomerase 
and thus telomere length is maintained, normal somatic cells mostly lack the expression of a telomerase resulting 
in shortened telomeres and therefore in senescence (Campisi & D’Adda di Fagagna, 2007). 
 
Besides the telomerase-dependent replicative senescence, the irreversible growth arrest of 
cultured cells can additionally arise by various stress stimuli and is thus referred to as stress-
induced premature senescence (SIPS), whereas the term premature is due to the fact that 
the stress-induced senescence occurs prior to the state at which it is induced by telomere 
shortening (Collado & Serrano, 2006 and Kuilman et al., 2010). It was shown that oxidative 
stress induced a proliferation arrest in cultured human cells and that this type of senescence 
results from inadequate culturing conditions, such as abnormal nutrient and growth factor 
concentrations (Packer & Fuehr, 1977; Yuan et al., 1995 and Sherr & DePinho, 2000). In 
agreement with these findings, it is also reported that an activation of premature senescence 
independently of telomere shortening senescence also occurs in mouse cells that have 
longer telomeres than humans and that express telomerases (Kipling & Cooke, 1990 and 
Prowse & Greider, 1995). Confirming this, several studies also revealed that mouse 
embryonic fibroblast (MEF) cells also undergo senescence after a restricted number of 
passages in culture and that an elongated life-span of cells is only accomplished by culturing 
cells in serum-free medium and a defined composition of growth factors as well as by 
culturing under physiological conditions (Loo et al., 1987 and Parrinello et al., 2003). 
Concluding, immortalization of cells requires also optimal culture conditions and not only 
telomere maintenance (Ramirez et al., 2001 and Herbert et al., 2002). 
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2.4.3 Oncogene-induced senescence (OIS) 
 
In contrast to the replicative and premature senescence, in 1997 a novel form of senescence 
induction, known as oncogene-induced senescence (OIS), was described by Serrano and 
colleagues (Serrano et al., 1997). This oncogene-induced senescence reflected by a cell 
cycle arrest was shown to be provoked by the overexpression of active forms of oncogenes 
or by the loss of anti-mitogenic tumor suppressor genes (Braig et al., 2005; Chen et al., 2005 
and Michaloglou et al., 2005). The first evidence for the existence of OIS was provided by the 
group of Serrano demonstrating that the overexpression of an active form of H-Ras (H-
RasV12) resulted in a senescent like growth and cell cycle arrest when introduced into normal 
human fibroblasts that were accompanied by an upregulation of the tumor suppressor 
proteins p16Ink4a, p53 and p21 (Serrano et al., 1997). In addition, the overexpression of not 
only oncogenic H-Ras but also of the oncogenic versions of the members of the Ras 
signaling pathway, like Raf, Mek and Braf, caused an oncogene-induced senescence 
response (Lin et al., 1998; Zhu et al., 1998 and Michaloglou et al., 2005). The fact that 
normal cells respond to the activation of a variety of oncogenes by undergoing senescence is 
underscored by studies in 2001, where some rodent cells are not able to replicatively 
senesce in serum-free medium suggesting that an excessive mitogenic stimulation is 
required for their senescence (Mathon et al., 2001 and Tang et al., 2001). The multitude of 
mitogenic signals is also shown in consideration of the fact that about 50 oncogenes are 
known that are able to induce oncogene-induced senescence (Gorgoulis & Halazonetis, 
2010). A hallmark in the field of oncogene-induced senescence was published by 
Michaloglou and colleagues in 2005, when they figured out that benign naevi in human skin 
contain cells expressing oncogenic BRAF (BRAFE600) and are senescent (Michaloglou et al., 
2005). They pointed out that the sustained expression of the oncogenic BRAFE600 in human 
melanocytes resulted in a senescence-like phenotype exhibiting a stable growth arrest, the 
induction of p16Ink4a and a senescence-associated β-galactosidase (SA-β-Gal) activity, 
explaining the phenomenon that naevi normally remain in a growth arrested state for a long 
time and only few of them progress into malignant melanoma (Bennett, 2003 and 
Michaloglou et al., 2005). This way oncogene-induced senescence serves as tumor 
suppressor mechanism in vivo. Several studies also attached importance to the in vivo 
relevance of OIS occurring during the early stages of tumorigenesis both in mice and in 
humans indicating that oncogene-induced senescence maintains the tumor in a 
premalignant, non-aggressive state and therefore restricts the further growth of oncogenically 
stressed cells, whereas cells lacking OIS progress to a malignant state (Braig et al., 2005; 
Collado et al., 2005 and Collado & Serrano, 2010). 
Pointing out the delimitation of the oncogene-induced senescence to the replicative 
senescence, the overexpression of the human telomerase catalytic subunit (hTERT) in 
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normal human lung fibroblasts revealed no bypassing of senescence, confirming its 
independence from telomere shortening (Wei et al., 1999). 
This way, the concept of oncogene-induced senescence emerged as a potential tumor 
suppressor mechanism depending on different effector mechanisms and several pathways 
are involved in, described in more detail in the following section. 
 
 
2.4.4 Pathways affected by senescence 
 
The complexity of senescence is driven by multiple oncogenic and senescence-activating 
pathways and a number of senescence triggers and various stimuli. The variety of proteins 
involved in senescence induction can be distinguished in those that are oncogenes itself and 
those that act upstream or downstream of the oncogenes. As depicted in Fig. 11, the shown 
pathways are leading to senescence when they are aberrantly activated, since the 
oncogenes and tumor suppressor genes shown in red, like Ras, Raf, PTEN or Akt, directly 
induce sensescence when they are mutated. The proteins functioning upstream and 
therefore controlling oncogenes are the phosphatase and tensin homolog (PTEN), von 
Hippel-Lindau (VHL), neurofibromin 1 (NF1) and the retinoblastoma (Rb) protein, which 
activity is necessary to prevent the induction of oncogene-induced senescence 
(Collado & Serrano, 2010). On the other hand, there are the proteins p53, INK4a and ARF 
that only inducibly function when the oncogenic signaling is activated and that way they all 
act downstream of oncogenes (Collado & Serrano, 2010). Several studies revealed the 
involvement of many different factors playing a crucial role in senescence activation in vitro 
and in vivo and among the mostly described and best characterized role of p53 or p16/Rb, 
also the loss of the VHL or of PTEN was shown to trigger senescence (Young et al., 2008 
and Alimonti et al., 2010). 
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Figure 11: Pathways of oncogene-induced senescence. The pathways leading to induced senescence when 
they are activated are shown, since the tumor suppressors and oncogenes are red and the effector and substrate 
proteins are blue (Collado & Serrano, 2010). 
 
Having a look at the multitude of studies on oncogene-induced senescence, the one hallmark 
and common feature shared by all cells undergoing senescence is the involvement of the 
p53 and p16/Rb pathways (Ben-Porath & Weinberg, 2005 and Campisi, 2005). All described 
pathways by which the oncogenic stimuli are signaled often activate p53 and nearly all of 
them converge in the activation of the cyclin dependent kinase (CDK) inhibitors, such as p15, 
p16, p21 and p27 (Campisi & D’Adda di Fagagna, 2007). The INK4A/ARF locus is under 
physiological conditions only expressed at low levels in most tissues of young organisms but 
becomes activated with ageing (Krishnamurthy et al., 2004). These two key tumor 
suppressors were also shown to be responsible for a cell cycle arrest and to be upregulated 
in oncogenically stressed cells, since INK4A activates proteins of the Rb family whereas ARF 
activates p53 (Lowe et al., 2004). As shown in Fig. 12, in the following a more detailed 
description of the two most essential pathways inducing senescence is given. Firstly, for the 
p53 pathway Serrano and colleagues postulated 20 years ago an increased transcriptional 
activity of the tumor suppressor p53 upon accumulation of cell doublings and stress stimuli 
(Serrano et al., 1997). The stability and expression levels of the tumor suppressor p53 are 
regulated by ARF via its inactivation of the p53-degrading E3 ubiquitin protein ligase 
Mdm2/Hdm2 disabling the ubiquitinylation and therefore forcing the activation of p53 
(Kim & Sharpless, 2006). ARF itself becomes activated by senescence inducing signals and 
then blocks the Mdm2/Hdm2 mediated p53 degradation (Levine & Oren, 2009). In 
consequence, p53 activates its transcriptional target, the CDK inhibitor protein p21 that leads 
to the senescence response (Brown et al., 1997).  In accordance to the senescence 
induction upon p21 activation and its accumulation in senescent cells, a loss of p21 was 
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shown to result in life-span extension (Tahara et al., 1995 and Brown et al., 1997). p21 
additionally inhibits the cyclin E/CDK2 complex and thus p16 and p21 act in concert to 
ensure that Rb becomes not phosphorylated indicating a crosslink between the p53 and the 
second important p16/Rb pathway (Serrano et al., 1997). Already in 1998, the p16/Rb or also 
termed Raf/MEK/ERK pathway downstream of the small GTPase Ras was revealed as the 
most relevant pathway for senescence induction (Lin et al., 1998 and Zhu et al., 1998). The 
CDK inhibitor protein p16Ink4a inhibits CDK4/6 by binding and therefore inhibiting their kinase 
activity and since implicated in the regulation of the G1 to S phase transition, activated 
p16Ink4a forces a G1 cell cycle arrest (Hara et al., 1996 and Serrano et al., 1997). Several 
studies also revealed remarkably increased levels of p16Ink4a RNA and protein levels when 
normal human fibroblasts underwent senescence (Hara et al., 1996 and Serrano et al., 
1997). These highly overexpressed p16Ink4a levels prevent the phosphorylation of Rb and this 
way contribute to the Rb maintenance in its activated, hypophosphorylated state serving as 
crucial component for induction of senescence (Futreal & Barrett, 1991 and Chicas et al., 
2010). Consequently, the hypophosphorylated form of Rb associates with the transcription 
factor E2F and inhibits the transcription of its target genes cyclin A and cyclin E which are 
required for the G1 to S phase transition and thus results in senescence (Serrano et al., 1997 
and Burkhart & Sage, 2008). Summing up, both pathways can proceed independently or 
interact with each other at different stages for an alteration of the cell cycle progression. The 
contribution of mechanisms that ultimately lead to senescence depends on the cell strain and 
may depend on the cell type as well as on the conditions.  
 
	  
Figure 12: Senescence controlled by the p53 and p16/Rb pathway. Senescence signals trigger the ARF 
pathway and thereby active p53 or the p16/Rb pathway leading to a growth arrest designated as senescence 
(Campisi & D’Adda di Fagagna, 2007). 
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2.5 Hepatocellular carcinoma (HCC) 
 
The hepatocellular carcinoma (HCC) is a malignant cancer, directly developed from healthy 
liver cells, and the most common type of liver cancer as well as the fifth most common 
cancer worldwide, representing 7 % of all cancers in the world (Jemal et al., 2011 and He et 
al., 2015). Since the 1980s the HCC’s incidence has significantly increased and also in the 
western countries additionally to the developing countries an increasing incidence was 
documented (Jemal et al., 2011 and Binder-Fouard et al., 2014). With 745 000 registered 
deaths per year HCC is the second common cause of cancer deaths worldwide (Jemal et al., 
2011 and Ferlay et al., 2015). HCC is more common in the male population than in the 
female one, with a ratio of 4:1 and is a result of hepatitis B and hepatitis C viral infections, 
chronic alcohol consumption, liver cirrhosis as well as alfatoxin-contaminated food in Asian 
and African countries, whereas HCC arises in the developed countries to a greater extend 
from type 2 diabetes and obesity, metabolic disorders and non-alcoholic fatty liver diseases 
(NAFLD) (Farazi & DePinho, 2006; Yang et al., 2015; Reeves et al., 2016 and Trojan et al., 
2016). Despite its rising incidence and its role as one of the most predominant malignancies, 
the reasons for HCC development are far from being fully understood and the underlying 
mechanisms driving the conversion of healthy hepatic cells into malignant tumor cells are still 
nebulous. Clarifying the underlying mechanisms turned out to be very complicated due to the 
formation of HCC being a complex and multistep process that involves several different 
accumulations of genetic as well as epigenetic alterations in important regulatory genes and 
the deregulation of multiple signaling pathways. Since the genetic changes of the cell are 
irreversible, the epigenetic changes, like DNA methylations or histone modifications that are 
attributed to initiation and progression of HCC by enhancing proliferation, invasion etc. are 
reversible (Ma et al., 2014). Therefore the epigenetic mechanisms open up the development 
of novel therapeutic biomarkers and drugs that reverse the epigenetic alterations serve as 
promising target for HCC treatment. 
Regarding all these described facts, the molecular mechanisms underlying the HCC 
formation remain to be enlightened and it also remains to be investigated how tumorigenesis 
and especially the development and progression of HCC can be efficiently limited and which 
molecules or proteins serve as promising therapeutic targets.  
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3 Aim of the thesis 
 
In previous studies of our group we could show that MKL1/2 depletion inhibits hepatocellular 
carcinoma (HCC) xenograft growth by inducing oncogene-induced senescence (OIS) (Hampl 
et al., 2013). For further insights into the mechanism of HCC regression and senescence 
induction, the aim of this thesis was to search for MKL1/2 dependent target genes that 
mediate the effect of MKL1/2. Therefore, a microarray analysis with HuH7 cells stably 
expressing a control shRNA and HuH7 cells stably expressing MKL1/2 shRNA (MKL1/2 KD) 
was performed. Taken a threshold at the 2.5-fold reduced expression of the MKL1/2 KD cells 
compared to the control cells, we identified 8 MKL1/2 dependent target genes, amongst 
those 2 of them, Transgelin/SM22 and myosin heavy chain 9 (MYH9), were already known. 
The other 6 novel identified genes were glioma pathogenesis-related 1 (GLIPR1), calponin 1 
(CNN1), transforming growth factor beta 1 (TGFß1), vestigial-like family member 3 (VGLL3), 
microtubule-associated protein 1B (MAP1B) and myoferlin (MYOF). These genes, except for 
VGLL3, were also downregulated in vivo in a xenograft model upon treatment of the mice 
with MKL1+2 siRNA. 
Based on these findings, the first aim of this thesis was to validate the MKL1/2 dependency 
of the above mentioned target genes and to characterize their regulation by the Rho/actin 
signaling pathway in different HCC cell lines. 
The second issue to address in this thesis was the dependency of the novel target genes on 
Filamin A (FLNa), the newly identified binding partner of MKL1 (Kircher et al., 2015) and the 
relevance of FLNa for target gene expression. 
Finally, the third aim was to characterize the novel MKL target gene myoferlin regarding its 
involvement in tumor development and senescence induction in hepatocellular carcinoma 
cell lines and its significance as potential therapeutic target in HCC patients. 
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4 Materials 
 
4.1 Cell culture 
 
4.1.1 Cell lines 
 
Table 1: Cell lines and their culture medium 
cell line origin / cell type culture medium provider 
A7 
human melanoma cell 
line stably expressing 
FLNa 
MEM 
Prof. Thomas P. Stossel, 
Harvard Medical School, 
Boston, MA, USA 
HEK293T human embryonic kidney cell line DMEM 
Anna-Lena Forst, Ludwig-
Maximilians-University Munich, 
Munich, Germany 
HepG2 human hepatocellular carcinoma cell line RPMI 
Dr. Stephan Singer, Ruprecht-
Karls-University Heidelberg, 
Heidelberg, Germany 
HepG2 MLC 
human hepatocellular 
carcinoma cell line 
with empty vector 
RPMI Dr. Scott Lowe, Cold Spring Harbor, New York, NY, USA 
HepG2 
shRNA DLC1 
human hepatocellular 
carcinoma cell line 
with stable DLC1 
knockdown  
RPMI Dr. Scott Lowe, Cold Spring Harbor, New York, NY, USA 
HLF human hepatocellular carcinoma cell line RPMI 
Dr. Stephan Singer, Ruprecht-
Karls-University Heidelberg, 
Heidelberg, Germany 
HuH6 human hepatocellular carcinoma cell line DMEM 
Dr. Stephan Singer, Ruprecht-
Karls-University Heidelberg, 
Heidelberg, Germany 
Heidelberg, Germany 
HuH7 human hepatocellular carcinoma cell line DMEM 
Dr. Stephan Singer, Ruprecht-
Karls-University Heidelberg, 
Heidelberg, Germany 
LT 
liver tumor cells 
derived from SRF-
VP16 expressing mice 
DMEM 
Prof. Alfred Nordheim, 
Eberhard Karls university 
Tuebingen, Tuebingen, 
Germany 
M2 
human melanoma cell 
line lacking 
expression of FLNa 
MEM 
Prof. Thomas P. Stossel, 
Harvard Medical School, 
Boston, MA, USA 
MDA-MB 468 human breast carcinoma cell line DMEM 
Dr. Ramon Parsons, Mount 
Sinai Hospital, New York, NY, 
USA 
NIH 3T3 mouse embryonic fibroblast cell line DMEM ATCC, Wesel, Germany 
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4.1.2 Cell culture media 
 
Table 2: Cell culture media and their supplements 
medium supplement manufacturer 
DMEM (Dulbecco’s 
Modified Eagle’s Medium) 
10 % (v/v) FBS 
  5 % (v/v) penicillin/streptomycin	  	  
Sigma-Aldrich, 
Taufkirchen, Germany 
MEM (Minimum Essential 
Medium) 
10 % (v/v) FBS  
  5 % (v/v) penicillin/streptomycin  
Sigma-Aldrich, 
Taufkirchen, Germany 
Opti-MEM / Gibco
® Invitrogen, 
Karlsruhe, Germany 
RPMI (RPMI 1640 
medium) 
10 % (v/v) FBS  
  5 % (v/v) penicillin/streptomycin 
Sigma-Aldrich, 
Taufkirchen, Germany 
 
 
4.1.3 Transfection reagents 
 
Table 3: Transfection reagents 
reagent manufacturer 
GenJet™ DNA In Vitro Transfection Reagent SignaGen Laboratories, Rockville, USA 
Lipofectamine® 2000 Reagent Invitrogen, Karlsruhe, Germany 
Lipofectamine® RNAiMAX™ Reagent  Invitrogen, Karlsruhe, Germany 
 
 
4.2 Antibodies 
 
4.2.1 Primary antibodies for immunoblotting 
 
Primary antibodies were diluted as indicated in TBS-T and enriched with a spatula tip BSA 
and a 2 % sodium azide solution (0.02 % final concentration) for conservation. 
 
Table 4: Primary antibodies used for immunoblotting and their dilution 
antibody dilution  manufacturer 
anti-EGFR (rabbit) 1:500 Cell Signaling Technology, Danvers, MA, USA 
anti-Erk1/2 (p44/42 MAPK) (rabbit) 1:10000 Cell Signaling Technology, Danvers, MA, USA 
anti-GAPDH (rabbit) 1:1000 Sigma-Aldrich, Taufkirchen, Germany 
anti-GLIPR1 (rabbit) 1:500 Thermo Fisher Scientific, Schwerte, Germany 
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anti-HA (3F10) (mouse) 1:1000 Santa Cruz Biotechnology, Santa Cruz, CA, USA 
anti-HSP90 (mouse) 1:500 Santa Cruz Biotechnology,  Heidelberg, Germany 
anti-MKL1 (rabbit) 1:500 Muehlich et al., 2008 
anti-MKL2 (rabbit) 1:500 Muehlich et al., 2008 
anti-Myoferlin (rabbit) 1:250 Sigma-Aldrich, Taufkirchen, Germany 
anti-p16INK4a (goat) 1:250 R&D Systems, Wiesbaden, Germany 
anti-phospho EGFR (Tyr1173) 
(rabbit) 1:1000 
Cell Signaling Technology, 
Danvers, MA, USA 
anti-phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) (rabbit) 1:1000 
Cell Signaling Technology, 
Danvers, MA, USA 
anti-pRb (mouse) 1:500 BD Biosciences, Heidelberg, Germany 
anti-Ras (mouse) 1:500 Cell Signaling Technology, Danvers, MA, USA 
anti-SM22 (rabbit) 1:1000 GeneTex, Inc., Irvine, CA, USA 
anti-VP16 (rabbit) 1:300 Abcam, Cambridge, UK 
monoclonal Anti-Flag® M2 (mouse) 1:1000 Sigma-Aldrich, Taufkirchen, Germany 
 
 
4.2.2 Secondary antibodies for immunoblotting 
 
Table 5: Secondary antibodies used for immunoblotting and their dilution  
antibody dilution (in TBS-T) manufacturer 
anti-goat IgG, HRP-linked antibody 1:50000 Santa Cruz Biotechnology, Santa Cruz, CA, USA 
anti-mouse IgG, HRP-linked 
antibody 1:10000 
Cell Signaling Technology, 
Frankfurt, Germany 
anti-rabbit IgG, HRP-linked 
antibody 1:10000 
Cell Signaling Technology, 
Frankfurt, Germany 
 
 
4.2.3 Antibodies for ChIP assay  
 
Table 6: Antibodies used for pulldown in ChIP assay  
antibody manufacturer 
anti-FLNa (mouse) Merck Millipore, Darmstadt, Germany 
anti-MKL1 (goat) Santa Cruz Biotechnology, Santa Cruz, CA, USA 
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4.3 Nucleic acids 
 
4.3.1 Plasmids 
 
Table 7: Plasmids and their expressing vectors 
plasmid DNA vector provider 
EGFR-GFP pEGFP-N1 Prof. Alexander Sorkin, University of Pittsburgh, PA, USA 
Flag GFP Dia1 ct (mDiact) pEF Prof. Guido Posern, Martin Luther university, Halle, Germany 
Mig6 (pCMV-Flag gene 
33) pCMV5 
Prof. John Kyriakis, Woburn, MA, 
USA 
Myc-FLNa wt pcDNA 3 Prof. John Blenis, Weill Cornell Medical College, New York, NY, USA 
Myoferlin promoter 200bp pGL2 
Prof. Elizabeth M. McNally, 
Northwestern university, Chicago, IL, 
USA 
Myoferlin promoter 400bp pGL2 
Prof. Elizabeth M. McNally, 
Northwestern university, Chicago, IL, 
USA 
Myoferlin promoter 500bp pGL2 
Prof. Elizabeth M. McNally, 
Northwestern university, Chicago, IL, 
USA 
Myoferlin promoter 900bp pGL2 
Prof. Elizabeth M. McNally, 
Northwestern university, Chicago, IL, 
USA 
Myoferlin promoter 
1500bp pGL2 
Prof. Elizabeth M. McNally, 
Northwestern university, Chicago, IL, 
USA 
Myoferlin promoter Δ304-
363 bp pGL2 Hermanns et al., 2017 
P3 x Flag MKL1 N100 pCin4 Prof. Ron Prywes, Columbia University New York, NY, USA 
P3 x Flag MKL1 S454A pCin4 Prof. Ron Prywes, Columbia University New York, NY, USA 
P3 x Flag MKL1 wt P3 x Flag-CMVTM-7.1  Prof. Ron Prywes, Columbia University New York, NY, USA 
P3 x Flag MKL1 Δ301-310 P3 x Flag-CMVTM-7.1  Kircher et al., 2015 
P3 x Flag MKL1 Δ301-342 P3 x Flag-CMVTM-7.1  Kircher et al., 2015 
pcDNA 3.1 empty vector pcDNA3.1 
Prof. Konstanze F. Winklhofer, 
Ludwig-Maximilians-University 
Munich, Munich, Germany 
Renilla luciferase SV40 pSV Prof. Ron Prywes, Columbia University New York, NY, USA 
SRF-VP16 pMLV 
Prof. Margarete Goppelt-Strübe, 
Friedrich-Alexander-University 
Erlangen-Nürnberg, Erlangen, 
Germany 
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4.3.2 Primers 
 
4.3.2.1 Human primers for qRT-PCR 
 
Table 8: Human primers for qRT-PCR and their sequence 
primer sequence manufacturer 
18S rRNA Fw 
18S rRNA Rv 
5’-TCG AGG CCC TGT AAT TGG AAT-3’ 
5’-CCC TCC AAT GGA TCC TCG TTA-3’ 
Sigma-Aldrich, Taufkirchen, 
Germany 
CNN1 Fw 
CNN1 Rv 
5’-GCT GTC AGC CGA GGT TAA GA-3’ 
5’-CCC TCG ATC CAC TCT CTC AG-3’ 
Metabion, Martinsried, 
Germany 
CTGF Fw 
CTGF Rv 
5’-TTG GCA GGC TGA TTT CTA GG-3’ 
5’-GGT GCA AAC ATG TAA CTT TTG G-3’ 
Metabion, Martinsried, 
Germany 
CXCL10 Fw 
CXCL10 Rv 
5’-CCC CAC GTT TTC TGA GAC AT-3’ 
5’-TGG CAG TTT GAT TCA TGG TG-3’ 
Metabion, Martinsried, 
Germany 
EGFR Fw 
EGFR Rv 
5’-TTC CTC CCA GTG CCT GAA-3’ 
5’-GGG TTC AGA GGC TGA TTG TG-3’ 
Metabion, Martinsried, 
Germany 
FLNa Fw 
FLNa Rv 
5’-TCG CTC TCA GGA ACA GCA-3’ 
5’-TTA ATT AAA GTC GCA GGC ACC TA-3’ 
Metabion, Martinsried, 
Germany 
GLIPR1 Fw 
GLIPR1 Rv 
5’-TCT TTC CAA TGG AGC ACA TTT-3’ 
5’-TCT TAT ATG GCC AAG TTG GGT AA-3’ 
Metabion, Martinsried, 
Germany 
MAP1B Fw 
MAP1B Rv 
5’-GAC GCT TTG TTG GAA GGA AA-3’ 
5’-CTG AGT CAT GAG TTG GGA TCA G-3’ 
Metabion, Martinsried, 
Germany 
Mig6 Fw 
Mig6 Rv 
5’-ACC CAC TGA AGT AGC TCA TCG-3’ 
5’-TTC CAT CTG AGT CTA ACG TAC CC-3’ 
Sigma-Aldrich, Taufkirchen, 
Germany 
MKL1 Fw 
MKL1 Rv 
5’-CCC AAT TTG CCT CCA CTT AG-3’ 
5’-CCT TGG CTC ACC AGT TCT TC-3’ 
Metabion, Martinsried, 
Germany 
MKL2 Fw 
MKL2 Rv 
5’-CTT ACC CCC TCT GAA CGA AA-3’ 
5’-CTC TCG TCC TCC TTT GTT GC-3’ 
Metabion, Martinsried, 
Germany 
MYH9 Fw 
MYH9 Rv 
5’-TGG AGG ACC AGA ACT GCA A-3’ 
5’-GGT TGG TGG TGA ACT CAG CTA-3’ 
Metabion, Martinsried, 
Germany 
MYOF Fw 
MYOF Rv 
5’-CCA TTA CTG GCT TCT AAG CTG AC-3’ 
5’-TTC CCC TGA GGA AGC ATA AA-3’ 
Metabion, Martinsried, 
Germany 
SM22 Fw 
SM22 Rv 
5’-GGC CAA GGC TCT ACT GTC TG-3’ 
5’-CCC TTG TTG GCC ATG TCT-3’ 
Metabion, Martinsried, 
Germany 
SRF Fw 
SRF Rv 
5’-AGC ACA GAC CTC ACG CAG A-3’ 
5’-GTT GTG GGC ACG GAT GAC-3’ 
Metabion, Martinsried, 
Germany 
TGFβ1 Fw 
TGFβ1 Rv 
5’-ACT ACT ACG CCA AGG AGG TCA C-3’ 
5’-TGC TTG AAC TTG TCA TAG ATT TCG-3’ 
Metabion, Martinsried, 
Germany 
TNFSF10 Fw 
TNFSF10 Rv 
5’-TTC ACA GTG CTC CTG CAG TC-3’ 
5’-GCC ACT TTT GGA GTA CTT GTC C-3’ 
Metabion, Martinsried, 
Germany 
VGLL3 Fw 
VGLL3 Rv 
5’-TCC CAG TAT CTG CCC AAC C-3’ 
5’-TGC TGA ATA CCG CTA ACT TCT TC-3’ 
Metabion, Martinsried, 
Germany 
Random 
Hexamers 5’-NNN NNN-Wobbles-3’ 
Metabion, Martinsried, 
Germany 
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4.3.2.2 Mouse primers for qRT-PCR 
 
Table 9: Mouse primers for qRT-PCR and their sequence 
primer sequence manufacturer 
CNN1 Fw 
CNN1 Rv 
5’-CGG CTT GTC TGC TGA AGT AA-3’ 
5’-ACC CCC TCA ATC CAC TCT CT-3’ 
Metabion, Martinsried, 
Germany 
CTGF Fw 
CTGF Rv 
5’-TGA CCT GGA GGA AAA CAT TAA GA-3’ 
5’-AGC CCT GTA TGT CTT CAC ACT G-3’ 
Metabion, Martinsried, 
Germany 
CXCL10 Fw 
CXCL10 Rv 
5’-GCT GCC GTC ATT TTC TGC-3’ 
5’-TCT CAC TGG CCC GTC ATC-3’ 
Sigma-Aldrich, Taufkirchen, 
Germany 
EGFR Fw 
EGFR Rv 
5’-CAA CAA AGA AAT CCT TGA CGA A-3’ 
5’-GGA CAG TGG AGG TCA GAC AGA-3’ 
Sigma-Aldrich, Taufkirchen, 
Germany 
FLNa Fw 
FLNa Rv 
5’-GAC CTC AGC CTG AAG ATT CCT-3’ 
5’-ATG GGT CTT GCC TGA TGG-3’ 
Metabion, Martinsried, 
Germany 
GLIPR1 Fw 
GLIPR1 Rv 
5’-TGC CCT AAT GGA GCA AAT TTT A-3’ 
5’-TTA TAT GGC CAC GTT GGG TAA-3’ 
Metabion, Martinsried, 
Germany 
ITGA5 Fw 
ITGA5 Rv 
5’-CAC CAT TCA ATT TGA CAG CAA-3’ 
5’-TCC TCT CCC TTG GCA CTG TA-3’ 
Metabion, Martinsried, 
Germany 
MAP1B Fw 
MAP1B Rv 
5’-CCT GGA TGC CTT GTT GGA-3’ 
5’-GGA GTC ATG TGT CGG AAT CA-3’ 
Metabion, Martinsried, 
Germany 
MYOF Fw 
MYOF Rv 
5’-TGA AGA TCC ATC TGT GGT AGG A-3’ 
5’-ATC CGG CAA GGG GTA GAT-3’ 
Sigma-Aldrich, Taufkirchen, 
Germany 
p16 Fw 
p16 Rv 
5’-GAC AGG AAA GGA ATT GCA TGA-3’ 
5’-TTA AAC AAT CCA GCC ATT ATT CC-3’ 
Sigma-Aldrich, Taufkirchen, 
Germany 
SRF Fw 
SRF Rv 
5’-CTG ACA GCA GTG GGG AAA C-3’ 
5’-GCT GGG TGC TGT CTG GAT-3’ 
Metabion, Martinsried, 
Germany 
SM22 Fw 
SM22 Rv 
5’-CCT TCC AGT CCA CAA ACG AC-3’ 
5’-GTA GGA TGG ACC CTT GTT GG-3’ 
Metabion, Martinsried, 
Germany 
TNFSF10 Fw 
TNFSF10 Rv 
5’-GCT CCT GCA GGC TGT GTC-3’ 
5’-CCA ATT TTG GAG TAA TTG TCC TG-3’ 
Sigma-Aldrich, Taufkirchen, 
Germany 
 
 
4.3.2.3 Primers for ChIP qRT-PCR 
 
Table 10: Primers for ChIP qRT-PCR and their sequence 
promoter sequence manufacturer 
Actin 5’-AGG GTC TTC CCA GGC TGG CTT TGA-3’ 5’-CAA GAC TCC ATG TGC CAC AGA GGA T-3’ 
Sigma-Aldrich, 
Taufkirchen, Germany 
CTGF 5’-GGA GTG GTG CGA AGA GGA TA-3’ 5’-GCC AAT GAG CTG AAT GGA GT-3’ 
Sigma-Aldrich, 
Taufkirchen, Germany 
GAPDH 5’-CGG GAT TGT CTG CCC TAA TTA T-3’  5’-GCA CGG AAG GTC ACG ATG T-3’ 
Sigma-Aldrich, 
Taufkirchen, Germany 
MYOF 5’-TAG ATT CCA ACC TAT GGA ACT GA-3’  5’-TTC CTC ATT AAA GGC ATT CCA-3’ 
Sigma-Aldrich, 
Taufkirchen, Germany 
MYOF-1167 
(neg. control) 
5’-TCT GAC TTT CCT GAG ACA TTT GAA-3’  
5’-TTT TTG CTT CTG ACA TAC AAC CA-3’	  
Sigma-Aldrich, 
Taufkirchen, Germany 
α-SMA 
5’-AGC AGA ACA GAG GAA TGC AGT GGA AGA 
GAC-3’  
5’-CCT CCC ACT CGC CTC CCA AAC AAG GAG C-3’ 
Sigma-Aldrich, 
Taufkirchen, Germany 
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4.3.3 siRNAs 
 
Table 11: siRNAs and their sequence 
siRNA sequence (sense und antisense) manufacturer 
scrambled (neg. 
control) 
5’-CGUACGCGGAAUACUUCGA[dt][dt]-3’ 
5’-UCGAAGUAUUCCGCGUACG[dt][dt]-3’ 
Sigma-Aldrich, Taufkirchen, 
Germany 
EGFR 
(human) 
5’-GCUGCUCUGAAAUCUCCUUUA[dt][dt]-3’ 
5’-UAAAGGAGAUUUCAGAGCAGC[dt][dt]-3’ 
Sigma-Aldrich, Taufkirchen, 
Germany 
FLNa 
(human) 
5’-GCACAUGUUCCGUGUCCUA[dt][dt]-3’ 
5’-UAGGACACGGAACAUGUGC[dt][dt]-3’ 
Dharmacon, Lafayette, CO, 
USA 
FLNa 
(mouse) 
5’-GGUACACAAUCCUCAUCAATT[dt][dt]-3’ 
5’-UUGAUGAGGAUUGUGUACCGG[dt][dt]-3’ Qiagen, Hilden, Germany 
Mig6 
(human) 
5’-CUACACUUUCUGAUUUCAA[dt][dt]-3’ 
5’-UUGAAAUCAGAAAGUGUAG[dt][dt]-3’ 
Sigma-Aldrich, Taufkirchen, 
Germany 
MKL1 
(human) 
5’-GAAUGUGCUACAGUUGAAA[dt][dt]-3’ 
5’-UUUCAACUGUAGCACAUUC[dt][dt]-3’ 
Sigma-Aldrich, Taufkirchen, 
Germany 
MKL1 V2 
(human) 
5’-GUGUCUUGGUGUAGUGUAA[dt][dt]-3’ 
5’-UUACACUACACCAAGACAC[dt][dt]-3’ 
Sigma-Aldrich, Taufkirchen, 
Germany 
MKL1/2 
(human) 
5’-AUGGAGCUGGUGGAGAAGAA[dt][dt]-3’ 
5’-UUCUUCUCCACCAGCUCCAU[dt][dt]-3’ 
Sigma-Aldrich, Taufkirchen, 
Germany 
MKL2 (human) 5’-GUAACAGUGGGAAUUCAGC[dt][dt]-3’ 5’-GCUGAAUUCCCACUGUUAC[dt][dt]-3’ 
Sigma-Aldrich, Taufkirchen, 
Germany 
MKL2 V2 
(human) 
5’-AAGAGCTCGACTAGCAGATGA[dt][dt]-3’ 
5’-TCATCTGCTAGTCGAGCTCTT[dt][dt]-3’ 
Sigma-Aldrich, Taufkirchen, 
Germany 
MYOF (human) 5’-CCCUGUCUGGAAUGAGA[dt][dt]-3’ 5’-UCUCAUUCCAGACAGGG[dt][dt]-3’ 
Sigma-Aldrich, Taufkirchen, 
Germany 
MYOF (mouse) 5’-AACCCUGUCUGGAAUGAGAUU[dt][dt]-3’ 5’-AAUCUCAUUCCAGACAGGGUU[dt][dt]-3’ 
Sigma-Aldrich, Taufkirchen, 
Germany 
MYOF V2 
(human) 
5’-CGGCGGAUGCUGUCAAAUA[dt][dt]-3’ 
5’-UAUUUGACAGCAUCCGCCG[dt][dt]-3’ 
Sigma-Aldrich, Taufkirchen, 
Germany 
 
	  
4.4 Antibiotics  
 
Table 12: Antibiotics 
antibiotic manufacturer 
ampicillin Gibco® Invitrogen, Karlsruhe, Germany  
G418 (Geneticin disulphate) Carl Roth, Karlsruhe, Germany 
kanamycin Gibco® Invitrogen, Karlsruhe, Germany  
penicillin/streptomycin   Sigma-Aldrich, Taufkirchen, Germany 
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4.5 Enzymes 
 
Table 13: Enzymes 
enzyme manufacturer 
Proteinase K Sigma-Aldrich, Taufkirchen, Germany 
RNase A Thermo Scientific, Schwerte, Germany  
SuperScript® II Reverse Transcriptase Invitrogen, Karlsruhe, Germany 
Trypsin-EDTA solution 0.05 % Sigma-Aldrich, Taufkirchen, Germany 
 
 
4.6 Stimulants and inhibitors 
 
Table 14: Stimulants and inhibitors and their final working concentration 
reagent final concentration  manufacturer 
Actinomycin D 1 µg/mL AppliChem, Darmstadt, Germany 
Cytochalasin D 2 µM Sigma-Aldrich, Taufkirchen, Germany 
FBS 20 % Life Technologies, Darmstadt, Germany 
Jasplakinolide 0.5 µM CalBiochem, Darmstadt, Germany 
Latrunculin B 0.3 µM Merck, Darmstadt, Germany 
LPA 10 µM Sigma-Aldrich, Taufkirchen, Germany 
MG132 10 µM Sigma-Aldrich, Taufkirchen, Germany 
SOS SH3 domain 
inhibitor 20 µM 
Santa Cruz Biotechnology, Santa Cruz, CA, 
USA 
Tyrphostin AG1478 10 µM Sigma-Aldrich, Taufkirchen, Germany 
 
 
4.7 Ladders 
 
Table 15: DNA and protein ladders  
ladder manufacturer 
100 bp DNA ladder Invitrogen, Karlsruhe, Germany 
Spectra™ Multicolor Broad Range Protein Ladder Thermo Scientific, Schwerte, Germany 
Spectra™ Multicolor High Range Protein Ladder Thermo Scientific, Schwerte, Germany 
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4.8 Kits 
 
Table 16: Kits 
kit manufacturer 
Active Ras Detection Kit Cell Signaling Technology, Danvers, MA, USA 
Dual-Luciferase® Reporter Assay System Promega, Mannheim, Germany 
GenEluteTM HP Plasmid Midiprep Kit Sigma-Aldrich, Taufkirchen, Germany 
MinElute PCR Purification Kit Qiagen, Hilden, Germany 
Q5® Site-Directed Mutagenesis Kit  New England Biolabs GmbH, Frankfurt am Main, Germany 
QIAquick PCR Purification Kit Qiagen, Hilden, Germany 
Senescence β-Galactosidase Staining Kit Cell Signaling Technology, Danvers, MA, USA 
 
 
4.9 Buffers und solutions 
 
4.9.1 Agarose gels 
 
Table 17: Buffers used for agarose gel electrophoresis  
50x TAE buffer 
 242.0 g Tris 
   57.1 mL acetic acid (100%) 
 100.0 mL 0.5 M EDTA, pH 8.0 
  ad 1 L H2Oultrapure 
1x TAE buffer 
 100 mL 50x TAE buffer 
  ad 5 L H2Oultrapure 
 
 
4.9.2 Bacteria cultivation 
 
Table 18: LB agar and LB medium used for bacteria cultivation 
LB agar 
 10 g tryptone 
   5 g yeast extract 
 10 g NaCl 
 15 g agar 
  ad 1 L H2Oultrapure, pH 7.5 
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  -> autoclave 
optionally: 100 µg/mL antibiotic  
LB medium 
 10 g tryptone 
   5 g yeast extract 
 10 g NaCl 
  ad 1 L H2Oultrapure, pH 7.5 
  -> autoclave 
 
 
4.9.3 Calcium phosphate transfection 
 
Table 19: Solutions used for calcium phosphate transfection  
2x HBS 
 8.0 g NaCl 
 0.2 g Na2HPO4 x 7 H2O 
 6.5 g HEPES 
  ad 500 mL H2Oultrapure, pH 7.0 
2.5 M CaCl2 
 87.6 g CaCl2 x 6 H2O 
  ad 200 mL H2Oultrapure 
  -> sterile filtration 
 
 
4.9.4 cDNA synthesis and qRT-PCR 
 
Table 20: Reagents used for cDNA sytnthesis and qRT-PCR  
reagent manufacturer 
5x First-Strand Buffer Invitrogen, Karlsruhe, Germany 
Deoxynucleoside triphosphates (dNTPs) (10 mM) Invitrogen, Karlsruhe, Germany 
LightCycler® 480 SYBR Green I Master Roche, Penzberg, Germany 
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4.9.5 ChIP assay 
 
Table 21: Buffers used for ChIP assay 
Farnham Lysis buffer 
      0.76 g (5 mM) PIPES, pH 8.0 
      3.17 g (85 mM) KCl 
      2.50 mL (0.5%) NP-40 
  ad 500 mL H2Oultrapure 
Lysis buffer 0,1% 
      5.00 mL (10 mM) 1 M Tris, pH 7.5 
      1.00 mL (1 mM) 0.5 M EDTA 
      5.00 mL (0.1%) 10% SDS  
  ad 500 mL H2Oultrapure 
LiCl Wash buffer 
     50.00 mL (100 mM) 1 M Tris, pH 7.5 
     10.60 g  (500 mM) LiCl 
       5.00 mL (1%) NP-40 
       5.00 g (1%) sodium deoxycholate 
  ad 500 mL H2Oultrapure 
IP buffer 
      6.70 g (56.25 mM) HEPES 
      4.60 g (157.5 mM) NaCl 
      1.00 mL (1 mM) 0.5 M EDTA 
    5.625 mL (1.125%) Triton X-100 
  0.5625 g (0.1125%) sodium deoxycholate 
  ad 500 mL H2Oultrapure 
IP Elution buffer 
    50.00 mL (1%) 10% SDS 
      4.20 g (100 mM) NaHCO3 
  ad 500 mL H2Oultrapure 
TE buffer 
      5.00 mL (10 mM) 1 M Tris, pH 7.5 
      1.00 mL (1 mM) 0.5 M EDTA 
  ad 500 mL H2Oultrapure 
Sonication buffer 
    5.00 mL (10 mM) 1 M Tris, pH 7.5 
    1.00 mL (1 mM) 0.5 M EDTA 
  20.00 mL (0.4%) 10% SDS 
  ad 500 mL H2Oultrapure 
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4.9.6 Immunoblotting 
 
Table 22: Buffers used for immunoblotting  
5x transfer buffer 
 7.25 g Tris 
 3.65 g glycine 
 0.47 g SDS 
 200 mL methanol 
  ad 1 L H2Oultrapure 
10x TBS 
 60.55 g Tris 
 85.20 g NaCl 
  ad 1 L H2Oultrapure, pH 7.6 
with HCl 
1x TBS-T 
 500 mL 10x TBS 
     5 mL Tween 20 
  ad 5 L H2Oultrapure 
 
 
4.9.7 Immunoblotting detection 
 
Table 23: Reagents and solutions used for immunoblotting detection 
Luminol stock solution 
      5 mL 1 M HEPES, pH 7.4 
      3 mL 5 M NaCl 
      1 mL 100 % Triton X-100 
   0.2 mL 0.5 M EDTA, pH 8.0 
    10 mL 100 % glycerin 
  ad 100 mL H2Oultrapure 
add freshly to 1 mL:        2 µL 0.25 M PMSF 
      4 µL 0.25 M DTT 
    10 µL 10x Protease Inhibitor 
stabilizer solution 
      2 mL 1 M Tris/HCl, pH 8.0 
 2.92 g NaCl 
   0.5 mL 1 M imidazole 
  ad 100 mL 8 M Urea, pH 7.9 
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S1 solution 
  80.0 mL H2Oultrapure 
  10.0 mL 1 M Tris/HCl, pH 8.5 
  1.00 mL luminol stock solution 
  0.44 mL stabilizer solution 
  ad 100 mL H2Oultrapure 
S2 solution 
    80 mL H2Oultrapure 
    10 mL 1 M Tris/HCl, pH 8.5 
    60 µL 30 % H2O2 
  ad 100 mL H2Oultrapure 
working solution 
    1:1 S1 solution:S2 solution 
reagent manufacturer 
Roti®-Lumin 1+2 Carl Roth, Karlsruhe, Germany 
SuperSignalTM West Femto Chemiluminescent 
Substrate 
Thermo Scientific, Schwerte, Germany 
 
 
4.9.8 Immunofluorescence 
 
Table 24: Solution used for immunofluorescence  
4% PFA 
 250 mL H2Oultrapure 
  -> 60 °C 
   20 g PFA 
   50 µL 10 M NaOH 
   50 mL 10x PBS 
  ad 500 mL H2Oultrapure 
 
 
4.9.9 Invasion assay 
 
Table 25: Solutions used for invasion assay  
Staining Solution 
    40 mL 1x PBS 
      8 mL (20%) methanol 
 0.04 g (0.1%) crystal violet 
Destaining Solution 
    40 mL 1x PBS 
      8 mL (20%) methanol 
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4.9.10 Protein isolation and purification 
 
Table 26: Buffer and solution used for protein isolation and purification  
Kralewski lysis buffer 
      5 mL 1 M HEPES, pH 7.4 
      3 mL 5 M NaCl 
      1 mL 100 % Triton X-100 
   0.2 mL 0.5 M EDTA, pH 8.0 
    10 mL 100 % glycerin 
  ad 100 mL H2Oultrapure 
add freshly to 1 mL:       2 µL 0.25 M PMSF 
      4 µL 0.25 M DTT 
    10 µL 10x Protease Inhibitor 
0.25 M PMSF 
 435.5 mg PMSF 
      10 mL isopropanol 
 
 
4.9.11 SDS-PAGE 
 
Table 27: Buffers used for SDS-PAGE 
4x SDS sample buffer 
     8 mL 1 M Tris, pH 8.8 
   16 mL 20 % SDS 
   16 mL glycerin 
 320 µL 0.5 M EDTA 
     4 mg bromophenol blue 
add freshly to 960 µL:   40 µL β-mercaptoethanol 
10x SDS-PAGE running buffer 
   30.26 g  Tris 
   10.00 g SDS 
 143.20 g glycine 
  ad 1 L H2Oultrapure 
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4.9.12 Washing and dilution solutions 
 
Table 28: PBS used for washing and dilutions 
10x PBS 
      2 g KCl 
      2 g KH2PO4 
    80 g NaCl 
 21.6 g Na2HPO4 x 7 H2O 
  ad 1 L H2Oultrapure, pH 7.4 
 
Table 29: DEPC H2O used for RNA resuspension 
DEPC H2O 
   0.5 g DEPC 
 500 mL H2Oultrapure 
  1 h, 37 °C 
  -> autoclave 
 
 
4.10 Gels 
 
Table 30: Composition of running and stacking gels used for SDS-PAGE 
5 % running gel 
   8.50 mL H2Oultrapure 
   2.50 mL 30 % acrylamide 
   3.75 mL 1.5 M Tris, pH 8.8 
 0.150 mL 10 % SDS 
 0.200 mL 10 % APS 
 0.012 mL TEMED 
10 % running gel 
   3.97 mL H2Oultrapure 
   3.33 mL 30 % acrylamide 
   2.50 mL 1.5 M Tris, pH 8.8 
 0.100 mL 10 % SDS 
 0.100 mL 10 % APS 
 0.004 mL TEMED 
12 % running gel 
   4.80 mL H2Oultrapure 
   6.00 mL 30 % acrylamide 
   3.90 mL 1.5 M Tris, pH 8.8 
 0.150 mL 10 % SDS 
 0.150 mL 10 % APS 
 0.006 mL TEMED 
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5 % stacking gel 
   5.40 mL H2Oultrapure 
   1.34 mL 30 % acrylamide 
   2.00 mL 1.0 M Tris, pH 6.8 
 0.080 mL 10 % SDS 
 0.080 mL 10 % APS 
 0.008 mL TEMED 
 
 
4.11 Bacterial strains 
 
Table 31: Bacterial strains 
strains manufacturer 
E. coli DH5α Takara Bio, Kyoto, Japan 
NEB® 5-alpha competent E. coli New England Biolabs GmbH, Frankfurt am 
Main, Germany 
 
 
4.12 Chemicals 
 
Table 32: Chemicals  
chemical manufacturer 
16% Formaldehyde (w/v), methanol-free Thermo Fisher Scientific, Schwerte, Germany 
6x DNA loading dye Thermo Fisher Scientific, Schwerte, Germany 
Agar Carl Roth, Karlsruhe, Germany 
Ammonium peroxodisulfate (APS) Carl Roth, Karlsruhe, Germany 
Bovine Serum Albumin (BSA) Carl Roth, Karlsruhe, Germany 
Bromophenol blue Carl Roth, Karlsruhe, Germany 
CaCl2 x 6 H2O Carl Roth, Karlsruhe, Germany 
Chloroform Emsure® Merck, Darmstadt, Germany 
Crystal violet Merck Millipore, Darmstadt, Germany 
Diethyl dicarbonate (DEPC) Carl Roth, Karlsruhe, Germany 
Dimethyl sulfoxide (DMSO) Carl Roth, Karlsruhe, Germany 
Dithiothreitol (DTT) Invitrogen, Karlsruhe, Germany 
Dynabeads® Protein G Thermo Fisher Scientific, Schwerte, Germany 
ECM matrigel from Engelbreth-Holm-
Swarm murine sarcoma Sigma-Aldrich, Taufkirchen, Germany 
Ethanol Emsure® Merck, Darmstadt, Germany 
Ethylenediaminetetraacetic acid (EDTA) Carl Roth, Karlsruhe, Germany 
FBS (Fetal Bovine Serum) Gibco® Invitrogen, Karlsruhe, Germany  
Fluoromount Sigma-Aldrich, Taufkirchen, Germany 
Glycerin Carl Roth, Karlsruhe, Germany	  
Glycine Carl Roth, Karlsruhe, Germany	  
HEPES Carl Roth, Karlsruhe, Germany 
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Hydrochloric acid (HCl) Merck, Darmstadt, Germany 
Imidazole Carl Roth, Karlsruhe, Germany 
Immersion oil Immersol 518 F Carl Zeiss AG, Oberkochen, Germany 
Isopropyl alcohol Carl Roth, Karlsruhe, Germany 
Lithium chloride Merck Millipore, Darmstadt, Germany 
Low fat milk powder Heirler, Radolfzell, Germany 
Methanol Carl Roth, Karlsruhe, Germany 
N,N-Dimethylformamide (DMF) Sigma-Aldrich, Taufkirchen, Germany 
N,N,N’,N’-	  Tetramethylethylenediamine 
(TEMED) Carl Roth, Karlsruhe, Germany 
Nonidet P-40 (NP-40) Sigma-Aldrich, Taufkirchen, Germany 
Nuclease free H2O Thermo Scientific, Schwerte, Germany  
Paraformaldehyde (PFA) Carl Roth, Karlsruhe, Germany 
peqGold universal agarose Peqlab Biotechnology GmbH, Erlangen, Germany 
phenylmethylsulfonyl fluoride (PMSF) Calbiochem, Darmstadt, Germany 
Piperazine-N,N′-bis(2-ethanesulfonic acid) 
(PIPES) Carl Roth, Karlsruhe, Germany 
Potassium chloride (KCl) Carl Roth, Karlsruhe, Germany 
Potassium dehydrogen phosphatase 
(KH2PO4) 
Carl Roth, Karlsruhe, Germany 
Propidium iodide Sigma-Aldrich, Taufkirchen, Germany 
Protease Inhibitor Cocktail Set III, Animal-
Free Merck Millipore, Darmstadt, Germany 
Roti®-Quant Carl Roth, Karlsruhe, Germany 
Roti®-Safe GelStain Carl Roth, Karlsruhe, Germany 
Rotiphorese® Gel 30 (37.5:1) (30% 
acrylamide) Carl Roth, Karlsruhe, Germany 
Sodium azide Carl Roth, Karlsruhe, Germany 
Sodium chloride (NaCl) Carl Roth, Karlsruhe, Germany 
Sodium deoxycholate Carl Roth, Karlsruhe, Germany 
Sodium dodecyl sulfate (SDS) Carl Roth, Karlsruhe, Germany 
Sodium hydrogen carbonate (NaHCO3) Carl Roth, Karlsruhe, Germany 
Sodium hydrogen phosphate (Na2HPO4) Carl Roth, Karlsruhe, Germany 
Sodium hydroxide (NaOH) Carl Roth, Karlsruhe, Germany 
Tris Carl Roth, Karlsruhe, Germany 
Triton X-100 Carl Roth, Karlsruhe, Germany 
TRIzol® Reagent Invitrogen, Karlsruhe, Germany 
Tryptone Carl Roth, Karlsruhe, Germany 
Tween® 20 Carl Roth, Karlsruhe, Germany 
Urea Carl Roth, Karlsruhe, Germany 
Yeast extract Carl Roth, Karlsruhe, Germany 
β-Mercaptoethanol Serva, Heidelberg, Germany 
 
 
 
 
4 Materials	  
	   	  
	  
     46 
	  
	   	  
4.13 Consumables 
 
Table 33: Consumables  
consumable manufacturer 
24-well hanging cell culture inserts, 8.0 µm Merck Millipore, Darmstadt, Germany 
Cell culture dishes, 6 cm, 10 cm and 6well 
plates Sarstedt, Nümbrecht, Germany 
Cell scraper Sarstedt, Nümbrecht, Germany 
Cover slips 20x20 mm Carl Roth, Karlsruhe, Germany 
Cryovials CryoPure 1.6 mL Sarstedt, Nümbrecht, Germany	  
Falcon tubes, 15 mL and 50 mL Sarstedt, Nümbrecht, Germany	  
Glas pearls Carl Roth, Karlsruhe, Germany 
LightCycler® 480 Multiwell Plate 96 Roche, Penzberg, Germany 
LightCycler® 480 Sealing Foil Roche, Penzberg, Germany 
Microscope slides 76x26 mm Carl Roth, Karlsruhe, Germany 
Multiply®-Pro tubes, 0.2 mL Sarstedt, Nümbrecht, Germany	  
Pasteur pipettes, 230 mm Carl Roth, Karlsruhe, Germany 
PVDF membrane Millipore, Schwalbach, Germany 
Reaction tubes SafeSeal, 1.5 mL and 2.0 mL Sarstedt, Nümbrecht, Germany	  
Serological pipettes, 2 mL, 5 mL, 10 mL and 
25 mL	   Sarstedt, Nümbrecht, Germany	  
Tube with ventilation cap, 13 mL Sarstedt, Nümbrecht, Germany 
UV-transparent cuvettes Sarstedt, Nümbrecht, Germany	  
Whatman paper 0.8 mm Optilab, München, Germany	  
 
	  
4.14 Technical devices 
 
Table 34: Technical devices  
tool manufacturer 
Analytical balance Acculab, Sartorius Group, Göttingen, Germany 
BioPhotometer plus Eppendorf, Hamburg, Germany 
Blotting equipment Mini Protean® Tetra Cell Bio-Rad, Munich, Germany 
Centrifuge 5424 Eppendorf, Hamburg, Germany 
Centrifuge 5424R Eppendorf, Hamburg, Germany 
Chemi-SmartTM 5100 (chemiluminescent 
imager) 
Peqlab Biotechnology GmbH, Erlangen, 
Germany 
DynaMag™-2 magnet Thermo Fisher Scientific, Schwerte, Germany 
Electrophoresis equipment Peqlab Biotechnology GmbH, Erlangen, Germany 
Electrophoresis Power Supply EPS 301 GE Healthcare GmbH, Freiburg, Germany 
FlexCycler² Analytik Jena AG, Jena, Germany 
Freezer (-20 °C) Liebherr, Biberach an der Riss, Germany 
Fridge Liebherr, Biberach an der Riss, Germany 
HERAcell® 240 incubator Thermo Scientific, Schwerte, Germany 
HeraeusTM BiofugeTM Stratos Thermo Scientific, Schwerte, Germany 
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HeraeusTM LabofugeTM 400  Thermo Scientific, Schwerte, Germany 
Incubator MaxQ 6000 Thermo Scientific, Schwerte, Germany 
Infinity 3026 WL/26 MX gel documentation 
system 
Peqlab Biotechnology GmbH, Erlangen, 
Germany 
Laminar flow HERASafe KS18 Kendro, Langenselbold, Germany 
LightCycler® 480 II Roche, Penzberg, Germany 
Lumat³ LB 9508 Single Tube Luminometer Berthold Technologies Bio & Co.KG, Bad Wildbad, Germany 
Microscope Axiovert 135M Carl Zeiss AG, Oberkochen, Germany 
Microscope Axiovert 40 CFL Carl Zeiss AG, Oberkochen, Germany 
Microscope CKX41 Olympus, Hamburg, Germany 
Neubauer cell counting chamber (0.1 mm) Marienfeld, Lauda-Königshofen, Germany 
pH meter Lab850 Schott Instruments, SI Analytics, Mainz, Germany 
Pipetus  Hirschmann, Eberstadt, Germany 
Power Supply EV231 Peqlab Biotechnology GmbH, Erlangen, Germany 
Power supply peqPOWER 300 Peqlab Biotechnology GmbH, Erlangen, Germany 
SDS-PAGE equipment Bio-Rad, Munich, Germany 
Shaker Polymax 1040 Heidolph, Schwabach, Germany 
sonicator MSE, London, UK 
Thermomixer compact Eppendorf, Hamburg, Germany 
Vortex-Genie™ Bender & Hobein AG, Zürich, Switzerland 
Water bath Memmert, Schwabach, Germany 
 
 
4.15 Software  
 
Table 35: Software programs  
software manufacturer 
ChemiCapt™ Software Peqlab Biotechnology GmbH, Erlangen, Germany 
EndNote X8 Thomson Reuters, New York, NY, USA 
Excel 2011 Microsoft, Redmond, WA, USA 
ImageJ 1.43u Wayne Rasband, National Institutes of Health, Bethesda, MD, USA 
InfinityCapt 14.2 Vilber Lourmat Deutschland GmbH, Eberhardzell, Germany 
LightCycler® 480 Software Roche, Penzberg, Germany 
Loading Calculator Dr. Susanne Muehlich, Walther-Straub-Institut, Munich, Germany 
NEBaseChanger™ New England Biolabs GmbH, Frankfurt am Main, Germany 
Powerpoint 2011 Microsoft, Redmond, WA, USA 
Prism 5 GraphPad Software, La Jolla, CA, USA 
Word 2011 Microsoft, Redmond, WA, USA 
ZEN Carl Zeiss AG, Oberkochen, Germany 
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5 Methods 
 
5.1 Cell culture methods 
  
5.1.1 Cultivation of cell lines 
 
All cell lines were cultured as monolayers in the appropriate medium containing 10 % (v/v) 
fetal bovine serum (FBS) and 1 % (v/v) penicillin/streptomycin in 10 cm cell culture dishes 
until a confluence of 80-100 %. Cells were cultured at 37 °C and 5 % CO2. For passaging, 
adherent cells were washed with 5 mL prewarmed 1x phosphate-buffered saline (PBS) and 
detached with 2 mL Trypsin-EDTA. After incubation at 37 °C for 4 min, 8 mL prewarmed 
medium was added and cells were resuspended. A defined volume of the cell suspension 
was added to a new 10 cm culture dish with fresh medium containing FBS and 
penicillin/streptomycin. Cells were usually splitted in a range from 1:2 to 1:20. Cell lines and 
their culture medium are listed in table 1. 
 
5.1.2 Thawing cells 
 
Cells frozen in liquid nitrogen for long-term storage were thawed by gently shaking the 
cryovials in a 37 °C water bath. Cell suspension was transferred to a falcon tube with 5 mL of 
the relevant prewarmed medium and centrifuged for 5 min at 1000 rpm and room 
temperature. The pellet was resuspended in 1 mL medium and given in a culture dish with 
the adequate amount of prewarmed medium. The thawed cells were cultivated in an 
incubator at 37 °C and 5 % CO2. 
 
5.1.3 Freezing cells 
 
For long-term storage, cells were frozen in liquid nitrogen. Therefore, cells were washed with 
PBS, trypsinized and resuspended in 3 mL of the appropriate medium. Cell suspension was 
centrifuged for 5 min at 1000 rpm and room temperature and cell pellet was resuspended in 
900 µL ice-cold FBS and 100 µL DMSO. Cell suspension was aliquoted in 3 cryovials and 
placed in a cryofreezing box containing isopropanol for slow cooling to -80 °C. After 1 month, 
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cells were stored in liquid nitrogen. 
 
5.1.4 Serum stimulation 
 
Before serum stimulation, cells were washed twice with PBS and then serum-starved by 
adding the appropriate medium containing 0.2 % FBS for 16 h. After starvation, cells were 
stimulated for 2 h with 20 % FBS by directly adding the FBS to the starvation medium. 
 
5.1.5 Drug treatment 
 
Stimulants and inhibitors listed in table 14 were directly added to the medium of the seeded 
cells in the appropriate amount to obtain the final working concentration and the cells were 
incubated with the reagents for the adequate period of time. 
 
5.1.6 Transient siRNA mediated knockdown by Lipofectamine® RNAiMAX™ 
  
For transient knockdown of target gene expression by RNA interference (RNAi), cells were 
transfected with Lipofectamine® RNAiMAX™ by reverse transfection according to the 
manufacturer’s instructions. Briefly, in a 6 cm cell culture dish, 50 nM negative control or 
50 nM gene-specific small-interfering RNA (siRNA) and 10 µL Lipofectamine® RNAiMAX™ 
were incubated in 1 mL OptiMEM for 20 min at room temperature. Meanwhile, cells were 
trypsinized and pelleted by centrifugation for 5 min at 1000 rpm and room temperature. Cell 
pellet was resuspended in 10 mL OptiMEM and an adequate number of cells was diluted in 
3 mL OptiMEM and then added to the siRNA/RNAiMAX™ mix. Cells were incubated at 37 °C 
and 5 % CO2 overnight. The next day, transfection medium was removed and fresh culture 
medium containing FBS and antibiotics was added. Analysis of the target gene knockdown 
was assessed by quantitative real-time PCR (qRT-PCR) or western blot 48 h or 5 days post 
transfection for senescence experiments. Used siRNAs are listed in table 11. 
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5.1.7 Transient transfection by Lipofectamine® 2000 
 
For transient overexpression of plasmids, all cell lines, except for HepG2, were transfected 
with Lipofectamine® 2000 according to the manufacturer’s instructions. Therefore, cells were 
seeded in 6 cm culture dishes with culture medium without antibiotics 24 h before 
transfection. 4 µg of plasmid DNA and 5 µL Lipofectamine® 2000 were each incubated in 
250 µL OptiMEM for 5 min at room temperature. Then both transfection solutions were mixed 
and incubated for 20 min at room temperature. Transfection mix was added to cells and 
incubated at 37 °C and 5 % CO2. After 4-6 h, medium was replaced by fresh medium 
containing FBS and antibiotics. Cells were cultivated and further experiments were done 24 h 
post transfection.  
 
5.1.8 Transient transfection by GenJetTM transfection reagent 
 
For transient transfection of HepG2 cells, the GenJetTM transfection reagent was used 
according to the manufacturer’s instructions. Thus, cells were seeded in 6 cm culture dishes 
24 h before transfection in culture medium and 60 min before transfection, medium was 
replaced by fresh medium. Plasmid DNA and GenJetTM transfection reagent in a ratio of 1:3 
were each diluted in 250 µL medium without serum and then mixed. Transfection cocktail 
was added to cells and incubated at 37 °C and 5 % CO2. After 16 h, medium was replaced 
by fresh medium containing FBS and antibiotics.  
 
5.1.9 Calcium phosphate transfection method  
 
Cells were transfected with the calcium phosphate transfection method for transient 
transfection and overexpression of proteins. The day before transfection, cells were seeded 
and medium was replaced by fresh medium supplemented with FBS but without antibiotics 
2 h before transfection. For each 6-well, 2 µg of plasmid DNA and 3.5 µL CaCl2 (2 M) were 
mixed with sterile H2O for a total volume of 62.5 µL. This cocktail was added dropwise to an 
eppendorf tube with 62.5 µL 2x HBS while vortexing. After 5 min incubation at room 
temperature, cocktail was added to cells in 6-well plates. The next day, medium was 
replaced by fresh medium containing FBS and antibiotics.  
 
5 Methods	  
	   	  
	  
     51 
	  
	   	  
5.1.10 Cell proliferation assay 
 
For cell proliferation assays, 2.4 x 105 HepG2 cells or 1.2 x 105 of all other cell lines were 
seeded in 6-well plates and cultured at 37 °C and 5 % CO2. Cell number was counted at 24 h 
intervals for 4 to 6 days. 
 
5.1.11 Cell invasion assay 
 
Performing the cell invasion assay, cell culture inserts were placed in a 24-well plate and 
100 µL ECM matrigel solution (diluted 1:2 with cold DMEM) was placed into the inserts. After 
incubation of the plate at 37 °C for around 1 h, 600 µL DMEM with 10 % FBS were laid in the 
lower chamber, whereas 4 x 104 cells in 200 µL DMEM supplemented with 1 % FBS were 
placed into the upper chamber. Cells were allowed to invade through the matrigel due to the 
concentration gradient for around 24 h at 37 °C. The next day, invaded cells were stained by 
incubating the cell inserts in a crystal violet staining solution for 5 min, washing them 
with PBS and holding them afterwards into the destaining solution. Non-invasive cells were 
removed from top of the matrigel with cotton swabs. Images were taken at the Zeiss Axiovert 
40 CFL microscope and quantification of cells was carried out by counting the invasive, 
magenta-colored cells using the ZEN software.  
 
5.1.12 Senescence-associated ß-Galactosidase staining 
 
Cellular senescence was determined by using the Senescence ß-Galactosidase staining kit 
according to the manufacturer’s instructions. Cells were seeded and incubated at 37 °C and 
5 % CO2 for 5 days. Then cells were stained with staining solution and X-Gal and incubated 
overnight at 37 °C and 0 % CO2. The number of blue cells per 100 cells was counted and the 
percentage of SA-β-gal-positive cells was calculated. 
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5.2 Methods of protein analyses  
 
5.2.1 Protein isolation  
 
Adherent cells were washed twice with ice-cold 1x PBS and harvested with 80-150 µL 
Kralewski lysis buffer per 6 cm culture dish depending on the cell density. Cells were 
scrapped by a cell scraper and transferred to an eppendorf tube. Cells were lysed on ice for 
15 min. After centrifugation at 12700 rpm for 15 min at 4 °C, the clear supernatant was 
transferred to a new eppendorf tube. Lysates were kept on ice for further treatment or frozen 
at -20 °C. 
 
5.2.2 Measurement of protein concentration by Bradford assay 
 
For determination of the cell lysates protein concentration, 2 µL of the lysate or 2 µL of the 
Kralewski lysis buffer as control were given to 1 mL 1x Roti®-Quant. Solutions were 
incubated at room temperature for 5-10 min. Measurement was performed in UV-transparent 
cuvettes at the BioPhotometer at 595 nm. The amount of cell lysate for 10-30 µg protein for 
SDS-PAGE loading was calculated. 
 
5.2.3 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
 
SDS-PAGE was used for separating proteins in an electric field according to their molecular 
weight and their electrophoretic mobility. Determined amounts of cell lysates and 1/4 of the 
volume of 4x Laemmli SDS sample buffer were boiled at 95 °C for 10 min for protein 
denaturation. Samples were centrifuged at 12700 rpm for 1 min and then together with a 
protein ladder loaded onto a polyacrylamide gel. Protein separation was performed with 1x 
running buffer at 100 V constant for around 1:45 h until the dye front reached the end of the 
running gel. 
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5.2.4 Immunoblotting  
 
By SDS-PAGE resolved proteins were transferred to a polyvinylidene fluoride (PVDF) 
membrane, which was activated by methanol and equilibrated in transfer buffer before. The 
immunoblotting was performed at 350 mA constant for 1:15 h in transfer buffer while the 
blotting chamber was cooled with ice. Membrane was blocked in 5 % milk powder solution in 
TBS-T for 1 h for avoiding unspecific antibody binding and then 3 times washed with TBS-T 
for 5 min. Specific primary antibody in the appropriate dilution was added to the membrane 
and incubated at 4 °C overnight. The next day, membrane was washed 3 times with TBS-T 
for 15 min, incubated with the secondary antibody for 1 h at room temperature and then 
washed again 3 times with TBS-T for 5 min. TBS-T was replaced by TBS and membrane 
was incubated with 1.5 mL of each detection solution S1 and S2 for 1 min. Detection of 
proteins was performed via chemiluminescene at the luminescent imager Chemi-SmartTM 
5100. Analysis was done with the ChemiCapt™ and the ImageJ software. 
 
5.2.5 Agarose gel electrophoresis 
 
By using an agarose gel electrophoresis, DNA fragments were separated by size in an 
electric field. For a 1 % agarose gel, 1.5 g agarose were solved in 150 mL 1x TAE buffer 
while boiling the solution in a microwave. 7.5 µL Roti®-Safe GelStain and the agarose 
solution were added to the electrophoresis chamber. After curing of the gel, the chamber was 
filled with 1x TAE buffer and 1 µg DNA mixed with 6x DNA loading dye and also an 
appropriate ladder mixed with 6x DNA loading dye were filled in the slots. Gel was running at 
100 V for 1 h. For visualization of the DNA bands, the gel was photographed at the Infinity 
gel documentation imager and the bands were made visible with the Infinity software.  
 
5.2.6 Ras assay 
 
Ras activation indicated by the level of GTP-bound Ras was analysed by using the Active 
Ras Detection Kit according to the manufacturer’s instructions. Cells were seeded and after 
5 days, cells were harvested and lysed under nondenaturing conditions. Glutathione resin, 
the fusion protein GST-Raf1-RBD that binds the activated GTP-bound Ras and the cell 
lysate were added to a spin column and incubated at 4 °C for 1 h. After washing, activated 
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Ras was eluted with SDS buffer and heated for 5 min at 95 °C. Ras activation levels were 
determined by western blotting using a specific Ras antibody. 
 
5.2.7 Chromatin Immunoprecipitation (ChIP) 
 
4.5 x 106 cells per ChIP were seeded in cell culture flasks. The next day, adherent cells were 
cross-linked with 1% methanol-free formaldehyde and quenched with 0.125 M glycine. Nuclei 
were pelleted and lysed for 10 min on ice. After washings, lysates were sonicated four times 
for 30 sec into DNA fragments of 200-2000 bp. Sheared chromatin was immunoprecipitated 
with 15 µg anti-MKL1 or anti-FLNa antibody coupled to Dynabeads Protein G overnight at 
4 °C. A fraction (1%) of sonicated chromatin was set aside as input without antibody. After 
washings of immune complexes and elution of DNA of both input and ChIP samples using 
the MinElute PCR Purification Kit, qRT-PCR was performed using specific primers for target 
gene and GAPDH promoters for normalization. 
 
5.2.8 Immunofluorescence 
 
Cells were seeded on coverslips in 6-well plates and incubated at 37 °C and 5 % CO2 for 
48 h. Then cells were washed 3 times with 1 mL 1x PBS and fixed with 700 µL of 4% 
paraformaldehyde (PFA) in PBS for 10 min at room temperature. Cells were washed again 3 
times with 1 mL 1x PBS and mounted with Fluoromount on a slide. After drying, coverslips 
were sealed with nail polish. Slides were stored at 4 °C in the dark until images were taken at 
the microscope. 
 
 
5.3 Methods of nucleic acids analyses  
 
5.3.1 RNA isolation using TRIzol® reagent 
 
Adherent cells were washed twice with 5 mL 1x PBS and scrapped by a cell scraper after 
addition of 500 µL TRIzol® reagent. Cell suspension was transferred to an eppendorf tube, 
homogenized by pipetting up and down and incubated for 5 min at room temperature. 200 µL 
chloroform were added and suspension was shaken for 15 sec and incubated for 3 min at 
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room temperature. After centrifugation at 13000 rpm for 15 min at 4 °C, the upper clear 
phase that contains the RNA was transferred to a new eppendorf tube and 250 µL 
isopropanol were added. The solution was mixed, incubated for 15 min at room temperature 
and centrifuged at 13000 rpm for 15 min at 4 °C. The pellet was resuspended in 1 mL 
ethanol and centrifuged at 12000 rpm for 5 min at 4 °C. The supernatant was discarded and 
the pellet was dried for 10 min at room temperature, resuspended in 15 µL DEPC-H2O and 
heated to 55 °C for 10 min. RNA was stored at -80 °C. 
 
5.3.2 cDNA synthesis 
 
For transcribing RNA into cDNA, 1 µg RNA was mixed with 1 µL random hexamers (50 µM) 
and fulfilled with nuclease free H2O to 5 µL. Incubation took place at 70 °C for 5 min and then 
on ice for 5 min. Meanwhile, the following mix (table 36) was pipetted, added to the 
incubated solution and cDNA synthesis was performed in the FlexCycler2 using the 
SuperScript® II Reverse Transcriptase under the following conditions (table 37). 
 
 Table 36: Mix for cDNA synthesis                         Table 37: Reaction conditions for cDNA synthesis   
cDNA mix 
4 µL 5x First Strand Buffer 
2 µL DTT (0.1 M) 
1 µL dNTPs (10 mM) 
1 µL SuperScript
® II Reverse 
Transkriptase 
ad 15 µL nuclease free H2O 
   
All pipetting steps were performed on ice. cDNA was stored at -20 °C. 
 
5.3.3 Quantitative real-time polymerase chain reaction (qRT-PCR) 
 
For amplification and quantification of nucleic acids, a quantitative real-time polymerase 
chain reaction (qRT-PCR) was performed. 6 µL cDNA in a 1:10 dilution were placed in a 96-
well plate and 14 µL of the following qRT-PCR mix (table 38) with the respective target gene 
primers were added. mRNA expression was normalized to the endogenous housekeeping 
control gene 18S rRNA. Therefore, cDNA was diluted 1:100 before placing in the multiwell 
plate. The gene specific primers used for amplification are listed in tables 8 and 9. 
temperature time 
25 °C 5 min 
42 °C       60 min 
70 °C 5 min 
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          Table 38: Mix for qRT-PCR 
qRT-PCR mix 
10 µL LightCycler® 480 SYBR Green I Master 
1 µL primer forward (10 µM) 
1 µL primer reversed (10 µM) 
ad 14 µL nuclease free H2O 
 
The qRT-PCR was carried out at the LightCycler® 480 II under the following reaction 
conditions (table 39):  
 
                                   Table 39: Reaction conditions and temperature profile for qRT-PCR 
step temperature time cycles 
preincubation 42 °C 5:00 min 1 
denaturation 
amplification     
elongation 
95 °C 
55 °C 
72 °C	  
0:10 min 
0:10 min 
0:10 min	  
50 
melting curve 
analysis 
95 °C 
60 °C 
95 °C 
0:30 min 
1:00 min 
0:10 min 
1 
cooling 4 °C 0:30 min 1 
 
Analyses of the measurements were done by the LightCycler® 480 Software. The statistical 
evaluations and also the graphic illustrations were performed with GraphPad Prism 5. 
 
5.3.4 Transformation of DNA into bacteria 
 
DNA was transformed into bacteria via the heatshock method. First, competent bacteria, that 
were stored at -80 °C, were thawed on ice for 15 min and 50 µL bacteria suspension per 
reaction were transferred to a precooled eppendorf tube. 1 µL plasmid DNA was added and 
suspension was incubated 30 min on ice while thoroughly tipping the tube every 5 min. 
Heatshock was performed by holding the tube into a 42 °C waterbath for 90 sec and then for 
2 min on ice. 0.9 mL prewarmed LB medium was added and transferred to a tube with 
ventilation cap for incubation at 37 °C and 150 rpm for 1 h. Then 150 µL of the suspension 
were plated onto a LB plate with antibiotic before incubating the plate at 37 °C overnight for 
colony growing. 
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5.3.5 Plasmid preparation 
 
16 h before plasmid preparation, one bacteria colony grown on an agar plate was added with 
a pipette tip in an Erlenmeyer flask with 50 mL LB medium and 50 µL of the appropriate 
antibiotic (50 mg/ml), ampicillin or kanamycin, and incubated at 37 °C and gentle agitation. 
The next day, plasmid DNA was isolated by using the GenEluteTM HP Plasmid Midiprep Kit 
according to the manufacturer’s instructions. Briefly, the overnight culture was centrifuged at 
3500 rpm for 10 min at 4 °C. The pellet was resuspended, lysed and neutralized. After 
washing of the binding column, bacteria solution was added to the binding column, washed 
and finally eluted with 800 µL elution solution. Plasmid DNA was transferred to a precooled 
eppendorf tube and put on ice immediately. Plasmids were stored at -20 °C. 
	  
5.3.6 Generation of MKL1 and myoferlin (MYOF) mutants 
 
The MKL1 Δ301-310 bp deletion mutant and the MYOF Δ304-363 bp promoter deletion 
mutant were generated by using the Q5® Site-Directed Mutagenesis Kit according to the 
manufacturer’s instructions. Therefore, the P3x Flag MKL1 wt plasmid was used as template 
for the MKL1 deletion mutant and the 1500 bp myoferlin promoter construct expressed in 
pGL2 vector was used for the MYOF promoter deletion mutant. The mix shown in table 40 
containing the specific deletion primer pair was prepared. The amplification was carried out 
in the FlexCycler2 under the following conditions (table 41). 
 
 Table 40: Mix for mutagenesis PCR         Table 41: Reaction conditions for PCR 
	  
 
            
 
 
Q5® site-directed mutagenesis mix 
12.5 µL Q5
® Hot Start High-Fidelity 
2x Master Mix 
1.25 µL primer forward (10 µM) 
1.25 µL primer reversed (10 µM) 
1.00 µL template DNA (20 ng/µL) 
9.00 µL nuclease free H2O 
step temperature time cycles 
initial 
denaturation 98 °C 0:30 min 1 
denaturation 
amplification     
elongation 
98 °C 
58 °C 
72 °C	  
0:10 min 
0:20 min 
3:00 min	  
25 
final 
extension 72 °C 2:00 min 1 
cooling 4 °C ∞ 1 
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The PCR product was prepared for the KLD digest with the following reagents and incubated 
for 5 min at room temperature (table 42). 5 µL of the KLD mix were transformed into NEB® 5-
alpha competent E. coli bacteria by heatshock method and bacteria colonies were grown on 
LB plates with ampicillin at 37 °C overnight. 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Table 42: Mix for KLD digest 
KLD digest 
1 µL PCR product 
5 µL 2x KLD Reaction Buffer 
1 µL 10x KLD Enzyme Mix 
3 µL nuclease free H2O 
 
 
5.4 Luciferase assay 
 
For reporter gene assays, the Dual-Luciferase® Reporter Assay System was used according 
to the manufacturer’s instructions. Cells were transfected with 500 ng of a myoferlin promoter 
construct, 1 µg of an empty vector (pcDNA), the SRF-VP16 or the MKL1-N100 plasmid and 
250 ng of the Renilla luciferase simian virus 40 (SV40) plasmid as internal control. Cells were 
washed twice with 1x PBS and harvested with 70 µL 1x Passive Lysis Buffer 24 h post 
transfection. Cells were lysed on ice for 15 min and centrifuged for 1 min at top speed and 
4 °C. 5 µL of the supernatant was transferred to a glass tube. 20 µL LAR II and 20 µL 
Stop&Glo were added consecutively to the sample while the luciferase assay was performed 
at the Lumat³ LB 9508 Single Tube Luminometer. 
 
5.5 Statistical analysis 
 
Statistical analysis among two groups was performed using Student’s unpaired t-test. Unless 
otherwise indicated, data were analysed from three independent experiments and values are 
presented as mean and standard deviation (mean ± SD). P-values are *p<0.05, **p<0.01 and 
***p<0.001.	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6 Results 
 
6.1 MKL1/2 target gene expression in HCC cells 
 
6.1.1 Newly identified target genes are MKL1 and MKL2 dependent  
 
6.1.1.1 Transient knockdown of MKL1/2  
 
The first aim of this thesis was the validation of a performed microarray in HuH7 
hepatocellular carcinoma (HCC) control cells versus HuH7 cells with a stable MKL1/2 
knockdown and the verification of the newly found MKL1/2 dependent target genes by qRT-
PCR.  
By transfecting HuH7 HCC cells with MKL1/2 siRNA that is directed against MKL1 and MKL2 
at once, we obtained a knockdown efficiency of about 80% for MKL1 and around 65% for 
MKL2 (Fig. 13, top). For almost all newly in the microarray identified target genes, GLIPR1, 
TGFβ1, MAP1B and MYOF, but not for CNN1, we observed a strongly reduced mRNA 
expression upon transient knockdown of MKL1/2 (Fig. 13). The already known MKL1 and 
MKL2 target genes SM22 and MYH9 were also highly significantly downregulated, serving as 
a positive control of our experimental RNA interference (RNAi) approach. 
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Figure 13: Target gene expression upon transient MKL1/2 knockdown. HuH7 cells were transfected with 
negative control (ctrl) or MKL1/2 siRNA. mRNA expression was assessed by qRT-PCR using the respective gene 
specific primers and 18S rRNA primers for normalization. Values are mean ± SD (n=3); *p<0.05, **p<0.01, 
***p<0.001. 
	  
 
The same transient knockdown using MKL1/2 siRNA was performed in HuH6 (Fig. 14A) and 
HepG2 (Fig. 14B) hepatocellular carcinoma cells. In both cell lines, the MKL1 expression 
was reduced by around 70% in the MKL1/2 knockdown cells compared to the control cells. 
The new target genes GLIPR1 and CNN1 and also the known target genes SM22 and MYH9 
as positive controls were significantly downregulated upon MKL1/2 knockdown. This way, we 
could show that the expression of the target genes found by microarray analysis are also 
MKL1/2 dependent in HuH6 and HepG2 cells concluding that this dependency is not only cell 
line specific but rather a general finding in HCC cell lines. 
 
0.0
0.5
1.0
1.5
0.0
0.5
1.0
1.5
0.0
0.5
1.0
1.5
0.0
0.5
1.0
1.5
0.0
0.5
1.0
1.5
SM
22
 m
R
N
A 
HuH7    
ctrl       
HuH7 
siMKL1/2       
G
LI
PR
1 
m
R
N
A 
* 
HuH7    
ctrl       
HuH7 
siMKL1/2       
C
N
N
1 
m
R
N
A 
0
1
2
3 * 
HuH7    
ctrl       
HuH7 
siMKL1/2       
M
YH
9 
m
R
N
A 
HuH7    
ctrl       
HuH7 
siMKL1/2       
TG
F!
1 
m
R
N
A 
** 
HuH7    
ctrl       
HuH7 
siMKL1/2       
M
A
P1
B
 m
R
N
A 
HuH7    
ctrl       
HuH7 
siMKL1/2       
M
YO
F 
m
R
N
A 
HuH7    
ctrl       
HuH7 
siMKL1/2       
*** 
0.0
0.5
1.0
1.5
*** * 
0.0
0.5
1.0
1.5
*** 
0.0
0.5
1.0
1.5
M
K
L1
 m
R
N
A 
* 
HuH7    
ctrl       
HuH7 
siMKL1/2       
M
K
L2
 m
R
N
A 
HuH7    
ctrl       
HuH7 
siMKL1/2       
* 
6 Results	  
	   	  
	  	  
     61 
	  
	   	  
	  
Figure 14: Target gene downregulation upon MKL1/2 depletion in HuH6 and HepG2 cells. mRNA 
expression of the indicated target genes in (A) HuH6 and (B) HepG2 ctrl and siMKL1/2 cells was measured by 
qRT-PCR. Values are mean ± SD (n=3); **p<0.01, ***p<0.001. 
 
 
6.1.1.2 Knockdown of MKL1 or MKL2 alone or in combination 
 
Next, we investigated the role of MKL1 and MKL2 siRNA alone or in combination in HuH7 
cells. The MKL1 siRNA had a knockdown efficiency of nearly 90% and the MKL2 siRNA of 
80% (Fig. 15A, top). All target genes, except for TGFβ1, showed a strongly reduced mRNA 
expression upon a single MKL1 knockdown and also all genes a reduced mRNA expression 
upon a single MKL2 knockdown (Fig. 15A). The expression levels of the genes after single 
siRNA treatment were comparable to those of the combined knockdown of both MKL1 and 
MKL2 siRNA. The mRNA expression of SRF as target gene of MKL1/2 itself was also 
affected by MKL1 and MKL2 siRNA (Fig. 15A). Furthermore, we also observed a significant 
reduction of GLIPR1 protein expression in HuH7 siMKL1 and HuH7 siMKL2 single 
knockdown and also in HuH7 siMKL1+2 cells compared to control cells (Fig. 15B). Regarding 
these results, we could show for the first time that MKL1 and MKL2 siRNA alone are very 
efficient and sufficient for target gene downregulation and that a double knockdown of both 
MKL1 and MKL2 is not necessary.  
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Figure 15: MKL1 or MKL2 knockdown is sufficient for target gene downregulation. (A) HuH7 cells were 
transfected with negative control (ctrl), MKL1, MKL2 or the combination of MKL1 and MKL2 siRNAs. mRNA 
expression of target genes was analysed by qRT-PCR using the respective gene specific primers and 18S rRNA 
primers for normalization. Values are mean ± SD (n=3); *p<0.05, **p<0.01, ***p<0.001. (B) Lysates of HuH7 cells 
transfected as in (A) were immunoblotted with anti-GLIPR1, anti-MKL1 and anti-HSP90 antibodies as loading 
control. 
 
 
6.1.2 Mutual dependence of MKL1 and MKL2 in HCC cell lines  
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cells (Fig. 15A, top), we tried to confirm these findings in HuH6 (Fig. 16A) and HepG2 
(Fig. 16B) cells. In both cell lines, we could observe the same result as in HuH7 cells. The 
MKL1 knockdown resulted in reduced protein (Fig. 16A) and mRNA (Fig. 16B) expression 
levels of MKL2 and the other way around. This result explains also why a single knockdown 
of MKL1 or MKL2 was sufficient for target gene downregulation and no combination of both 
siRNAs was needed. 
 
	  
Figure 16: Mutual dependence of MKL1 and MKL2 in HCC cells. (A) HuH6 cells were transfected with 
negative control, MKL1 or MKL2 siRNA. Lysates were immunoblotted with anti-MKL1, anti-MKL2 and anti-HSP90 
antibodies as loading control. (B) MKL1 and MKL2 mRNA expression of HepG2 cells transfected as in (A) was 
determined by qRT-PCR. Values are mean ± SD (n=3); *p<0.05, ***p<0.001. 
	  
 
In order to demonstrate that the given results of MKL1/2 target gene downregulation and 
mutual dependence of MKL1 and MKL2 in HCC cell lines are not only an effect of unspecific 
binding and a crossreactivitiy of the used siRNAs, we used second variants of MKL1 and 
MKL2 siRNAs that are directed against another sequence of MKL1 and MKL2 mRNA. The 
siRNA mediated silencing of MKL1 or MKL2 in HuH7 cells with these second variants of 
siRNA (siRNA V2) showed a good knockdown efficiency and also a mutual dependence of 
MKL1 and MKL2 where MKL1 knockdown reduced the MKL2 mRNA expression and vice 
versa (Fig. 17A). We also observed a downregulation of the new target genes, like GLIPR1 
and CNN1 upon MKL1 knockdown and a downregulation of SM22 and MYOF upon MKL2 
knockdown (Fig. 17B). Summing up the results of the RNAi experiments described above 
and the demonstration of the specificity of MKL1 and MKL2 downregulation, we can 
postulate the discovery of 6 new MKL1 and MKL2 dependent target genes functioning as 
possible mediators of the effects of MKL1/2 on HCC growth arrest and senescence induction 
(Hampl et al., 2013). 
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Figure 17: MKL1 or MKL2 knockdown by second variants of MKL1 and MKL2 siRNA. HuH7 cells were 
transfected with negative control or a second variant of MKL1 or MKL2 siRNA. Knockdown efficiency of MKL1 
and MKL2 (A) and mRNA expression of GLIPR1, CNN1, SM22 and MYOF (B) were subjected to qRT-PCR. 
Values are mean ± SD (n=3); **p<0.01, ***p<0.001.  
 
 
6.1.3 Regulation of newly identified target genes upon stimulant or inhibitor treatment 
 
After demonstrating the dependency of the target genes on MKL1 and MKL2, we next 
focused our interest on the influence of stimuli or inhibitors on gene expression of the newly 
identified target genes. Since MKL1 is activated via the Rho/actin signaling axis (Miralles et 
al., 2003 and Muehlich et al., 2008), we wanted to focus our next experiments on the direct 
effect of stimulating or inhibiting reagents on the target gene level. 
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6.1.3.1 Inhibition of target genes upon LatB treatment   
 
The first extracellular inhibitor whose role on target gene expression we investigated was 
Latrunculin B (LatB). LatB is still known as an actin polymerization inhibitor and prevents 
filamentous F-actin polymerization from monomeric G-actin by binding to G-actin monomers 
(Yarmola et al, 2000). Performing qRT-PCR analysis, we found a significantly reduced gene 
expression of the transcription factor SRF and also of the MKL1/2 target genes SM22, 
CNN1, GLIPR1, MYH9 and MYOF upon LatB treatment of the cells (Fig. 18).  
	  
Figure 18: Downregulation of target genes upon LatB treatment. SRF and target gene mRNA expression of 
A7 cells treated with or without 0.3 µM LatB for 45 min was analysed by qRT-PCR with SRF, SM22, CNN1, 
GLIPR1, MYH9, MYOF and 18S rRNA primers for normalization. Values are mean ± SD (n=3 for SRF, SM22 and 
CNN1); **p<0.01, ***p<0.001. 
 
 
6.1.3.2 Stimulation of target genes upon serum (FBS) treatment   
 
In contrast to the LatB induced target gene inhibition we next assessed the role of serum, in 
detail fetal bovine serum (FBS) treatment on gene expression. Serum acting on the 
Rho/actin signaling pathway has been shown to increase the actin polymerization from 
monomeric G-actin to filamentous F-actin leading to nuclear localization of MKL1 (Miralles et 
al., 2003). As expected, FBS treatment of NIH 3T3 fibroblast and HepG2 hepatocellular 
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carcinoma cells having cytoplasmic MKL1 under unstimulated conditions showed a 
stimulatory effect on gene expression (Fig. 19). SRF itself, SM22 and CNN1 expression is 
induced in NIH 3T3 (Fig. 19A) and HepG2 (Fig. 19B) cells upon serum stimulation confirming 
the known mechanism of MKL1 translocation into the nucleus, its activation of SRF and 
therefore enhanced target gene transcription. 
Figure 19: Increased target gene expression upon serum (FBS) stimulation. NIH 3T3 (A) and HepG2 (B) 
cells were serum-starved for 16 h and then stimulated with 20% FBS for 2 h. mRNA expression of SRF, SM22 
and CNN1 was analysed by qRT-PCR. 
 
 
6.1.3.3 Stimulation of target genes upon LPA treatment   
 
As additional stimulation of cells and as an active component of serum we analysed the role 
of lysophosphatidic acid (LPA) on gene expression. LPA is a potent signaling molecule 
involved in the alteration of many cellular processes and enhances, similar to serum, actin 
polymerization into F-actin filaments (Muehlich et al., 2004 and Lin et al., 2010). In this 
experiment, we found SRF and many target genes upregulated by LPA stimulation in HepG2 
(Fig. 20A) and MCF7 cells (Fig. 20B) and also in human primary fibroblasts (Fig. 20C) all 
showing MKL1 in the cytoplasm in an unstimulated status.  
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Figure 20: Upregulation of target genes upon LPA treatment. HepG2 (A), MCF7 (B) and primary human 
fibroblasts (C) were serum-starved for 16 h and then stimulated with 10 µM LPA for 2 h. mRNA expression of the 
indicated genes was analysed by qRT-PCR. Values are mean ± SD (n=3 for HepG2); **p<0.01, ***p<0.001. 
 
 
6.1.3.4 Stimulation of target genes upon CytoD treatment   
 
Following the target gene inhibition by LatB and the stimulation by FBS and LPA, we next 
focused on the gene expression alteration due to Cytochalasin D (CytoD) treatment. 
Performed qRT-PCR analyses revealed a strong stimulatory effect on target gene mRNA 
expression in different cell lines, namely NIH 3T3, HepG2, HLF and MCF7 (Fig. 21A-D), all 
having MKL1 in the cytoplasm under untreated conditions.  
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Figure 21: Upregulation of target gene expression upon CytoD treatment in cell lines with cytoplasmic 
MKL1. NIH 3T3 (A), HepG2 (B), HLF (C) and MCF7 (D) cells were treated with 2 µM CytoD for 2 h and mRNA 
expression of the indicated genes was determined by qRT-PCR using the gene specific primers and 18S rRNA 
primers for normalization. 
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In contrast to the shown stimulating effect of CytoD, treatment of HuH7 and MDA-MB 468 
cells with CytoD revealed no or only modest effects on target gene expression (Fig. 22A-B). 
These two cell lines still own nuclear MKL1 due to their deficiency in DLC1 (Muehlich et al., 
2012) and therefore have activated SRF and constant high levels of target gene expression 
explaining why stimulation with CytoD doesn’t result in enhanced gene expression. 
 
	  
Figure 22: CytoD treatment has nearly no effect on target gene expression in cell lines with nuclear MKL1. 
HuH7 (A) and MDA-MB 468 (B) cells were treated with 2 µM CytoD for 2 h. mRNA expression of the indicated 
genes was analysed by qRT-PCR.  
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6.2 FLNa as novel binding partner of MKL1 
 
In a recent study of our group, we identified a new interaction partner for MKL1, the Filamin A 
(FLNa) protein (Kircher et al., 2015). We therefore analysed the requirement of the MKL1-
FLNa interaction for the expression of the newly identified target genes and tested the 
dependency of the novel MKL1/2 target genes on FLNa. 
 
6.2.1 The effect of MKL1/2 in A7 cells 
 
We performed all the following experiments in A7 melanoma cells constitutively expressing 
FLNa or in FLNa deficient M2 melanoma cells. Both cell lines were dominantly used for 
experiments showing the interaction of FLNa and MKL1 in the study of Kircher et al. (2015) 
and thus we first investigated the role of MKL1/2 in A7 cells expressing FLNa additionally to 
the experiments in HCC cell lines shown above. 
 
6.2.1.1 MKL1/2 target gene downregulation upon MKL1/2 knockdown in A7 cells 
 
We first focused on the MKL1/2 dependent target genes and looked for their responsiveness 
to MKL1/2 knockdown in A7 melanoma cells. qRT-PCR experiments revealed a good 
knockdown efficiency for MKL1 and MKL2 and also a strong downregulation of the target 
genes SM22, GLIPR1, CNN1, MAP1B and MYH9 (Fig. 23). Also the expression of FLNa, the 
novel binding partner of MKL1, was strongly decreased (Fig. 23) showing the direct influence 
of MKL1/2 on the FLNa expression. 
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Figure 23: Downregulation of FLNa and MKL1/2 target genes upon MKL1/2 knockdown in A7 cells. A7 cells 
were transfected with negative control or MKL1/2 siRNA and mRNA expression was measured by qRT-PCR 
using the gene specific primers. Values are mean ± SD (n=2). 
 
 
Additionally, we assessed the role of a single MKL1 knockdown on target gene regulation. 
We obtained a good knockdown efficiency by using MKL1 siRNA and also observed reduced 
MKL2 and FLNa mRNA levels in the knockdown cells (Fig. 24, top). Here we found the same 
phenomenon like in HCC cells showing a mutual dependence of MKL1 and MKL2 where a 
depletion of MKL1 results also in decreased MKL2 expression. The FLNa mRNA expression 
was also strongly reduced after the single MKL1 knockdown demonstrating the relevance of 
MKL1 expression for FLNa once again (Fig. 24, top). Also the target genes MAP1B and an 
already known and characterized target gene of MKL1, the connective tissue growth factor 
(CTGF) (Muehlich et al., 2007), were downregulated by MKL1 depletion (Fig. 24, bottom) 
pointing out an important role for MKL1 in the regulation of target genes in melanoma cells. 
We also looked for the endogenous expression levels of MKL1 and MKL2 in A7 cells and 
observed much higher mRNA expression levels of MKL1 compared to MKL2 mRNA 
expression (Fig. 24 bottom, right) also explaining that a single MKL1 knockdown suffices for 
target gene downregulation and that a knockdown of both MKL1 and MKL2 is not required in 
A7 cells. 
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Figure 24: Downregulation of FLNa, MAP1B and CTGF upon MKL1 knockdown in A7 cells. MKL1 
knockdown efficiency and MKL2, FLNa, MAP1B and CTGF mRNA expression of A7 ctrl and A7 siMKL1 were 
analysed by qRT-PCR. Values are mean ± SD (n=2). Also the mRNA expression levels of MKL1 and MKL2 in A7 
cells were investigated by qRT-PCR. 
 
 
6.2.1.2 Knockdown of MKL1/2 leads to proliferation arrest and senescence in A7 cells 
 
After showing a dependence of the target gene expression on MKL1 and MKL2 in A7 
melanoma cells, we also performed a proliferation assay for further characterization of A7 
cells. We therefore transiently depleted MKL1/2 via RNAi and compared the proliferation 
properties of A7 control and A7 siMKL1/2 cells. This assay revealed a strongly inhibited cell 
proliferation of cells lacking MKL1/2 expression (Fig. 25).  
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Figure 25: MKL1/2 siRNA leads to proliferation arrest in A7 cells. A7 cells were transfected with negative 
control or MKL1/2 siRNA and counted daily for 4 days. 
 
 
Since in MKL1+2 depleted HCC cells the reduced proliferation rates were due to oncogene-
induced senescence, we also tested the senescence induction of A7 cells with MKL1+2 
knockdown. Performing senescence associated β-galactosidase staining, we observed a 
potent increase of senescent A7 cells upon MKL1+2 knockdown (Fig. 26, left). Also a single 
knockdown of MKL1 alone was sufficient for senescence induction in A7 cells very similar to 
the amount of senescent cells with a knockdown of both MKL1 and MKL2 (Fig. 26, right).  
 
	  
Figure 26: Senescence induction upon MKL1+2 and MKL1 siRNA in A7 cells. Senescence associated β-
galactosidase staining was performed in A7 ctrl and A7 siMKL1+2 (left) and siMKL1 (right) cells. Numbers of SA-
β-gal positive cells were counted. Values are mean ± SD (n=3); *p<0.05, **p<0.01. 
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Based on these results that MKL1 and/or MKL2 contribute to cell proliferation and 
senescence induction also in melanoma cells thereby recapitulating the results shown in 
HCC cells above we could demonstrate that senescence induction is a general phenomenon. 
 
 
6.2.2 Impact of FLNa on target gene expression  
 
6.2.2.1 Newly identified target genes are FLNa dependent  
 
Another aim of this thesis was to demonstrate the dependency of the newly identified 
MKL1/2 target genes on FLNa in different cell lines. Therefore, we introduced FLNa siRNA 
into HepG2 hepatocellular carcinoma cells, MDA-MB 468 mammary carcinoma cells, A7 
melanoma cells and NIH 3T3 fibroblasts (Fig. 27A-D) and found strongly reduced target gene 
mRNA expressions as well as a good knockdown efficiency of FLNa itself. We can conclude 
that the MKL1/2 dependent target genes are not only MKL1/2 dependent but also FLNa 
dependent and thus, FLNa was shown to be essential for MKL1 transcriptional activity. 
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Figure 27: Target gene downregulation upon FLNa knockdown in different cell lines. HepG2 (A), MDA-MB 
468 (B), A7 (C) and NIH 3T3 (D) cells were transfected with negative control or FLNa siRNA. Knockdown 
efficiency of FLNa and mRNA expression of the indicated genes were analysed by qRT-PCR and normalized to 
18S rRNA expression levels. Values are mean ± SD (n=3); *p<0.05, **p<0.01, ***p<0.001. 
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6.2.2.2 Target gene upregulation upon MKL1 S454A expression  
 
To give further mechanistic insights into the activation of target genes by MKL1 and the 
influence of FLNa expression, we transfected A7 cells with MKL1 wt or the MKL1 S454A 
plasmid, bearing a mutation in the phosphorylation site of MKL1 preventing MKL1 from being 
phosphorylated. This way, we found increased SRF and GLIPR1 expression levels upon 
MKL1 wt expression compared to the endogenous levels of MKL1 in A7 cells (Fig. 28). 
Furthermore, we still observed an even stronger induction of SRF and GLIPR1 expression 
upon MKL1 S454A mutant overexpression (Fig. 28) suggesting that MKL1 becomes 
constitutively active due to reduced phosphorylation and therefore stronger activates the 
target gene expression. The same effect of increased target gene expression with the MKL1 
S454A mutant compared to the MKL1 wt expression was detectable in A7 cells silenced of 
FLNa by siRNA, in which however the total amount of SRF and GLIPR1 expression was 
much less than in the FLNa expressing cells (Fig. 28) suggesting an important role for FLNa 
also in the presence of activated MKL1. 
 
	  
Figure 28: Increased mRNA expression of SRF and GLIPR1 upon MKL1 S454A overexpression. A7 ctrl and 
A7 siFLNa cells were transfected with MKL1 wt or the MKL1 S454A mutant. SRF and GLIPR1 mRNA expression 
was assessed by qRT-PCR. 
 
	  
 
 
	  
0
1
2
3
4
5
A7 A7 +  
MKL1 
 wt  
A7 +  
MKL1 
S454A  
SR
F 
m
R
N
A 
A7 +  
MKL1 
 wt  
A7 +  
MKL1 
S454A  
0
2
4
6
8
10
G
LI
PR
1 
m
R
N
A 
A7 A7 +  
MKL1 
 wt  
A7 +  
MKL1 
S454A  
A7 +  
MKL1 
 wt  
A7 +  
MKL1 
S454A  
siFLNa! siFLNa!
6 Results	  
	   	  
	  	  
     77 
	  
	   	  
6.2.2.3 Enhanced target gene expression upon constitutive active MKL1 in the presence of 
FLNa 
 
Beside the described important role of FLNa existence for a stronger target gene 
upregulation, also in the context of constitutively active MKL1, we further wanted to analyze 
the FLNa dependency of MKL1-induced target gene expression. For comparing the effects 
obtained by FLNa presence or absence, we used the FLNa expressing cell line A7 and the 
FLNa deficient cell line M2. We overexpressed the MKL1 wildtype (wt) or a constitutively 
active and siRNA resistant form of MKL1, the MKL1 N100 mutant, in A7 control cells and A7 
cells with FLNa knockdown (siFLNa) and also in M2 cells and verified the mRNA expression 
levels of the target genes SM22 and GLIPR1 by qRT-PCR analysis. SM22 as well as 
GLIPR1 expressions were significantly upregulated upon constitutive active MKL1 
expression in A7 control cells (Fig. 29). In contrast, the induction of SM22 and GLIPR1 upon 
MKL1 N100 overexpression in FLNa lacking cells showed only modest effects compared to 
the MKL1 wt expression and also compared to the strong gene induction in A7 control cells 
(Fig. 29). This experiment underscores the importance of FLNa presence for MKL1/2 
dependent target gene expression.	  
	  
 
Figure 29: Target gene downregulation in FLNa deficient cells upon MKL1 N100 overexpression. SM22 
and GLIPR1 mRNA expressions in A7 ctrl, A7 siFLNa and M2 cells either transfected with MKL1 wt or MKL1 
N100 mutant were analysed by qRT-PCR using SM22, GLIPR1 and 18S rRNA primers. Values are mean ± SD 
(n=3); *p<0.05, **p<0.01. 
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6.2.3 Generation of MKL1 mutants lacking FLNa binding 
 
After confirming the relevance of FLNa presence for MKL1 activation and subsequently 
target gene expression, we wanted to figure out the effect of FLNa nonbinding mutants on 
MKL target gene expression. By a recent study of our group, the MKL1 mutant lacking the 
amino acids 301-342 (MKL1 Δ301-342) was found to be essential for FLNa binding (Kircher 
et al., 2015). To prove the effect of this mutant on the target gene induction, we performed 
qRT-PCR analysis in A7 control cells and A7 cells overexpressing the MKL1 wt and the 
MKL1 Δ301-342 mutant. Beside a strong MKL1 induction upon overexpression of MKL1 wt, 
SM22 and GLIPR1 were, as expected, strongly upregulated in cells expressing the MKL1 wt 
plasmid (Fig. 30). However, mRNA expression of SM22 and GLIPR1 in A7 cells with 
overexpressed MKL1 Δ301-342 was significantly reduced compared to the cells expressing 
MKL1 wt (Fig. 30) showing that FLNa binding to MKL1 is essential for target gene 
expression. 
	  
Figure 30: Reduced target gene expression upon overexpression of MKL1 deletion mutant Δ301-342. A7 
cells were transfected with empty vector (ctrl), MKL1 wt or the MKL1 deletion mutant Δ301-342 for 24 h. mRNA 
expression of MKL1, SM22 and GLIPR1 was measured by qRT-PCR with MKL1, SM22, GLIPR1 and 18S rRNA 
primers for normalization. Values are mean ± SD (n=3); *p<0.05, **p<0.01, ***p<0.001. 
 
 
For postulating a more precise binding site sequence of FLNa on MKL1, we generated MKL1 
mutants deleted of only the amino acids 301-310 and overexpressed this mutant or the 
MKL1 wt in A7 cells. Again, we found strongly increased levels of MKL1, SM22 and CTGF 
expression in A7 cells with overexpressed MKL1 wt (Fig. 31) but overexpression of MKL1 
Δ301-310 strongly decreased the induced mRNA expression of target genes observed upon 
MKL1 wt expression. 
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Figure 31: Reduced target gene expression upon overexpression of MKL1 deletion mutant Δ301-310. 
mRNA expression of MKL1, SM22 and CTGF in A7 cells overexpressing an empty vector (ctrl), MKL1 wt or the 
MKL1 deletion mutant Δ301-310 was analysed by qRT-PCR as described above. Values are mean ± SD (n=2). 
 
 
6.2.4 Direct recruitment of FLNa to promoters 
 
To further investigate the role of FLNa in activating target genes, we performed chromatin 
immunoprecipitation (ChIP) analysis with a specific FLNa antibody for pulldown in both A7 
and M2 cells. CTGF and actin promoters were strongly amplified from FLNa 
immunoprecipitates whereas GAPDH serving as negative control doesn’t show induced 
promoter occupancy in A7 cells (Fig. 32). This enrichment of CTGF and actin was only 
observable in A7 but not in M2 cells (Fig. 32) concluding that FLNa directly controls the 
target gene and actin expression by binding to its promoters. 
 
	  
Figure 32: FLNa recruitment to the CTGF and actin promoters. ChIP was performed using a specific FLNa 
antibody for immunoprecipitation in FLNa-expressing A7 and FLNa-deficient M2 cells and specific primers for 
CTGF (left), actin (right) and GAPDH promoters for qRT-PCR. Values are mean ± SD (n=3); *p<0.05, **p<0.01. 
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6.2.5 Influence of actin expression  
 
6.2.5.1 Increased target gene expression upon mDiact expression 
 
In the last part of this chapter, we further analysed the impact of actin on FLNa and thus the 
target gene expression. We overexpressed for the following approaches the FLNa wt and/or 
mDiact, a protein of the formin family and Rho effector that is a constitutively active variant of 
mDia1 being predominantly located in the nucleus, in M2 or A7 cells and monitored gene 
expression by qRT-PCR analysis. Since mDiact interacts with the barbed ends of actin it 
accelerates the actin nucleation and elongation of G-actin into F-actin (Watanabe et al., 1999 
and Baarlink et al., 2013). M2 cells with overexpressed FLNa showed, as expected, a strong 
induction of FLNa and GLIPR1 (Fig. 33) but a much stronger induction of GLIPR1 expression 
was obtained by transfection with FLNa wt and mDiact in parallel (Fig. 33).  
 
	  
Figure 33: Increased GLIPR1 mRNA expression upon FLNa and mDiact overexpression. M2 cells were 
transfected with mDiact and/or FLNa wt. mRNA expression of FLNa and GLIPR1 was determined by qRT-pCR. 
Values are mean ± SD (n=3 for GLIPR1); *p<0.05, **p<0.01. 
 
 
Similar to the experiments performed in M2 cells, we overexpressed mDiact in A7 cells still 
expressing FLNa and observed higher mRNA expression rates of the transcription factor 
SRF and the target genes SM22, GLIPR1 and CTGF (Fig. 34). Underlying these results, 
mDiact seems to provoke enhanced mRNA expression by actin nucleation and F-actin 
formation in the presence of FLNa. 
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Figure 34: Increased target gene expression upon mDiact overexpression. mRNA expression of A7 cells 
transfected with or without mDiact was analysed by qRT-PCR. Values are mean ± SD (n=2). 
 
 
 
6.3 The target gene myoferlin 
 
Based on the performed microarray and the identified 8 target genes strongly depending on 
MKL1/2 expression, we had to choose one of these genes that may mediate the effects of 
MKL1/2 on reduction of tumorigenesis and senescence induction. The identified target gene 
myoferlin (MYOF) showed the strongest downregulation in HCC xenografts after MKL1/2 
siRNA treatment (Hermanns et al., 2017) and also plays an important role in mammary 
carcinoma cells as reported in a recent study (Turtoi et al., 2013). We therefore focused in 
this thesis on the transmembrane protein myoferlin to get a deeper insight into the 
mechanism of the MKL1/2 mediated effects on cell signaling pathways and essential 
biological processes, such as cell proliferation, cell migration and cell invasion. 
 
 
6.3.1 Characterization of myoferlin 
 
First of all, we had to characterize myoferlin in greater detail especially in the context of 
hepatocellular carcinoma and had a look at the signaling pathways of myoferlin activation 
and regulation. In Fig. 13 and Fig. 15 we demonstrated that MYOF is directly depending on 
the MKL1 and MKL2 expression levels where a knockdown of MKL1 and/or MKL2 resulted in 
strongly reduced levels of MYOF mRNA expression.  
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6.3.1.1 Myoferlin expression is enhanced upon stimulation 
 
To show that MYOF is regulated by the RhoA-actin signaling pathway, we serum-starved 
HuH7 and MDA-MB 468 cells for 16 h and then stimulated them with FBS (serum), 
lysophosphatidic acid (LPA), Cytochalasin D or Jasplakinolide. In both cell lines we found 
increased myoferlin expression levels upon treatment with the mentioned stimulants (Fig. 35) 
indicating that MYOF is directly regulated by this agents and activated by the RhoA signaling 
pathway. 
 
Figure 35: Myoferlin expression is upregulated upon stimulants. HuH7 cells were serum-starved for 16 h and 
then stimulated with 20 % FBS (serum) or 10 µM LPA for 2 h (A) and MDA-MB 468 cells were treated with 20 % 
FBS (serum), 10 µM LPA, 2 µM Cytochalasin D or 0.5 µM Jasplakinolide (B). Lysates were immunoblotted with 
anti-MYOF and anti-HSP90 antibodies. 
 
 
6.3.1.2 MKL1 and SRF bind to the myoferlin promoter 
 
Next, we generated various MYOF promoter constructs and investigated the role of MKL1 
and SRF on MYOF expression as direct transcriptional regulators and performed reporter 
gene assays with these different MYOF promoter constructs (Fig. 36A). The activity of the 
indicated MYOF promoter constructs was measured due to the overexpression of the 
constitutively active forms of SRF, SRF-VP16, and MKL1, MKL1 N100. The activity of the 
900 bp promoter construct but not of the 200 bp promoter construct was increased by 
expression of SRF-VP16 and also MKL1 N100 (Fig. 36B). We also generated a promoter 
deletion mutant that lacks a CArG box between the basepairs 304-363 (MYOF Δ304-363) 
and found that the activity of this promoter construct was not activated by MKL1 N100 
expression anymore. This way, we can assume that MYOF is directly activated by either 
SRF or MKL1 and that SRF and MKL1 bind the CArG box of the myoferlin promoter between 
the 200 - 900 bp segment. 
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Figure 36: The 900 bp promoter construct of myoferlin is activated by SRF and MKL1. (A) Promoter 
constructs of MYOF used in reporter gene assays. (B) Luciferase assays in HEK293T cells transfected with 
empty vector (ctrl), SRF-VP16 or MKL1-N100 vector together with a 200 bp, a 900 bp or a MYOF promoter 
deletion construct (Δ304-363) and a pRLSV40 Renilla luciferase construct. Values are mean ± SD (n=3); *p<0.05, 
**p<0.01, ***p<0.001. 
 
To validate this concept of MYOF activation we performed a chromatin immunoprecipitation 
(ChIP) assay with MKL1 pulldown. The α-smooth muscle actin (α-SMA) promoter that serves 
as positive control and the MYOF promoter itself were strongly amplified by MKL1 as 
compared to the control GAPDH promoter (Fig. 37A, left). Also the other negative control, an 
upstream site in the MYOF promoter (MYOF 1167), showed no enrichment by MKL1 
(Fig. 37A, left). Next, we tested whether the MYOF promoter amplification was inducible by 
stimulation. Here we found that the MYOF promoter was stronger amplified by MKL1 upon 
LPA treatment of the cells (Fig. 37A, right), being in accordance to the results obtained in 
Fig. 35. We also investigated the role of FLNa, the novel MKL1 interaction partner, on the 
MYOF promoter occupancy. Thus, we performed the ChIP assay additionally in FLNa 
expressing A7 and FLNa-deficient M2 cells with FLNa pulldown and observed that the MYOF 
promoter was only amplified in A7 but not in M2 cells compared to the GAPDH control 
promoter (Fig. 37B). Based on these experiments we could show the direct recruitment of 
MKL1 and FLNa to the MYOF promoter and therefore the direct transcriptional regulation of 
MYOF. 
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Figure 37: MKL1 and FLNa recruitment to the myoferlin promoter. (A) ChIP was performed using a specific 
antibody against MKL1 for immunoprecipitation and specific primers for α-SMA, MYOF and GAPDH promoters for 
qRT-PCR. As an additional negative control, primers spanning an upstream site in the myoferlin promoter (MYOF 
1167) were used (left). Values are mean ± SD (n=3); *p<0.05, ***p<0.001. ChIP was also performed in serum-
starved and LPA (10 µM) stimulated cells for 2 h (right). (B) ChIP assay with a specific FLNa antibody in FLNa-
expressing A7 and FLNa-deficient M2 cells. Values are mean ± SD (n=3); *p<0.05. 
 
 
6.3.2 Myoferlin expression in vivo  
 
In order to show also the in vivo contribution of MYOF in hepatocellular carcinoma, we 
thankfully obtained RNA samples and protein lysates isolated from SRF-VP16iHep mice 
(Ohrnberger et al., 2015) from Prof. Alfred Nordheim (University of Tuebingen, Tuebingen, 
Germany). These mice express the constitutively active SRF-VP16 in hepatocytes resulting 
in hyper proliferative premalignant nodules that rapidly develop to lethal HCC tumors. 
Importantly, MYOF mRNA (Fig. 38A) and protein (Fig. 38B) expression was upregulated in 
the nodule tissue and even stronger upregulated in the tumor tissue indicating an important 
role for MYOF in HCCs and the in vivo relevance of MYOF.  
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Figure 38: Myoferlin is upregulated in murine HCCs. MYOF mRNA (A) and protein (B) expression in control, 
premalignant nodule and tumor tissue was analysed by qRT-PCR with murine MYOF and 18S rRNA primers for 
normalization and immunoblotting with anti-MYOF, anti-VP16 and anti-GAPDH antibodies as loading control. The 
ratio of myoferlin protein expression was quantitated (right). Values are mean ± SD (n=6) *p<0.05, ***p<0.001. 
 
 
6.3.3 Tumorigenic characteristics of myoferlin 
 
Choosen MYOF as target gene of interest, we had to find out if MYOF is able to be the 
transducer of the MKL1/2 effects on tumorigenesis and oncogene-induced senescence. 
Beside its direct regulation and dependency on MKL1 and FLNa, we next investigated the 
role of MYOF on different essential tumorigenic properties, like proliferation and invasion of 
cells, hallmarks of nearly all cancer cells. 
 
 
6.3.3.1 Myoferlin depletion leads to proliferation arrest 
 
One characteristic property of tumor cells is their rapid proliferation for which reason we 
analysed the proliferation rate of HuH6 hepatocellular carcinoma cells transfected with 
negative control or MYOF siRNA, which displayed a knockdown efficiency of MYOF of over 
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90% (Fig. 39, right). Counting the cell number for 6 days we observed a significant decrease 
in proliferation upon MYOF depletion (Fig. 39), suggesting that the presence of MYOF seems 
to be important for aberrant cell proliferation. 
 
	  
Figure 39: Proliferation arrest upon MYOF depletion. HuH6 cells were transfected with negative control or 
MYOF siRNA and counted daily for 6 days. Values are mean ± SD (n=3); ***p<0.001. Lysates of the HuH6 ctrl 
and HuH6 siMYOF cells were subjected to immunoblotting with anti-MYOF and anti-HSP90 antibodies as loading 
control. 
 
 
6.3.3.2 Myoferlin depletion resulted in decreased invasion 
 
As another important tumor cell specific property we analysed the invasive behavior of HuH6 
cells transfected with negative control or MYOF siRNA and here we also got a knockdown 
efficiency of over 90% (Fig. 40, right). Performing a matrigel invasion assay and then 
counting the invaded cells after 24 h, a significant decrease of invasive cells due to MYOF 
depletion was observed concluding that MYOF is also required for cell invasion (Fig. 40). 
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Figure 40: Decreased invasion upon MYOF depletion. HuH6 ctrl and HuH6 siMYOF cells were subjected to a 
three-dimensional matrigel invasion assay. Number of invaded cells after 24 h at 37 °C was counted. Values are 
mean ± SD (n=3); *p<0.05. Lysates of the HuH6 cells were immunoblotted with anti-MYOF and anti-HSP90 
antibodies as loading control. 
 
 
6.3.3.3 Myoferlin depletion induces senescence  
 
Due to the findings above, the requirement of MYOF for cell proliferation and invasion, and 
the fact that MKL1/2 depletion inhibits HCC xenograft growth by inducing senescence, we 
also analysed the possibility of senescence induction by MYOF depletion. Therefore, a 
senescence associated β-galactosidase staining was performed and the blue cells in 
negative control and MYOF depleted HuH6 cells were counted. In HuH6 cells with MYOF 
knockdown we observed a significant induction of cellular senescence indicating a role for 
MYOF in senescence induction (Fig. 41).  
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Figure 41: Induction of cellular senescence upon MYOF depletion. Senescence associated β-galactosidase 
staining was performed in HuH6 ctrl and HuH6 siMYOF cells. Numbers of SA-β-gal positive cells were counted. 
Values are mean ± SD (n=3); **p< 0.01. 
 
 
All these results are conform with the fact that the examined HCC cells show characteristic 
features of tumor cells, like cell proliferation and invasion, while MYOF presence. These 
tumorigenic properties can be inhibited by MYOF depletion and may be due to the 
senescence-inducing strategy upon MYOF knockdown. Based on the given results, we can 
hypothesize that the target gene MYOF is able to transduce the known effects of MKL1/2 on 
evading tumorigenesis and tumor growth by inducing a senescence response. 
 
 
6.3.4 Myoferlin depletion provokes phosphorylation of the EGFR 
 
After characterizing MYOF presence as relevant for tumor cell specific behavior we focused 
on the mechanistic insights and the signaling pathways MYOF can act on. In a recent study, 
Turtoi and colleagues showed an effect of MYOF knockdown on the activation and 
phosphorylation of the EGF receptor (EGFR) in breast cancer cells (Turtoi et al., 2013). We 
therefore investigated the role of MYOF depletion on activation of the EGFR in HuH6 and 
HuH7 HCC cells. Our experiments also revealed a strong phosphorylation of the EGFR at 
tyrosin 1173 upon a stable MKL1/2 as well as a stable MYOF knockdown in HuH7 and a 
transient knockdown of MYOF in HuH6 cells (Fig. 42A). We could also show that the 
phosphorylation of the EGFR is a reversible process because the strong EGFR 
phosphorylation in HuH7 MKL1/2 knockdown cells was reverted by overexpression of MYOF 
in the MKL1/2 KD cells (Fig. 42B). These results indicate a direct effect of MYOF on the 
EGFR activation by phosphorylation. We wanted to verify this result also in vivo and found a 
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strongly phosphorylated EGFR in the HCC xenograft samples treated with MKL1+2 siRNA 
(Fig. 42C, top). In tumor tissue of SRF-VP16iHep mice expressing high amounts of MYOF 
(Fig. 38) the EGFR is not phosphorylated compared to the control cells expressing no MYOF 
(Fig. 42C, bottom). Concluding, we found a strong upregulation of the EGFR phosphorylation 
in MYOF depleted hepatocellular carcinoma cells in vitro as well as in vivo. 
 
	  
Figure 42: MYOF depletion leads to phosphorylation of the EGFR. (A) Lysates of HuH7 cells stably 
expressing negative control, MKL1/2 or MYOF shRNA (left; performed by V. Hampl) and lysates of HuH6 cells 
transfected with negative control or MYOF siRNA (right) were immunoblotted with anti-EGFRpTyr1173, anti-EGFR, 
anti-MYOF and anti-HSP90 antibodies as loading control. (B) Immunoblotting of HuH7 cells stably expressing 
negative control or MKL1/2 shRNA with or without reconstitution of HA-tagged MYOF with the indicated 
antibodies (performed by V. Hampl). (C) Lysates of HCC xenografts after treatment with PEI/control siRNA or 
PEI/MKL1+2 siRNA were immunoblotted with anti-EGFRpTyr1173, anti-EGFR and anti-GAPDH antibodies as 
loading control (top). Immunoblotting of control, premalignant nodule and tumor tissue of SRF-VP16iHep mice with 
anti-EGFRpTyr1173 and anti-GAPDH antibodies (bottom). 
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Next, we investigated the role of MYOF in internalization of the EGFR in HuH7 cells by GFP-
tagged EGFR transfection into HuH7 control and HuH7 siMYOF cells. In the HuH7 cells 
without MYOF distinct dots of EGFR are visible by immunofluorescence analysis in contrast 
to diffuse coloring of the cell in the control cells (Fig. 43). To test the mechanism underlying 
the degradation arrest of the EGFR upon MYOF knockdown we treated cells with negative 
control siRNA with the proteasome inhibitor MG132 and observed similar to the effects of 
MYOF depletion distinct dots of non-degraded EGFR (Fig. 43) suggesting that MYOF 
depletion leads to a degradation arrest of the EGFR internalization by blocking the 
proteasome. 
	  
Figure 43: EGFR degradation is inhibited by MYOF depletion. HuH7 ctrl cells treated with or without 10 µM 
MG132 and HuH7 siMYOF cells were transfected with GFP-tagged EGFR and analysed by immunofluorescence. 
Representative images are shown. 
 
 
6.3.5 Myoferlin depletion induces oncogene-induced senescence 
 
After demonstrating an activating effect of MYOF depletion on the EGF receptor via EGFR 
phosphorylation and also a senescence-inducing strategy upon MYOF depletion revealed by 
β-galactosidase staining we tried to figure out if the knockdown of MYOF also leads to 
oncogene-induced senescence (OIS) as MKL1/2 depletion does (Hampl et al., 2013). We 
therefore focused our analyses shown in the following figures on established markers of OIS 
such as ERK1/2 phosphorylation, p16Ink4a activation, hypophosphorylation of Rb and the 
CXCL10 and TNFSF10 expression upon silencing of MYOF (Peeper et al., 1994; Weinberg, 
1995; Alcorta et al., 1996; Cristofalo & Pignolo, 1996; Hara et al., 1996 and Serrano et al., 
1997). 
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6.3.5.1 Myoferlin depletion causes Ras activation and ERK1/2 phosphorylation 
 
Following the signal cascade of EGFR activation by autophosphorylation, the adaptor protein 
growth factor receptor-bound protein 2 (GRB2) binds to the phosphorylated tyrosine residues 
of the EGFR and also binds to the guanine nucleotide exchange factor son of sevenless 
(SOS) that becomes activated. This subsequently leads to the exchange of inactive GDP to 
active GTP of Ras. Activated Ras then activates via further kinase activities the extracellular 
signal-regulated kinase 1/2 (ERK1/2) by phosphorylation. Based on this known signaling 
pathway we looked for Ras and ERK1/2 activation upon MYOF depletion and found Ras in 
HuH7 cells transfected with MYOF or MKL1/2 siRNA strongly activated (Fig. 44A, top). 
ERK1/2 was also phosphorylated in HuH7 cells with stable MKL1/2 or MYOF knockdown 
(Fig. 44A, bottom) and HuH6 cells transfected with MYOF siRNA (Fig. 44B). Confirming that 
MYOF is the gene mediating the effect of MKL1/2 on Ras GTP loading we overexpressed 
MYOF in MKL1/2 depleted cells resulting in suppression of Ras activation (Fig. 44A, top). To 
further demonstrate that MYOF directly acts on the Ras/Raf/MEK/ERK pathway, we 
analysed the influence of cell treatment with a SOS SH3 domain inhibitor in combination with 
MYOF knockdown. Our results impressingly show a strong decrease of phosphorylated 
ERK1/2 (Fig. 44A, bottom) and also of induced senescence monitored by senescence 
associated β-galactosidase staining (Fig. 44C) after SOS inhibitor treatment of cells lacking 
MYOF or MKL1/2 expression.  
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Figure 44: ERK1/2 phosphorylation upon MYOF depletion. (A) HuH7 cells transfected with control, MYOF, 
MKL1/2 or MKL1/2 siRNA reconstituted with HA-tagged MYOF and a negative (GDP) and positive (GTPγS) 
control were subjected to the active Ras detection kit. Eluates were immunoblotted with anti-Ras antibody (top). 
Immunoblotting of HuH7 cells stably expressing a negative control vector or MKL1/2 or MYOF shRNA and HuH7 
cells transfected with MYOF siRNA treated with or without 20 µM SOS SH3 domain inhibitor using anti-
ERK1/2pT202/pY204, total anti-ERK1/2 and anti-HSP90 antibodies. (B) HuH6 ctrl and HuH6 siMYOF cells were 
immunoblotted with anti- ERK1/2pT202/pY204, total anti-ERK1/2, anti-MYOF and anti-HSP90 antibodies. (C) 
Senescence associated β-galactosidase staining in HuH7 cells transfected with negative control, MYOF or 
MKL1/2 siRNA and treated as in (A). Numbers of SA-β-gal positive cells were counted. Values are mean ± SD 
(n=3); **p<0.01, ***p<0.001.  
 
 
6.3.5.2 Activation of senescence markers upon Myoferlin depletion 
 
Analysing more markers being characteristic for oncogene-induced senescence, we tested 
the effect of MYOF downregulation on the phosphorylation status of the retinoblastoma 
protein (Rb). Immunoblotting revealed a hypophosphorylation of Rb indicated by a strong 
decrease of phosphorylated Rb expression upon MYOF knockdown in HuH7 (Fig. 45A) and 
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HuH6 (Fig. 45B) cells. Treatment with SOS inhibitor reversed the MYOF induced effect and 
Rb gets phosphorylated (Fig. 45A) confirming the given results of SOS inhibitor treatment on 
reduced ERK1/2 phosphorylation and senescence induction described above. Demonstrating 
that MYOF depletion induced oncogene-induced senescence is mediated by the EGFR, we 
inhibited EGFR in parallel with MYOF siRNA in HuH7 cells and observed, as expected, a 
decline in senescence associated β-galactosidase activity and a potent inhibition of p16Ink4a 
expression compared to cells with a single MYOF knockdown (Fig. 45C, D).  
	  
Figure 45: Hypophosphorylation of Rb upon MYOF depletion. (A) HuH7 ctrl or HuH7 siMYOF cells treated 
with or without 20 µM SOS SH3 domain inhibitor were immunoblotted with anti-pRb and anti-HSP90 antibodies. 
(B) Immunoblotting of HuH6 ctrl and HuH6 siMYOF cells as in (A). (C) Senescence associated β-galactosidase 
staining in HuH7 cells transfected with negative control, MYOF or MYOF+EGFR siRNAs. Numbers of SA-β-gal 
positive cells were counted. Values are mean ± SD (n=3); ***p<0.001. (D) HuH7 ctrl, HuH7 siMYOF+siEGFR and 
HuH7 siMYOF cells were immunoblotted with anti-p16Ink4a, anti-EGFR and anti-HSP90 antibodies. 
 
 
Additionally to the senescence inhibiting effect of the SOS inhibitor we wanted to investigate 
the potential role of the EGFR inhibitor Tyrphostin AG1478 on senescence induction. 
Therefore, we performed immunoblotting and β-galactosidase staining in HuH7 cells 
transfected with MYOF or MKL1/2 siRNA and treated them with AG1478 (Fig. 46A-B). A 
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strong EGFR inhibiting effect of AG1478 shown by decreased phosphorylation of the EGFR 
was observable (Fig. 46A, top) but no alteration in the p16Ink4a expression (Fig. 46A, bottom) 
or in the senescence induction (Fig. 46B) was detectable after addition of AG1478 to HuH7 
MKL1 or MYOF knockdown cells.  
	  
Figure 46: Inhibition of EGFR phosphorylation by AG1478. (A) HuH7 cells were transfected with negative 
control or MYOF siRNA and treated with or without 10 µM AG1478. Lysates were immunoblotted with anti-
EGFRpTyr1173, anti-EGFR, anti-p16Ink4a and anti-HSP90 antibodies as loading control. (B) HuH7 ctrl, HuH7 
siMKL1/2 and HuH7 siMYOF cells were treated with or without 10 µM AG1478 and subjected to β-galactosidase 
staining. Numbers of SA-β-gal positive cells were counted. Values are mean ± SD (n=3); *p< 0.05, **p< 0.01. 
 
 
To complete the markers for oncogene-induced senescence affected by MYOF knockdown 
we analysed the expression levels of the senescence messaging secretome (SMS) factors 
C-X-C motif chemokine 10 (CXCL10) and tumor necrosis factor superfamily member 10 
(TNFSF10) (Fig. 47A-B). In HuH7 cells with a stable MYOF knockdown (Fig. 47A) as well as 
in HuH6 cells with a transient MYOF knockdown (Fig. 47B) TNFSF10 and CXCL10 (only in 
HuH7 cells) were significantly upregulated compared to the negative control cells. 
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Figure 47: Upregulation of senescence markers upon MYOF depletion. (A) HuH7 cells transfected with 
negative control or MYOF shRNA were subjected to qRT-PCR with CXCL10, TNFSF10 and 18S rRNA primers for 
normalization. Values are mean ± SD (n=3); *p< 0.05. (B) HuH6 cells were transfected with negative control or 
MYOF siRNA. MYOF knockdown efficiency and TNFSF10 mRNA expression were analysed by qRT-PCR as in 
(A). Values are mean ± SD (n=3); *p< 0.05, ***p< 0.001. 
 
 
In a further experiment, we treated HuH7 control cells and HuH7 cells with a stable MKL1/2 
knockdown with the antitumor antibiotic Actinomycin D (ActD). MKL1 mRNA expression was 
strongly reduced after ActD treatment very similar to a stable knockdown of MKL1/2 (Fig. 48, 
top). The combination of MKL1/2 knockdown and ActD treatment of cells revealed an even 
stronger decrease of MKL1 expression compared to a single treatment of the cells (Fig. 48, 
top). Confirming the results described above we here also found decreased SRF expression 
but increased EGFR and TNFSF10 expression upon MKL1/2 knockdown (Fig. 48). After 
treatment with ActD we observed mRNA levels of SRF, EGFR and TNFSF10 strongly 
reduced in control as well as in MKL1/2 depleted HuH7 cells (Fig. 48). Since  ActD inhibits 
the transcription of genes by binding to the DNA and thereby preventing the RNA elongation 
we can conclude that all the analysed genes are repressed on the transcriptional level.	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Figure 48: Downregulation of EGFR and TNFSF10 mRNA expression upon ActD treatment. HuH7 ctrl and 
MKL1/2 KD cells were treated with or without 1 µg/mL Actinomycin D (ActD) for 24 h. mRNA expression of MKL1, 
SRF, EGFR and TNFSF10 was measured by qRT-PCR with the gene specific and the 18S rRNA primers for 
normalization. Values are mean ± SD (n=2 for SRF and EGFR and n=3 for MKL1 and TNFSF10); *p< 0.05, **p< 
0.01, ***p< 0.001. 
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6.3.6 Mig6 shows no effect on oncogene-induced senescence  
 
In further studies on inducing senescence mediating proteins we had a look at the tumor 
suppressor gene mitogen-inducible gene 6 (Mig6), an already known target gene of MKL1/2 
and known effector of EGFR and ERK signaling (Descot et al., 2009 and Reschke et al., 
2010). First, we verified the MKL1/2 dependency of Mig6 by qRT-PCR showing strongly 
decreased mRNA expression of Mig6 in HuH7 cells with a stable MKL1/2 knockdown 
(Fig. 49). 
	  
Figure 49: Downregulation of Mig6 upon MKL1/2 knockdown. Mig6 mRNA expression of HuH7 cells stably 
expressing control or MKL1/2 shRNA was analysed by qRT-PCR with Mig6 and 18S rRNA primers for 
normalization. Values are mean ± SD (n=2). 
 
 
Firstly, we depleted Mig6 transiently in HuH7 cells and got a knockdown efficiency of around 
60% (Fig. 50A, right). This HuH7 siMig6 cells showed no altered proliferation rate compared 
to the control cells while MKL1/2 depleted cells exerts strong inhibitory effects on cell 
proliferation serving as positive control for the performed proliferation assay (Fig. 50A). 
Confirming the result that Mig6 knockdown doesn’t influence the proliferation rate, we 
additionally overexpressed Flag-tagged Mig6 into MKL1/2 depleted HuH7 cells and again no 
difference in cell growth compared to the MKL1/2 knockdown cells was observed (Fig. 50A) 
suggesting that Mig6 isn’t involved in cell proliferation. Secondly, we investigated the role of 
Mig6 on oncogene-induced senescence and therefore analysed the expression levels of p16, 
CXCL10 and TNFSF10 in Mig6 depleted HuH7 cells by qRT-PCR. Neither p16 nor CXCL10 
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depletion or overexpression and found only MYOF as the suitable target gene mediating the 
effects of MKL1/2 on HCC avoiding strategies by oncogene-induced senescence induction. 
	  
Figure 50: Knockdown of Mig6 doesn’t provoke proliferation arrest or oncogene-induced senescence. (A) 
HuH7 cells were transfected with negative control, Mig6, MKL1/2 or MKL1/2 siRNA reconstituted with Flag-Mig6 
and counted daily for 4 days (left). Mig6 knockdown efficiency was determined by qRT-PCR using Mig6 and 18S 
rRNA primers for normalization (right). Values are mean ± SD (n=2) (B) mRNA expression of p16, CXCL10 and 
TNFSF10 was measured by qRT-PCR with the gene specific primers. Values are mean ± SD (n=2). 
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a strong knockdown efficiency (Fig. 51A, right). By performing invasion assays LT cells 
lacking MYOF expression revealed a significantly lower invasive behavior into a three-
dimensional matrigel than the control cells (Fig. 51A).  We also observed in LT cells with 
MYOF knockdown a reduced proliferation rate (Fig. 51B) and significantly increased 
senescence induction monitored by senescence-associated β-galactosidase staining 
(Fig. 51C) indicating that MYOF depletion prevents also tumor cells from tumorigenic 
features by a senescence-inducing strategy.  
 
	  
Figure 51: Downregulation of tumorigenic features upon MYOF depletion in murine liver tumor (LT) cells. 
(A) LT ctrl and LT siMYOF cells were subjected to a three-dimensional matrigel invasion assay. Number of 
invaded cells after 24 h at 37 °C was counted. Values are mean ± SD (n=3); **p< 0.01. Lysates of the LT cells 
were immunoblotted with anti-MYOF and anti-HSP90 antibodies. (B) LT cells were transfected with negative 
control or MYOF siRNA and counted daily for 6 days. Values are mean ± SD (n=3); ***p< 0.001. (C) Senescence 
associated β-galactosidase staining was performed in LT ctrl and LT siMYOF cells. Numbers of SA-β-gal positive 
cells were counted. Values are mean ± SD (n=3); ***p< 0.001. 
0 
2 
4 
6 
8 
10 
1 2 3 4 5 6 
ctrl 
siMYOF 
0
50
100
150
A 
B C 
ctrl siMYOF 
** 
%
 o
f i
nv
ad
ed
 c
el
ls
 
siMYOF ctrl 
ctrl siMYOF 
MYOF 
HSP90 90 
230 
kDa 
!!!!!!!!!!!!!
!!!!!!!!!!!!!
ce
ll 
nu
m
be
r (
x1
05
)  
time (days) 
*** 
0
10
20
30
40
ctrl siMYOF 
%
 o
f S
A
-!
-G
al
 p
os
. c
el
ls
 
*** 
6 Results	  
	   	  
	  	  
     100 
	  
	   	  
Furthermore, we analysed the effect of MYOF knockdown on EGFR activation and found a 
strong phosphorylation of the EGFR in LT siMYOF cells (Fig. 52) contributing to senescence 
induction described above. 
	  
	  
Figure 52: Phosphorylation of the EGFR upon MYOF depletion in LT cells. Lysates of LT ctrl and LT siMYOF 
were immunoblotted with anti-EGFRpTyr1173, anti-EGFR, anti-MYOF and anti-HSP90 antibodies.  
 
 
In additional experiments we checked for oncogene-induced senescence markers 
upregulated in MYOF depleted LT cells (Fig. 53). Our results obtained by immunoblotting 
and qRT-PCR demonstrate that MYOF depletion in LT cells leads to phosphorylation of 
ERK1/2 (Fig. 53A), to increased expression of p16Ink4a (Fig. 53B) and to hypophosphorylation 
of Rb (Fig. 53C). We also observed an enhanced expression of the senescence messaging 
secretome factor TNFSF10 in the MYOF silenced LT cells (Fig. 53D). The described results 
in this chapter show a reduction of tumorigenic properties mediated by an oncogene-induced 
senescence response via phosphorylation of the EGFR and activation of the MEK/ERK 
signaling pathway in MYOF depleted murine liver tumor derived cells suggesting MYOF or 
the OIS induction as potential promising therapeutic target abolishing or preventing 
hepatocarcinogenesis.  
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Figure 53: Induction of oncogene-induced senescence upon MYOF depletion. (A) Lysates of LT ctrl and LT 
siMYOF cells were immunoblotted with anti-ERK1/2pT202/pY204, total anti-ERK1/2, anti-MYOF and anti-HSP90 
antibodies. (B) MYOF knockdown efficiency and p16 mRNA expression was measured by qRT-PCR using 
MYOF, p16 and 18S rRNA primers for normalization. Values are mean ± SD (n=3); **p< 0.01, ***p< 0.001. (C) 
Immunoblotting of LT ctrl and LT siMYOF with anti-Rb, anti-MYOF and anti-HSP90 antibodies. (D) MYOF 
knockdown efficiency and mRNA expression of TNFSF10 were analysed by qRT-pCR with MYOF, TNFSF10 and 
18S rRNA primers. Values are mean ± SD (n=3); *p< 0.05, ***p< 0.001. 
 
 
 
 
B 
C 
A 
MYOF 
HSP90 
ctrl siMYOF 
kDa 
90 
230 
!!!!!!!!!!!!!
!!!!!!!!!!!!!
!!!!!!!!!!!!!
!!!!!!!!!!!!!
44 
44 ERK1/2pT202/pY204 
ERK1/2 
0
1
2
3
4
5
p1
6 
m
R
N
A 
ctrl       siMYOF       
** 
MYOF 
HSP90 
ctrl siMYOF 
kDa 
90 
230 
!!!!!!!!!!!!!
!!!!!!!!!!!!!
!!!!!!!!!!!!!
110 Rb 
0
2
4
6
TN
FS
F1
0 
m
R
N
A 
ctrl       siMYOF       
* 
0.0
0.5
1.0
1.5
M
YO
F 
m
R
N
A 
ctrl       siMYOF       
*** 
D 
0.0
0.5
1.0
1.5
M
YO
F 
m
R
N
A 
ctrl       siMYOF       
*** 
7 Discussion	  
	   	  
	  	  
     102 
	  
	   	  
7 Discussion 
 
7.1 MKL1/2 target gene expression in HCC cells 
 
7.1.1 MKL1 and/or MKL2 dependency of target genes  
 
One aim of this thesis was the identification and validation of Megakaryoblastic Leukemia 1 
and 2 (MKL1 and MKL2) dependent target genes and the discovery of one special target 
gene mediating the effects of MKL1 and/or MKL2 regarding their tumorigenic properties. 
Both proteins MKL1 and MKL2, acting as transcriptional coactivators of the transcription 
factor Serum Response Factor (SRF), are described to be involved in the activation of 
different target genes regulating processes being relevant for tumorigenesis of cells, such as 
cell growth, cell migration or cell differentiation (Pipes et al., 2006). The impact of MKL1 and 
MKL2 on cell migration and cell proliferation was demonstrated by Muehlich and colleagues 
by the finding that a depletion of MKL1/2 resulted in a reduced proliferation and migration 
rate of hepatocellular carcinoma (HCC) cells (Muehlich et al., 2012). By performing a 
microarray analysis by V. Hampl, the transcriptome of the HuH7 HCC cell line depleted of 
MKL1/2 in comparison to the HuH7 control cells was analyzed and thus several novel 
MKL1/2 dependent target genes were identified (Hermanns et al., 2017). The 8 genes with 
the strongest downregulation in the MKL1/2 knockdown cells compared to the control cells 
were smooth muscle protein 22 (SM22), glioma pathogenesis-related protein 1 (GLIPR1), 
calponin 1 (CNN1), myosin heavy chain (MYH9), transforming growth factor beta 1 (TGFß1), 
vestigial-like family member 3 (VGLL3), microtubule-associated protein 1B (MAP1B) and 
myoferlin (MYOF). These target genes, except for SM22, were then also validated in vivo in 
a HCC xenograft model treated with MKL1+2 siRNA (Hermanns et al., 2017). Confirming the 
microarray data also in vitro, we introduced a knockdown by RNAi of MKL1 or MKL2 alone or 
in combination and by a siRNA sequence directed against both sequences of MKL1 and 
MKL2 at the same time in hepatocellular carcinoma cells. We observed decreased mRNA as 
well as protein expressions of all 8 above mentioned target genes upon MKL1 and/or MKL2 
depletion, except for TGFß1 whose expression was not reduced by a single MKL1 
knockdown. This result illustrates the MKL1/2 dependency of the target genes and 
characterized GLIPR1, CNN1, VGLL3, MAP1B and MYOF the first time as novel MKL1 and 
MKL2 dependent target genes. The identified target genes SM22 and MYH9 were previously 
known as MKL1 dependent target genes, thus serving as a positive control of the validity of 
our microarray approach (Descot et al., 2009 and Medjkane et al., 2009). SM22 appeared to 
be regulated in NIH 3T3 fibroblasts by G-actin-MKL1 signaling, while it constitutes one of the 
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main components of differentiated smooth muscles and acts as regulator of the actin 
cytoskeleton (Gimona et al., 2003 and Descot et al., 2009). Its function as a tumor 
suppressor was also pointed out by the fact that breast, gut and prostate cancer cells lack an 
SM22 expression (Assinder et al., 2009). Contradictory to this finding, REF52 fibroblasts 
depleted of SM22 revealed a reduced cell migration, invasion and chemotaxis (Thompson et 
al., 2012). Given this discrepancy of cellular SM22 function, it may explain why the transient 
knockdown of MKL1+2 in vitro performed in this thesis resulted in reduced SM22 expression 
levels while the depletion of MKL1+2 in HCC xenografts in vivo revealed a strong increase in 
SM22 expression (Thompson et al., 2012 and Hermanns et al., 2017). MYH9, a component 
of the actomyosin contractile apparatus, showed an invasive behavior in tumor cells 
(Somlyo & Somlyo, 2003 and Betapudi et al., 2006). Supporting this involvement of MYH9, 
Medjkane and colleagues also revealed a contribution of MYH9 to metastasis and invasion in 
MDA-MB 231 breast cancer cells as well as in B16F2 melanoma cells by demonstrating that 
the depletion of MYH9 in MDA-MB 231 cells sequentially impaired the invasive growth 
significantly (Medjkane et al., 2009). GLIPR1 is described as proapoptotic tumor suppressor 
gene that is frequently downregulated in prostate cancer and also as potential target gene of 
p53 (Ren et al., 2002; Ren et al., 2004 and Ren et al., 2006). Besides its tumor inhibiting 
function, GLIPR1 exhibits also oncogenic properties exemplified by its specific expression in 
glioma and Wilms tumor (Murphy et al., 1995 and Chilukamarri et al., 2007). This way, the 
function of GLIPR1 on tumorigenesis seems to be cell-type specific. Despite its reduced 
expression in acute megakaryoblastic leukemia due to gene methylations in the GLIPR1 
gene, GLIPR1 is not described in the context of MKL1/2 so far (Xiao et al., 2011). The 
smooth muscle protein CNN1 regulates the actin-myosin interaction and the smooth muscle 
contraction and is also known for binding actin to promote or sustain actin polymerization 
(Winder & Walsh, 1990; Wills et al., 1994 and Winder et al., 1998). Beside its function as 
modulator of the actomyosin contraction, CNN1 exhibits also tumor suppressive properties 
revealed by reduced CNN1 expression in tumor vessels in hepatocellular, melanoma and 
colon cancer (Sasaki et al., 2002; Koganehira et al., 2003 and	  Yanagisawa et al., 2008). The 
tumor suppressive effects of CNN1 were also observed by several research groups when 
they induced CNN1 expression into tumor cells (Kaneko et al., 2002 and Takeoka et al., 
2002). The TGFß1 gene is known to be involved in epithelial-mesenchymal transition (EMT) 
of cells, a fundamental step in tumor cell progression from epithelial cells to invasive and 
migratory tumor cells (Thiery, 2002). In 2007, Morita and colleagues described for the first 
time a relation between TGFß1 and MKL1/2, when they demonstrated the requirement of 
MKL1/2 as critical mediators for the TGFß1-induced EMT (Morita et al., 2007). A structural 
microtubule-associated protein is MAP1B that is essential for the regulation of microtubule 
dynamics and their assembly as well as for the stability of neuronal cell cytoskeleton and the 
neuronal development and migration (Lu et al., 2004 and Tymanskyj et al., 2012). The last 
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target gene affected by MKL1/2 knockdown is represented by the transmembrane protein 
MYOF that is known to play a crucial role in cancer seen by a strong MYOF overexpression 
in a variety of different cancer cell lines and types, like breast, ovarian and liver cancer for 
example (Adam et al., 2003; Labhart et al., 2005 and Ponten et al., 2008) (see also the 
description under 2.3.2 in the introduction). The special role and involvement of MYOF in 
tumorigenesis, especially in hepatocellular carcinoma cells, will be discussed in more detail 
below in the following chapter under 7.3. The novel identified target genes have been shown 
to be downregulated upon MKL1/2 depletion in different HCC cell lines, such as HuH6, HuH7 
and HepG2, indicating a high relevance of these genes for hepatocarcinogenesis. Further, 
almost all of the newly identified genes are involved in cancer and most of them exhibit 
tumorigenic properties, this way the novel target genes may potentially be involved in the 
MKL1/2 knockdown-mediated tumor growth regression and induction of OIS response and 
may be responsible for the repressed tumorigenic properties that arise due to MKL1/2 
depletion (Muehlich et al., 2012).  
 
 
7.1.2 Mutual dependence of MKL1 and MKL2 in HCC cell lines 
 
While performing the target gene analysis with RNA interference (RNAi) experiments using 
MKL1, MKL2, MKL1/2 or a combination of both MKL1 and MKL2 siRNAs, we surprisingly 
found out that a single knockdown of MKL1 as well as a single knockdown of MKL2 in HCC 
cell lines reduced the mRNA expression level of target genes nearly in the same manner as 
a knockdown of both MKL1 and MKL2. This obtained result was not described in literature so 
far, rather in previous studies depletion of both MKL1 and MKL2 was required to inhibit the 
SRF target gene expression (Cen et al., 2003 and Medjkane et al., 2009). RNAi experiments 
in HeLa cells and MDA-MB 231 breast cancer cells showed that a single ablation of MKL1 or 
MKL2 was not sufficient for a reduced expression of immediate early genes (IEGs) (Cen et 
al., 2003 and Medjkane et al., 2009). Finding an explanation for the given phenomenon of 
the single MKL1 or MKL2 knockdown, we also observed a mutual dependence of MKL1 and 
MKL2, meaning that the introduction of MKL1 siRNA into HCC cells, like HuH6, HuH7 and 
HepG2 cells, resulted in strongly reduced MKL1 and also MKL2 expression as well as MKL2 
siRNA inhibited MKL2 and additionally MKL1 expression. Contradictory to our findings, this 
mutual dependence was not observed in HeLa cells as well as in human primary tubular 
epithelial cells, where MKL1 siRNA only decreased the MKL1 expression level without 
affecting the MKL2 expression level and similarly the other way around (Cen et al., 2003 and 
Hermanns et al., 2017). This prompted us to declare the mutual dependence as a HCC 
specific phenomenon that remains to be determined also for other cancer types and tumor 
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cells. The fact that we achieved a reduced target gene expression only due to a single MKL1 
or MKL2 knockdown may be a suitable explanation for the abolishment of HCC xenograft 
growth figured out by Hampl and colleagues (Hampl et al., 2013). In this study a knockdown 
of MKL1 was also sufficient for the tumor growth inhibition in vivo in which the HCC xenograft 
tumors in mice were significantly reduced due to the treatment with polyethylenimine (PEI)-
complexed MKL1 siRNA comparable to the combinatory treatment of MKL1 and MKL2 
siRNA (Hampl et al., 2013). Given the result that MKL1 or MKL2 silencing is sufficient for 
target gene inhibition this is also relevant for upcoming therapeutic approaches where only 
MKL1 or MKL2 siRNA is needed instead of a double knockdown of both MKL1 and MKL2.   
 
 
7.1.3 Regulation of newly identified target genes upon stimulant or inhibitor treatment 
 
Given that the transcriptional MKL1/SRF driven target gene expression is regulated via the 
RhoA-actin signaling, we investigated the effect of an alteration in this signaling pathway on 
the novel target genes using extracellular stimulating or inhibiting agents. Performing qRT-
PCR analysis revealed a strong downregulation of MKL target genes including SRF upon 
treatment with the actin polymerization inhibitor latrunculin B (LatB). Because LatB inhibits 
the binding of adenosine triphosphate (ATP) to monomeric G-actin, it is unable to polymerize 
into filamentous F-actin and results in a repressive MKL1-G-actin complex (Yarmola et al, 
2000; Miralles et al., 2003; Muehlich et al., 2008 and Kircher et al., 2015). The reduced target 
gene expression fits well to the MKL1 activation pathway and seems to be a result of the 
dissociated MKL1-FLNa complex due to LatB treatment that Kircher et al. recently found out 
(Miralles et al., 2003; Muehlich et al., 2008 and Kircher et al., 2015). On a molecular level, 
this blocked MKL1-FLNa complex formation in turn provokes a redistribution of MKL1 from 
the nucleus into the cytoplasm explaining the inhibitory effect of LatB on gene expression 
(Kircher et al., 2015). A result similar to ours was obtained by Medjkane and his group 
showing that LatB treatment in two different cancer cell lines inhibited the ability of MKL1 to 
activate an SRF reporter gene measured by luciferase activity illustrating a general effect of 
RhoA-actin signaling in cancer cell lines (Medjkane et al., 2009). As expected, experiments 
in NIH 3T3 fibroblasts and HepG2 hepatocellular carcinoma cells owing cytoplasmic MKL1 
under physiological conditions showed strongly induced SRF and MKL target gene 
expression upon fetal bovine serum (FBS) treatment. Contrary to the inhibiting effect of LatB, 
serum/FBS activates RhoA and its signaling pathway by supporting the actin polymerization 
from G-actin into F-actin leading to an accumulation of MKL1 in the nucleus and therefore to 
the activation of SRF (Miralles et al., 2003). In the same way, lysophosphatidic acid (LPA) 
activates RhoA and thus enhances actin polymerization (Muehlich et al., 2004). Treatment of 
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HepG2 and MCF7 cells as well as human primary fibroblasts with LPA having cytoplasmic 
MKL1 in an unstimulated state revealed a strong induction of SRF and MKL target genes 
requiring the necessary translocation of MKL1 from the cytoplasm to the nucleus (Vartiainen 
et al., 2007 and Kircher et al., 2015). As cellular response to LPA, an enhanced association 
of MKL1 and FLNa in the nucleus was observed that subsequently resulted in the obtained 
MKL target gene activation (Kircher et al., 2015). This correlated well with the induction of the 
MKL target genes upon LPA treatment. Next, we also investigated the role of cytochalasin D 
(CytoD) on target gene expression and observed a strong induction of SRF and MKL target 
genes in cell lines having MKL1 in the cytoplasm under non-stimulated conditions, for 
instance NIH 3T3 fibroblasts, HepG2, HLF and MCF7 cancer cells, upon CytoD stimulation. 
While CytoD, an actin-binding drug, induces a dimerization of G-actin and promotes ATP 
hydrolysis, it disrupts the regulatory function of G-actin and reduces the inhibitory association 
of MKL1 and G-actin in the cytoplasm and therefore causes a release and accumulation of 
MKL1 in the nucleus (Sotiropoulos et al., 1999; Miralles et al., 2003 and Vartiainen et al., 
2007). In a recent study of Muehlich and colleagues the stimulating effect of CytoD shown by 
CTGF induction due to an increased amount of nuclear MKL1 was reported (Muehlich et al., 
2017). Consistent with all these findings, we did not observe a potent SRF or MKL target 
gene induction upon CytoD treatment in HuH7 and MDA-MB 468 cells having in common 
that they already constitute nuclear MKL1 in the unstimulated state. Contradictory to our 
observations, the stimulation with CytoD activates in a luciferase assay the SRF reporter 
gene mediated by MKL1/2 and SRF in MDA-MB 231 as well as in B16F2 cells, the former 
harboring nuclear MKL1 in the unstimulated state (Medjkane et al., 2009). At least, they 
found out that the activation of the SRF reporter gene and also the target gene activation is 
stronger in the B16F2 cells than in the MDA-MB 231 cells, being more suitable to our 
findings (Medjkane et al., 2009). The effect of cytochalasin D may act cell line specific and 
still remains to be more investigated. It is tempting to speculate that the induction or decline 
of target gene expression in response to the activating or inhibiting reagents is a result of the 
association or dissociation of the MKL1-FLNa complex. Because FLNa is an F-actin binding 
protein (Flanagan et al., 2001 and van der Flier & Sonnenberg, 2001) and the reagents have 
a strong effect on the actin polymerization status, it might be possible that the binding of 
FLNa to F-actin is also responsible for target gene induction and that actin itself becomes a 
part of an MKL1-FLNa-F-actin complex. Overall, we found that the expression of the novel 
identified target genes can be regulated and thus becomes activated or inhibited by 
extracellular reagents acting on the RhoA-actin signaling axis and verified thereby their 
dependency and intimate connection on MKL1’s cellular localization. 
 
7 Discussion	  
	   	  
	  	  
     107 
	  
	   	  
7.2 The MKL1 binding protein Filamin A and its role in target gene expression 
 
7.2.1 Characterization of FLNa expressing A7 cells and the effect of MKL1/2 in A7 cells 
 
Filamin A (FLNa), belonging to the family of filamins, is an actin-binding protein being 
essential for actin filament crosslinking, stabilizing of orthogonal actin networks and linking 
them to cellular membranes (Flanagan et al., 2001; Stossel et al., 2001 and van der 
Flier & Sonnenberg, 2001). FLNa has also been described as multifunctional protein that is 
able to act on several different proteins and signaling pathways like binding to Rho family 
GTPases and therefore interacting with the Rho signaling cascade (Stossel et al., 2001). In a 
recent study of Kircher and colleagues FLNa was firstly characterized as novel MKL1 binding 
protein and interaction partner by a direct binding site on the MKL1 gene (Kircher et al., 
2015). Given this knowledge about FLNa as an MKL1 interaction partner, one aim of this 
thesis was the evaluation of the impact of FLNa on the MKL1/2 target gene expression. 
Therefore, we further analysed the A7 melanoma cell line expressing FLNa. Additionally to 
the downregulation of FLNa itself in HuH7 cells with silenced MKL1/2, we observed a strong 
decrease in the mRNA expression of the novel MKL1/2 target genes upon MKL1/2 silencing 
in A7 cells in the same manner as a single MKL1 knockdown. These data show that silencing 
of only MKL1 and not the combination of MKL1 and MKL2 is also in melanoma cells 
sufficient for target gene downregulation and that the depletion of only one compound, MKL1 
or FLNa, of the activating MKL1-FLNa complex suffices for reduced target gene expression. 
Here, a mutual dependence of MKL1 and MKL2 in the A7 melanoma cells was, additionally 
to the HCC cell lines described under 7.1.2, observable explaining the requirement of only 
MKL1 or MKL2 depletion for effects on target gene expression. Regarding this, the mutual 
dependence of MKL1 and MKL2 seems to be a phenomenon of cancer cells, at least shown 
in two different cancer types, the hepatocellular and the melanoma cancer. Furthermore, we 
found out that MKL1 and/or MKL2 downregulation in A7 cells resulted in a proliferation arrest 
of the melanoma cells and in a significant induction of cellular senescence, illustrated by β-
galactosidase staining suggesting a broader significance for the proliferation arrest and the 
senescence induction due to MKL1/2 knockdown in different cancer cell lines like in both 
HCC and melanoma cells. In this context, it remains to be investigated whether a FLNa 
knockdown in cancer cell lines may also result in an increase in senescence induction and 
thus showing that FLNa acting as MKL1 binding partner might also be responsible for the 
tumorigenic properties arising from MKL1/2 and MYOF overexpression. 
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7.2.2 FLNa dependency of MKL1/2 target genes  
 
In addition to the MKL1 dependency of the novel identified target genes described in 7.1.1, 
we verified their dependence on FLNa. Thus, we introduced FLNa siRNA into HepG2 
hepatocellular carcinoma cells, MDA-MB 468 mammary carcinoma cells, A7 melanoma cells 
and NIH 3T3 fibroblasts and observed strongly reduced mRNA expression levels of the 
MKL1/2 target genes in all the different cell lines indicating the broad significance and 
relevance of the given result. The expression of all the novel MKL target genes as well as of 
the previously known target genes SM22 and MYH9 seems to be dependent on FLNa 
expression and thus, the interacting complex of MKL1 and FLNa is also essential for the 
regulation of the MKL gene expression. Regarding this result, only one compound of the 
MKL1-FLNa complex, MKL1 or FLNa, has to be downregulated for an effect on target gene 
expression.  
 
 
7.2.3 Impact of FLNa on target gene expression and the influence of actin 
	  
Because the A7 melanoma cells show the same properties regarding the characteristics of 
tumor cells, like proliferation and senescence induction upon MKL1/2 knockdown, as the 
HuH6 and HuH7 hepatocellular carcinoma cells, we next focused our research concerning 
FLNa on the FLNa expressing A7 cells in comparison to the M2 cells lacking FLNa 
expression. Our aim was to figure out the impact of FLNa on the MKL1/2 dependent target 
gene expression and thus we overexpressed the MKL1 wildtype (wt) or the MKL1 S454A 
mutant in A7 control cells and additionally in A7 cells transfected with FLNa siRNA. qRT-
PCR analyses revealed a strong upregulation of SRF and GLIPR1 expression in A7 cells 
overexpressing MKL1 wt and to a greater extend in A7 cells overexpressing the MKL1 
S454A mutant compared to A7 cells endogenously expressing MKL1. This result perfectly 
corresponds to the study of Muehlich and colleagues generating the MKL1 S454A mutant 
being incapable of MKL1 phosphorylation due to its mutation at the phosphorylation site of 
MKL1 that enables MKL1 to enhanced nuclear accumulation and this way to activate SRF 
and its target genes (Miralles et al., 2003 and Muehlich et al., 2008). In contrast, 
overexpression of MKL1 wt and the MKL1 S454A mutant in A7 FLNa siRNA treated cells 
exhibited only modest effects on SRF and GLIPR1 induction and their expression is strongly 
reduced compared to the same MKL1 variants overexpression in FLNa expressing cells, 
whereas the SRF and GLIPR1 expression is also higher in cells transfected with the MKL1 
S454A phosphorylation mutant than with MKL1 wt. Regarding these data, we can conclude 
that FLNa is essential for SRF activation and the subsequent target gene upregulation and 
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that an increased MKL1 expression cannot compensate the lacking FLNa existence. To 
further substantiate our observations, we next investigated the role of the constitutive active 
variant of MKL1, MKL1 N100, on target gene expression depending on the FLNa status of 
the cells. For the MKL1/2 target genes SM22 and GLIPR1 we found significantly increased 
mRNA expression levels in A7 control cells overexpressing the MKL1 N100 mutant 
compared to the MKL1 wt, whereas their expression with the MKL1 N100 overexpression in 
A7 cells depleted of FLNa was significantly reduced. Confirming the strong effect of FLNa on 
target gene expression, we also performed this experiment in M2 melanoma cells naturally 
lacking FLNa expression and observed, as expected, also a strong decrease in SM22 and 
GLIPR1 expression, very similar to the A7 cells with FLNa knockdown. The very strong 
induction of target gene expression upon MKL1 N100 mutant overexpression in A7 control 
cells can be explained by its structure: lacking the N-terminal 100 amino acids of MKL1 that 
contain the RPEL motifs being essential for actin binding abolishes the MKL1 binding to G-
actin resulting in nuclear translocation and accumulation of the released MKL1, where it can 
now bind and activate SRF (Miralles et al., 2003 and Muehlich et al., 2008). The MKL1 N100 
mutant has already been reported by Muehlich and colleagues to activate target genes, such 
as vinculin, and the luciferase activity serving as positive control of our approach (Muehlich 
et al., 2008). The only modest effects of MKL1 N100 expression in M2 cells and also in A7 
cells with FLNa depletion on target gene expression illustrate again the importance of FLNa 
for the activation and induction of MKL1/2 target genes acting in concert with MKL1/2 and 
that constitutive active MKL1 is not sufficient for downstream gene expression in the absence 
of FLNa.  
Suggesting that FLNa and MKL1 interact with each other by constituting a complex, we were 
interested in discovering the binding site of FLNa on MKL1 and therefore we used the MKL1 
Δ301-342 mutant lacking the amino acids 301-342 for further investigations. qRT-PCR 
analysis revealed significantly reduced expression levels of SM22 and GLIPR1 in A7 cells 
overexpressing the MKL1 Δ301-342 mutant compared to the MKL1 wt indicating the 
existence of a potential FLNa binding site between the amino acids 301-342 of MKL1. Trying 
to identify a more precise binding site with a smaller amino acid range, we generated the 
MKL1 Δ301-310 mutant lacking only the amino acids 301-310 and observed the same strong 
decrease in target gene expression, exemplary shown for SM22 and CTGF, in A7 cells 
expressing the MKL1 Δ301-310 mutant in comparison to the MKL1 wt showing a great 
induction of gene expression. While narrowing down the binding site and pointing out that 
FLNa binds MKL1 between the amino acids 301-310, we focused our research on the 
deeper mechanism of FLNa acting on MKL1 activation and target gene expression. 
Performing chromatin immunoprecipitation (ChIP) assays, we observed an intense 
enrichment of CTGF and actin promoters from FLNa immunoprecipitates in A7 cells but not 
in M2 cells lacking FLNa expression demonstrating the direct recruitment of FLNa to the 
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CTGF and actin promoters leading to activation of their transcription. These data seem 
similar to the result obtained for the MYOF promoter in FLNa as well as in MKL1 
immunoprecipitates described above suggesting a general role for FLNa on direct target 
gene activation by binding to the gene’s promoter imaginable as MKL1-FLNa complex. 
Regarding the direct regulation of actin by FLNa via binding to the actin promoter, it inspired 
us to further investigate the role of actin in the context of FLNa expression and target gene 
activation. Overexpression of FLNa wildtype (wt) in M2 cells revealed, not surprisingly, a very 
strong induction in FLNa and also a strong activation in GLIPR1 mRNA expression, whereas 
the overexpression of both FLNa wt and the formin mDiact showed a significant induction of 
GLIPR1 expression compared to the single FLNa wt overexpression. It is recently reported 
that mDiact, the constitutively active variant of mDia1 predominantly located in the nucleus, 
is a member of the formin family accelerating the actin nucleation and the formation of 
filamentous F-actin (Watanabe et al., 1999; Copeland et al., 2007 and Baarlink et al., 2013). 
This perfectly corresponds to the known mechanism of mDiact having a positive effect on 
MKL1/2 by enhancing actin polymerization from G-actin into F-actin consequently promoting 
MKL1/2’s nuclear accumulation and therefore the activation of the MKL1/2 target genes 
(Staus et al., 2007 and Staus et al., 2014). The result that the target genes became more 
activated in the presence of mDiact and the simultaneous overexpression of FLNa proposes 
that the present actin status, such as monomeric G-actin or filamentous F-actin, is 
responsible for target gene expression. Our further observations in A7 cells exhibiting 
increased expression of SRF, SM22, GLIPR1 and CTGF upon mDiact expression are this 
way also in accordance with several published studies showing an effect of mDiact on 
different target genes and SRF activity that requires nuclear actin polymerization (Baarlink et 
al., 2013 and Staus et al., 2014). Kircher and colleagues also showed an effect on target 
genes upon mDiact overexpression only observable in A7 cells but not in M2 cells lacking 
FLNa expression suggesting that the presence of FLNa is required for the actin modulating 
activities (Kircher et al., 2015).  
In this thesis, we could demonstrate that the newly identified MKL1 binding partner FLNa is 
additionally to the MKLs responsible for the novel MKL1/2 dependent target gene expression 
and that all these target genes are also FLNa dependent, shown in different cell lines. The 
requirement of FLNa for the induction of the target genes as well as for the modulating 
effects of actin attributes FLNa a very important role in carcinogenesis. 
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7.3 The target gene myoferlin and its role in hepatocarcinogenesis 
 
7.3.1 Characterization of myoferlin as MKL and SRF dependent target gene 
 
The main aim of this thesis was the characterization of the transmembrane protein myoferlin 
(MYOF) regarding its dependency on the MKLs, its tumorigenic properties and also its 
involvement in hepatocellular carcinoma. Beside the fact that we found several target genes 
depending on MKL1 and MKL2 we had to choose one of them for further investigations and 
had to show if this one is able to transduce the effects of MKL1 and MKL2 on tumor inhibition 
and induction of oncogene-induced senescence (Hampl et al., 2013). Based on the result of 
the Cancer Genome Atlas showing the highest coexpression with MKL1 and MKL2 
compared to the other target genes and the recent study of Turtoi and colleagues 
demonstrating a strong impact of MYOF on breast cancer, we decided to choose MYOF as 
target gene of choice for further improvement (Cerami et al., 2012; Gao et al., 2013 and 
Turtoi et al., 2013).  
Stimulation of HuH7 and MDA-MB 468 cancer cells with FBS, LPA, cytochalasin D and 
jasplakinolide revealed an induction of MYOF protein expression, in which the stimulation 
with CytoD showed only a very modest effect compared to the other reagents on the MYOF 
expression that matches well to the results discussed above under 7.1.3. Jasplakinolide 
enhances like LPA the actin polymerization and therefore binds and stabilizes the 
filamentous F-actin network (Bubb et al., 1994 and Bubb et al., 2000). The results also 
confirm a regulation of MYOF via the RhoA-actin signaling way and thus also an involvement 
of MKL1 and MKL2 acting on this pathway. To further review the direct dependency of MYOF 
on the MKLs we performed reporter gene assays with constitutive active variants of MKL1, 
the MKL1 N100, and SRF, the SRF-VP16 plasmid, and different promoter constructs of 
MYOF. This way, we found out that only the 900 bp promoter but not the 200 bp promoter 
was activated by SRF-VP16 and that the activity of this 900 bp promoter construct was also 
increased by MKL1 N100 expression. To narrow down the binding site of SRF and MKL1 on 
the MYOF promoter, we generated a deletion mutant lacking the basepairs 304-363 in 
whose region one of the MYOF promoter CArG boxes is located. Not surprisingly, the activity 
of the reporter genes and thus the deletion mutant promoter construct (Δ304-363) was not 
enhanced due to MKL1 N100 expression shown by a reporter gene assay. These findings 
illustrate the direct involvement of MKL1 and SRF as transcriptional regulators of MYOF by 
binding its CArG box in the MYOF promoter within the basepairs 304-363. Additionally to the 
results obtained by luciferase assays, we investigated the direct recruitment of MKL1 to the 
MYOF promoter by performing a chromatin immunoprecipitation (ChIP) assay and found a 
strong enrichment of the MYOF promoter due to an MKL1 pulldown. The GAPDH promoter 
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and an upstream site in the MYOF promoter (MYOF 1167) were not enriched by MKL1, while 
the promoter of the known MKL target gene α-smooth muscle actin (α-SMA) was amplified 
(Zhao et al., 2007), whereas the induction of the MYOF promoter was much stronger 
showing the intense occupancy by MKL1. Confirming the mentioned regulation of MYOF 
expression via the RhoA-actin signaling pathway, we also performed this ChIP assay with 
serum-starved cells and cells with LPA stimulation and found, as expected, an inducible 
enrichment of the MYOF promoter upon LPA treatment. Next, we also checked for a direct 
recruitment of FLNa, the novel identified MKL1 interaction partner (Kircher et al., 2015), to 
the MYOF promoter and observed a strong increase in MYOF promoter activity in FLNa 
expressing A7 cells compared to FLNa-deficient M2 cells, where no promoter enrichment 
was detectable. This data argue for a responsibility of MKL1 as well as of its interaction 
partner FLNa for the MYOF expression by a direct recruitment of MKL1 and FLNa to a CArG 
box that is located within the position 304-363 in the MYOF promoter and strengthens the 
requirement of the activating MKL1-FLNa complex for target gene expression in general, as 
also shown for the target gene CTGF described under 7.2.3. 
While bringing to light that MYOF is directly dependent on MKL1 and MKL2 and thus MYOF 
may be the transducer of the effects arised by MKL1/2 and the fact that the induction of 
oncogene-induced senescence is reached by MKL1/2 downregulation as shown by Hampl 
and colleagues (Hampl et al., 2013), we asked for the tumorigenic properties of MYOF and if 
it mediates some characteristic features of cancer cells in order to be able to transduce the 
tumorigenic properties mediated by the MKLs.  
 
 
7.3.2 Tumorigenic characteristics of myoferlin  
 
Because previous studies pointed out oncogenic properties for activated, nuclear MKL1 and 
MKL2 and thus a strong decrease in cell proliferation, cell invasion and cell migration due to 
a depletion of MKL1/2 in tumor cells was shown (Medjkane et al., 2009, Muehlich et al., 2012 
and Hampl et al., 2013), we investigated the role of MYOF regarding its possessing 
tumorigenic features. Here, we found a significant proliferation arrest in HuH6 hepatocellular 
carcinoma cells due to a knockdown of MYOF that is also shown in HuH7 cells in the study 
of Hermanns et al. (2017) and is similar to the result of an MKL1/2 depletion found by Hampl 
and colleagues (Hampl et al., 2013). We also observed strongly decreased invasive 
properties of HuH6 cells depleted of MYOF compared to the invasive control cells. In 
agreement with our data, Eisenberg and colleagues demonstrated also a reduced invasive 
capacity of MDA-MB 231 breast cancer cells upon MYOF ablation and another study of 
7 Discussion	  
	   	  
	  	  
     113 
	  
	   	  
Leung and his group revealed a decreased proliferation rate in MYOF depleted mouse Lewis 
Lung carcinoma (LCC) cells in vitro as well as in LCC tumors in vivo (Eisenberg et al., 2011 
and Leung et al., 2013). The observed involvement of MYOF in regulating cancer cell 
invasion is additionally accompanied by a mesenchymal-epithelial transition (MET) in cells 
lacking MYOF and therefore they were converted from migratory and invasive cells into more 
epithelial like cells as shown by a correlation of the morphological changes as well as lower 
expression levels of mesenchymal EMT markers, such as fibronectin and vimentin 
(Kalluri & Weinberg, 2009 and Li et al., 2012). Because MYOF plays also a role in exocytosis 
of cells, it is not unattended that MYOF depletion alters the expression of matrix 
metalloproteinases (MMPs) being endopeptidases essential for degrading basement 
membrane and extracellular matrix (ECM) components and thus being targets of MYOF 
(Duffy et al., 2000; Cipta & Patel, 2009 and Li et al., 2012). A significant decrease in MMP 
production and secretion in breast cancer cells due to a MYOF knockdown is shown in 
several studies explaining the effects of MYOF on cell invasion because MMPs are known to 
play an important role in modulating the invasive properties of cells (Eisenberg et al., 2011 
and Li et al., 2012). Summing up, MYOF seems to play an important role in promoting the 
proliferative and invasive behavior of cancer cells by inducing EMT and mediating 
endocytosis as well as exocytosis of cells and thus MYOF contributes to the characteristic 
features of cancer cells.  
Because the described features occurring upon a MYOF depletion in cells, like the 
proliferation arrest, may possibly arise due to an induced apoptotic or senescent pathway of 
the cell as tumor evading strategy (Wyllie et al., 1980 and Wynford-Thomas, 1999), we next 
looked for an alteration of the cell’s senescence level due to rendered MYOF expression. 
Therefore, we performed a β-galactosidase staining in MYOF depleted HuH6 cells serving as 
a well established marker for senescent cells in vitro as well as in vivo (Dimri et al., 1995 and 
Debacq-Chainiaux et al., 2009). In accordance to the result of an MKL1/2 knockdown 
depicted by Hampl and colleagues (Hampl et al., 2013), the MYOF lacking cells in our 
approach exhibited a significantly induced cellular senescence compared to the control cells. 
Since MKL1/2 and SRF are still described in the context of inducing senescence when they 
are downregulated in HCC cells, in murine smooth muscle cells (SMCs) and in mice 
muscles, MYOF is for the first time characterised as a modulator of proliferation and cellular 
senescence in HCC cells (Angstenberger et al., 2007; Lahoute et al., 2008 and Hampl et al., 
2013). Indicating the cellular senescence as underlying mechanism for the observed 
proliferation arrest so far, we were next interested in this molecular mechanism of the 
induced senescence response upon MYOF depletion. 
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7.3.3 Induction of oncogene-induced senescence via EGFR phosphorylation due to 
myoferlin depletion  
 
For clarifying the molecular mechanisms and the mechanistic insights underlying the cellular 
senescence induction upon MYOF depletion, we first focused on the effect of MYOF on the 
expression and activation of the epidermal growth factor receptor (EGFR). Since a recent 
study of Turtoi and colleagues demonstrated a significant increase in the activation and 
phosphorylation of the EGFR due to MYOF knockdown in breast cancer cells (Turtoi et al., 
2013), we depleted MYOF as well as MKL1/2 in HuH6 and HuH7 HCC cells and also 
observed a strong phosphorylation of the EGFR at tyrosine 1173 both upon MYOF and 
MKL1/2 ablation. Showing that the induced EGFR phosphorylation due to the MKL1/2 
depletion was strongly reduced upon additional MYOF overexpression, we can assume that 
the phosphorylation and dephosphorylation of the EGFR is a dynamic and reversible process 
depending on the MYOF expression level. Further, we examined the role of the EGFR 
activation also in vivo in the HCC xenograft samples treated with MKL1+2 siRNA and found 
the EGF receptor strongly phosphorylated. In accordance with these data, we observed no 
phosphorylation of the EGFR in the tumor tissue of SRF-VP16iHep mice strongly expressing 
MYOF, but a strongly phosphorylated EGFR in the non-tumorous control tissue arguing for a 
prominent role of MYOF in modulating the phosphorylation state of the EGFR in vitro as well 
as in vivo. In an additional experiment, we checked for the reason of the sustained EGFR 
phosphorylation upon MKL1/2 and MYOF knockdown and performed an 
immunofluorescence staining in HuH7 control and HuH7 MYOF depleted cells transfected 
with GFP-tagged EGFR. In the MYOF lacking cells the EGFR was visible as distinct dots 
compared to a diffuse coloring of the EGFR in the control cells suggesting that MYOF 
depletion causes a degradation arrest and thus an accumulation of the EGFR in the cell, 
similar to the observations in the study of Turtoi and his group (Turtoi et al., 2013). To further 
verify this hypothesis, we also treated HuH7 cells with the proteasome inhibitor MG132 and 
observed the same result of EGFR accumulation as treated with MYOF siRNA, again 
confirming the result obtained by Turtoi and colleagues in breast cancer cells (Turtoi et al., 
2013). Because MG132 is known as a peptide effectively inhibiting the proteolytic activity of 
the 26S proteasome, MYOF seems to be involved in the regulation of the internalization and 
degradation process of the EGF receptor and the regulation of the proteasome activity 
(Lee & Goldberg, 1998). Since the EGFR is localized to the caveolae and the 
phosphorylation of the EGFR results in a dissociation from the caveolae accompanied by a 
reduced binding of the phosphorylated EGFR and caveolin-1, the main structural component 
of caveolae, the EGFR also colocalizes with MYOF in breast cancer cells that in turn is also 
colocalized with caveolin (Smart et al., 1995; Agelaki et al., 2009 and Turtoi et al., 2013). 
These data demonstrate the important interaction of MYOF and caveolin being essential for 
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the organization of caveolae and the endocytosis of the phosphorylated EGFR and that there 
is a relationship between MYOF and the caveolae in the context of endocytosis (Bernatchez 
et al., 2009). It remains to be investigated how MYOF interacts with the caveolae in detail 
and what the role of MYOF in the underlying mechanism of EGFR degradation is. Our 
observations are also confirmed by several other studies demonstrating an impact of MYOF 
on the stabilization of different receptor tyrosine kinases (RTKs), such as vascular 
endothelial growth factor (VEGF) or insulin-like growth factor (IGF) receptors, and the 
modulation of receptor recycling or the degradation rate (Bernatchez et al., 2007; 
Demonbreun et al., 2010 and Eisenberg et al., 2011). 
Following the known signaling cascade of activated EGFR, we next looked for the influence 
of MYOF on the important components of this downstream pathway. Here, we found that, 
beside the MKL1/2 knockdown, MYOF depletion strongly activated oncogenic Ras, shown by 
the increased expression level of GTP-bound Ras. The GTP load of Ras is a dynamic 
process in which MYOF seems to be involved, because the re-expression of MYOF in 
MKL1/2 depleted cells resulted in inactive GDP-bound Ras. In consequence of the activated 
Ras, the extracellular signal-regulated kinase 1/2 (ERK1/2) gets phosphorylated and thus 
activated upon MYOF silencing in HCC cells. Treatment of MYOF depleted cells with a SOS 
SH3 domain inhibitor revealed a strong decrease in the activation and phosphorylation of 
ERK1/2 as well as in the induction of cellular senescence, indicated by β-galactosidase 
staining, to nearly basal levels observed in the cells without MYOF knockdown. Because the 
SOS SH3 domain inhibitor blocks the interaction of the guanine nucleotide exchange factor 
son of sevenless (SOS) and the SH3 domain of the growth factor receptor-bound protein 2 
(GRB2) bound to the phosphorylated EGFR, SOS is now unable to bind the inactive GDP-
bound Ras and thus no exchange of GDP to active GTP can occur resulting in inactive Ras 
and no downstream signaling (Li et al., 1993; Vidal et al., 2003 and McKay & Morrison, 
2007). Because the inhibitor acts on the interface of EGFR phosphorylation, Ras activation 
and senescence induction, whereas SOS itself links the RTKs, such as EGFR, to Ras 
signaling, and the fact that the inhibitor altered the MYOF-silenced-mediated ERK1/2 
phosphorylation and the senescence induction we can assume that MYOF directly acts on 
the Ras/Raf/MEK/ERK pathway.  
The Ras/Raf/MEK/ERK pathway downstream of Ras is described as the most relevant one 
for senescence induction and thus proliferation arrest (Lin et al., 1998 and Zhu et al., 1998). 
In this context, Serrano and colleagues postulated for the first time the existence of the 
premature or so-called oncogene-induced senescence (OIS) arising due to the activation of 
oncogenes in contrast to the so far known replicative senescence characterized by a finite 
number of cell doublings (Serrano et al., 1997). This by activated oncogenes triggered OIS 
response is described to function as a very efficient cellular failsafe and tumor suppression 
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mechanism reducing the transforming potential of sustained Ras signaling (Serrano et al., 
1997; Lin et al., 1998 and Michaloglou et al. 2005). According to several studies showing that 
the OIS induction via the activation of the MAPK cascade is controlled by the two tumor 
suppressors p16Ink4a and p53, we observed an increased expression level of p16Ink4a upon 
MYOF deletion (Serrano et al., 1997 and Lin et al., 1998). In our recent study, we also 
demonstrated a strong phosphorylation and therefore activation of p53 on serine 15 in HuH7 
HCC cells lacking MYOF expression (Hermanns et al., 2017). In contrast, the HuH7 control 
cells, endogenously expressing MYOF, revealed only very low expression levels of p16Ink4a 
and phosphorylated p53, corresponding to the results found in literature showing also a very 
low expression and a high mutation rate of p16Ink4a and p53 due to many genetic or 
epigenetic alterations in many different tumor cell lines arguing for their important role in 
tumor development (Hollstein et al., 1991; Hollstein et al., 1996; Ruas & Peters, 1998 and 
Bennett, 2003). The fact that MYOF depletion increased the p16Ink4a and p53 activity and that 
their expression levels are always raised in senescent cells underscores the impact of MYOF 
on the induction of the OIS response (Alcorta et al., 1996; Hara et al., 1996 and Braig et al., 
2005). On the molecular level, the tumor suppressor protein p53 activates the cyclin 
dependent kinase (CDK) inhibitor p21 and this prevents proliferation and promotes a cell 
cycle arrest in response to cellular stress causing senescence (Waldmann et al., 1995 and 
Brown et al., 1997). The tumor suppressor and CDK inhibitor protein p16Ink4a inhibits the 
CDK4/6 activity and thus provokes a G1 cell cycle arrest consequently preventing the 
phosphorylation of the retinoblastoma (Rb) protein (Alcorta et al., 1996; Hara et al., 1996 and 
Serrano et al., 1997). This way, the Rb protein is maintained in its activated, 
hypophosphorylated state having a negative influence on the G1 to S phase cell cycle 
progression resulting in senescence induction (Peeper et al., 1994; Weinberg et al., 1995 
and Chicas et al., 2010). Given this molecular background, we monitored the effect of MYOF 
silencing on the phosphorylation status of Rb and observed a strong decrease of the 
phosphorylated Rb (pRb) expression in HuH6 as well as in HuH7 cells lacking MYOF. This 
way, MYOF ablation leads to induction of the OIS response due to forcing the Rb protein into 
its hypophosphorylated form that is also indicated by the molecular shift of Rb from the 
phosphorylated form to the hypophosphorylated form in HuH7 MYOF depleted cells seen in 
gelelectrophoresis in our recent study (Hermanns et al., 2017). The existence of the 
hypophosphorylated Rb protein is consistent with the observed G1 arrest of MYOF silenced 
cells and their inhibited G1 to S phase transition in our novel study, that is revealed by FACS 
analysis (Hermanns et al., 2017). For a deeper elucidation of the contribution of MYOF and 
the EGFR on the mechanism of senescence induction, we performed several experiments 
with inhibition of the MYOF-mediated effect on tumor suppressor activation. Additionally to 
the experiments described above, we treated HuH7 MYOF depleted cells again with the SOS 
SH3 domain inhibitor and observed a strong increase of the phosphorylated form of Rb 
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compared to the hypophosphorylated Rb in HuH7 cells without SOS inhibitor treatment. 
Silencing of the EGFR in parallel with MYOF knockdown also revealed a significant decrease 
in p16Ink4a expression as well as a decline in senescence induction induced by a single MYOF 
loss demonstrating once again the importance of MYOF on the OIS response executed by 
the EGFR and the downstream Ras/Raf/MEK/ERK as well as the p16/Rb pathway. 
Contradictory to these findings, silencing of the EGFR with tyrphostin AG1478, a specific 
tyrosine kinase inhibitor of the EGFR, in HuH7 MYOF depleted cells showed no alteration in 
the expression of p16Ink4a and the senescence induction in comparison to the cells lacking 
MYOF, although the EGFR gets dephosphorylated and the total EGFR expression was also 
diminished. AG1478 functions by competitive binding to the ATP pocket of the EGFR 
resulting in inhibiting its activity and by increasing the formation of inactive EGFR dimers 
(Han et al., 1996 and Gan et al., 2007). In several studies AG1478 treatment was able to 
inhibit the growth of tumors overexpressing EGFR in combination with an antibody against 
the EGFR that prevents the ligand binding to the receptor or the AG1478 inhibited the 
proliferation rate and forced a cell cycle arrest in nasopharyngeal carcinoma (NPC) cells 
(Zhu et al., 2001 and Johns et al., 2003). Whereas Gao and colleagues found out that 1 µM 
AG1478 was sufficient to reduce the cadmium-induced phosphorylated ERK1/2 expression 
in human uterine leiomyoma (ht-UtLM) cells, Zhu and his group observed an inhibition of the 
downstream AKT and MAPK pathway in NPC cells only upon treatment with a minimum of 
50 µM AG1478 although the EGFR phosphorylation was almost completely inhibited upon 
addition of only 1 µM AG1478 (Zhu et al., 2001 and Gao et al., 2015). The effect of AG1478 
on the downstream targets of the EGFR and the Ras/Raf/MEK/ERK pathway seems to be 
dose-dependent and also cell type specific, thus explaining that there is no observable 
modification in the p16Ink4a and senescence induction upon treatment of 10 µM AG1478 in 
MYOF depleted cells in our approach. Another suitable explanation for this finding might also 
be the known redundant kinase activation mechanism, for example the activation of IGFR, 
VEGFR or PDGFR, as escaping strategy from EGFR inhibiting reagents (Luo et al., 2014). It 
might also be possible that the developed acquired resistance mechanism of HCC cells 
against antitumor drugs, such as AG1478, is responsible for the inefficient treatment of HuH7 
HCC cells with AG1478 (Bagrodia et al., 2012 and Lackner et al., 2012).  
Finally showing the direct contribution of MYOF knockdown on OIS induction, we analysed 
the expression of two additional OIS markers being beside the increased β-galactosidase 
activity and the activation of the MAPK and p16/Rb pathway a characteristic feature of 
senescent cells. Alterations in the extracellular matrix (ECM) associated factors and the 
change of the secretome of cells are key events during senescence induction and referred to 
as senescence-messaging secretome (SMS) (Cristofalo & Pignolo, 1996 and 
Kuilman & Peeper, 2009). This SMS induction contributes to senescence by upregulation of 
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several secretory factors, including inflammatory cytokines, chemokines, matrix remodeling 
factors or growth factors (Kuilman et al., 2008; Kuilman et al., 2010; Rodier & Campisi, 2011 
and Ohtani & Hara, 2013). Our experiments revealed a significant increase in the expression 
of the SMS factors C-X-C motif chemokine ligand 10 (CXCL10) and tumor necrosis factor 
superfamily member 10	   (TNFSF10) in both HuH6 and HuH7 HCC cells depleted of MYOF. 
These data and the fact that CXCL10 as well as TNFSF10 are secreted by senescent cells 
and that they force cancer cells into a senescence response give evidence to the concept of 
MYOF silenced-mediated and induced OIS (Dabrowska et al., 2011 and Braumuller et al., 
2013).  
Although we focused our research on the effects of the target gene myoferlin, we cannot 
exclude a partial contribution of other MKL1/2 target genes on senescence induction. In this 
context, we also checked for the known MKL target gene mitogen-inducible gene-6	   (Mig6) 
that is reported to be a negative regulator of the EGFR family and the MAPK signaling 
cascade, especially in human hepatocellular carcinoma (Descot et al., 2009 and Reschke et 
al., 2010). Our performed experiments demonstrated also a dependency of Mig6 on MKL1/2, 
but we did not observe an alteration in the proliferative capacity of HuH7 cells either 
transfected with Mig6 siRNA compared to the control cells nor with an overexpression of 
Mig6 in MKL1/2 depleted cells in comparison to the cells with MKL1/2 knockdown. 
Downregulation of Mig6 mediated by RNAi showed also no effect on senescence induction, 
because there was no change in the expression levels of p16Ink4a, CXCL10 and TNFSF10 
observable. These data strongly argue against a potential role of Mig6 in the MKL1/2-
mediated senescence response induction so that Mig6 can be excluded as tumor properties 
transmitting gene despite its function to negatively regulate the EGFR. However, other target 
genes, especially those identified in the MKL1/2 dependent microarray, may have an impact 
on the MAPK signaling pathway and the senescence induction. To figure out these potential 
genes and their involvement in the induction of the OIS response might be an aim for future 
experiments. So far, it has already been reported that the target gene MYH9 does not alter 
the cell cycle phase distribution of cancer cells and does not induce apoptosis, whereas 
MYH9 silencing resulted in decreased invasive and metastatic properties suggesting that 
MYH9 may also be involved in senescence induction due to its invasive behavior observed in 
different cell lines (Medjkane et al., 2009 and Derycke et al., 2011). Like MYH9, SM22 
depleted fibroblasts also exhibit a reduced cell migration and invasion rate (Thompson et al., 
2012) and the target gene TGFß1 is described to play a key role in the epithelial-
mesenchymal transition (EMT), thus it forces cells into invasive and migratory tumor cells 
and it is shown to be involved in the expression of the EGFR and senescence induction in 
melanoma cells (Thiery, 2002; Morita et al., 2007 and Sun et al., 2014). In this context, one 
may assume that TGFß1 expression is also critical for inducing senescence in hepatocellular 
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carcinoma cells and that the described tumorigenic characteristics of HCC cells may be 
mediated by TGFß1 due to the EMT induction. This way, in addition to MYOF silencing 
(Kalluri & Weinberg, 2009 and Li et al., 2012), the downregulation of TGFß1 may be required 
for the MET, the reversion of the EMT, and consequently for HCC regression. Since some 
other target genes, like GLIPR1, exhibit besides its tumor suppressing features in some kind 
of cells also oncogenic properties exemplified by their specific expression in some tumors 
(Murphy et al., 1995 and Chilukamarri et al., 2007), there is a high variety of different MKL1 
and MKL2 target genes possibly involved in executing the MKLs mediated activation of the 
MAPK signaling cascade and the induction of the oncogene-induced senescence response 
that remains to be elucidated. 
After indicating the very important role of MYOF in senescence induction via the EGFR and 
activation of the Ras/Raf/MEK/ERK pathway in vitro, we assumed to verify also ex vivo the 
mechanism MYOF is acting on as illustrated in the model in Fig. 54. Thus, we used liver 
tumor (LT) cells, which were derived from developed HCCs in mice conditionally expressing 
SRF-VP16 (Ohrnberger et al., 2015). Also these LT cells transfected with MYOF siRNA 
showed strongly reduced invasive and proliferative capacities compared to the LT control 
cells and furthermore, the β-galactosidase activity and thus the senescence induction was 
increased in the MYOF depleted cells. These data also suggest an important role for MYOF 
in the mediation of tumorigenic features ex vivo. In additional experiments, we confirmed the 
contribution of MYOF depletion in LT cells on the EGFR as well as on ERK1/2 
phosphorylation and on the hypophosphorylation of Rb, illustrated by western blotting. qRT-
PCR analyses revealed also a strong induction of p16Ink4a expression and of the SMS factor 
TNFSF10 due to MYOF knockdown.  
Taken together, all these results strikingly show for the first time the direct involvement of 
MYOF in the OIS response of HCC cells via phosphorylation of the EGFR and activation of 
the Ras/Raf/MEK/ERK signaling pathway due to silencing of MYOF explaining the reduced 
tumorigenic properties of HCC cells upon MYOF knockdown in vitro as well as ex vivo. This 
way, we identified MYOF as novel MKL1 and MKL2 dependent target gene and 
characterized it as the special gene being responsible and mediating the effects of MKL1/2 
on tumor inhibition via OIS induction. Thus, MKL1, MKL2 or most notably MYOF serve as 
novel promising therapeutic target preventing or abolishing hepatocarcinogenesis. 
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Figure 54: Oncogene-induced senescence response upon MYOF depletion. MYOF depletion leads to 
phosphorylation and therefore activation of the EGFR that in consequence activates Ras by GTP binding resulting 
in ERK1/2 phosphorylation, p16Ink4a activation, hypophosphorylation of Rb and finally in senescence induction. 
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7.4 Hepatocellular carcinoma and possible therapeutic approaches 
	  
The hepatocellular carcinoma (HCC), being the most common type of liver cancer, 
represents with 745 000 registered deaths per year the second cause of cancer related 
deaths in the world (Jemal et al., 2011 and Ferlay et al., 2015). Although the incidence of 
HCC is steadily rising, the underlying mechanisms and the formation of the hepatocellular 
carcinoma are only rarely understood so far and this way, it is a very important research goal 
for the upcoming years to figure out the mechanisms driving the HCC development and to 
give novel insights into the transformation of healthy hepatic cells into malignant hepatic 
tumor cells. 
One already well known and documented signaling pathway involved in HCC formation and 
progression is the Ras/Raf/MEK/ERK pathway (Asati et al., 2016 and Wang et al., 2016). In 
this context it is reported that the aberrant activation of the Ras/Raf/MEK/ERK pathway is 
involved in cell proliferation, differentiation, motility and survival in general and thus in cancer 
growth and especially in HCC development (Yu et al., 2015; Asati et al., 2016 and Wang et 
al., 2016). More precisely, in 58 % of all HCCs MAPK/ERK signaling is activated and their 
corresponding genes are upregulated, demonstrated by MEK as well as ERK that are 
strongly overexpressed in hepatocirrhosis and HCC samples (Ho et al., 1998 and Liu et al., 
2006). Also mutations that activate the small GTPase Ras occur in around 30 % of all 
cancers, whereas H-Ras is activated in around 94 % of HCC cases (Zuo et al., 2012). On a 
cellular level and serving as mechanism, the Ras/Raf/MEK/ERK pathway is activated 
amongst others via receptor tyrosine kinases (RTKs) and thus, 47.1 % of the HCCs are 
positive for the EGFR overexpression being also responsible for the recurrence and 
invasiveness of HCC (Tang et al., 1998). These findings perfectly resemble our results 
described above showing that the Ras/Raf/MEK/ERK pathway as well as its trigger EGFR is 
activated upon myoferlin depletion in HCC cells and thus plays an essential role in the 
development of cancer and especially of liver cancer. Contradictory to the results of the 
activated Ras/Raf/MEK/ERK signaling pathway in advanced HCC tissues, we figured out that 
the activation of Ras and its downstream targets leads to the induction of senescence and 
therefore to a reduced HCC growth. The existence of both opposed approaches may explain 
the bad outcome of a drug therapy directed against the members of the signaling pathway, 
like Ras or ERK1/2, for HCC patients because the senescence induction gets prevented by 
the drug administration and thus a tumor regression is difficult to achieve. With regard to this 
problem the role of the Ras/Raf/MEK/ERK pathway has to be more investigated in detail to 
elucidate the complete underlying mode of action also in the context of a promising cancer 
therapy. Given this high impact of the Ras/Raf/MEK/ERK pathway on hepatocarcinogenesis, 
it seems to be obvious looking for inhibitors of the different kinases and molecules of this 
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pathway. Great importance to such inhibitors is also attached because surgical resections of 
the tumors lead to an increased 5-year survival rate, but the long-term survival remains only 
low and the rate of recurrence and metastasis is still high (Kim et al., 2011 and Baek et al., 
2012). Beside the well characterized therapeutic drug sorafenib, whose characteristics will be 
discussed below, the application of all other inhibitors ended up in preclinical or clinical 
studies without administration to patients with HCC so far. For example, the synthetic S-
prenyl-cysteine analog Salirasib is a potent inhibitor of the active Ras protein by degrading all 
Ras isoforms and this way prevents the activation of the Ras dependent signaling cascades 
(Marom et al., 1995; Haklai et al., 1998 and McMahon et al., 2005). The farnesylthiosalicyclic 
acid	  Salirasib is reported to partially induce apoptosis and to inhibit the proliferation rate of 
HCC cells, and it reduced the tumor growth and prevented the development of hepatic 
tumors in xenograft models confirming its therapeutic potential in vitro and in vivo 
(Schneider-Merck et al., 2009 and Charette et al., 2010). In addition to the mentioned Ras 
inhibitor, the benzimidazole derivate Selumetinib that already entered the clinical trial phase 
inhibited the activation and phosphorylation of ERK1/2 in various cancer cell lines as well as 
in a xenograft model and showed an induction of apoptosis upon treatment (Davies et al., 
2007; Huynh et al., 2007; Huynh et al., 2007a and Quan-Jun et al., 2017). However, 
Selumetinib was not able to reduce the progression time of advanced HCC cases (O’Neil et 
al., 2011). A secondary MEK inhibitor is the preclinical drug UO126 that also inhibits the 
phosphorylation of ERK1/2, but showed only a low bioavailability and solubility excluding this 
reagent as potential drug against HCC (Favata et al., 1998; Wiesenauer et al., 2004 and 
Montagut & Settleman, 2009). The only by the Food and Drug Administration (FDA) in 2007 
approved drug therapy and most successful inhibitor against HCC is the agent Sorafenib 
strongly inhibiting a variety of kinases, especially several subtypes of the kinase Raf (Llovet 
et al., 2008). The importance of the Raf-1 suppression is given by the fact that this kinase is 
overexpressed in 91.2 % of patients with hepatocirrhosis and in 100 % of patients with HCC 
and that Raf-1 becomes activated by the HCV core protein when HCC is activated via 
hepatitis C virus infections (Gollob et al., 2006; Schmitz et al., 2008 and Nakamura et al., 
2011). Sorafenib is reported to inhibit HCC cell proliferation as well as tumor growth and also 
to inhibit angiogenesis due to the altered Ras/RAF/MEK/ERK pathway by Raf-1 inhibition 
(Liu et al., 2006 and Gedaly et al., 2012). The kinase inhibitor has also been proven to 
significantly increase the survival time as well as the time to cancer progression in patients 
with advanced HCC, but the survival time was only around 3 months longer than that of the 
patients treated with placebos (Llovet et al., 2008 and Lee et al., 2015). The use of sorafenib 
against HCC progression is also hampered by adverse side effects, including the occurrence 
of diarrhea, hand-foot skin reactions or weight loss in patients treated with sorafenib (Wilhelm 
et al., 2006). Another important point challenging the treatment with sorafenib are the 
preclinical and also clinical observations showing that the drug has only a limited efficacy to 
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tumor regression due to primary resistance or the development of acquired resistance 
against the kinase inhibitor (Blivet-Van Eggelpoël et al., 2012 and Zhai & Sun 2013). On the 
one hand, one explanation for the poor treatment efficacy of HCC is its genetic heterogeneity 
causing the primary resistance, the fact that some patients are initially resistant to sorafenib 
(O’Connor et al., 2007 and Friemel et al., 2015). Since the exact mechanism is still unknown, 
some predictive biomarkers for this primary resistance are identified so far. These 
biomarkers are for example the existence of JNK and VEGFA (Hagiwara et al., 2012 and 
Llovet, 2014) as well as the EGFR status of the cell because it is reported that a high number 
of HCC patients exhibit a strong overexpression of the EGFR and its downstream ligands 
being able to inhibit the effects of sorafenib treatment (Ito et al., 2001; Blivet-Van Eggelpoël 
et al., 2012 and Ezzoukhry et al., 2012). Additionally, the cellular levels of pERK are also 
shown to be responsible for the inhibition of the antitumor effects of sorafenib because the 
downregulation of phosphorylated ERK seems to be associated with sorafenib resistance in 
HCC patients (Zhang et al., 2009). On the other hand, due to long-term exposure to 
antitumor drugs the so-called acquired resistance against kinase inhibitors can develop and 
negatively affect the sorafenib therapy. This acquired resistance provoking mechanisms 
involve the crosstalk of different signaling pathways, the induction of hypoxia, the epithelial-
mesenchymal transition (EMT), etc. (Bagrodia et al., 2012 and Lackner et al., 2012). So far, it 
is known that an activation of the PI3K/Akt pathway and thus the increased expression of 
phosphorylated Akt and the subsequent phosphorylation of the downstream targets are 
associated with sorafenib resistance (Gedaly et al., 2010 and Chen et al., 2011). Also 
abnormal changes in the JAK/STAT pathway and this way the raised levels of 
phosphorylated STAT3, JAK1 and JAK2 contribute to the acquired resistance mechanism 
(Chen et al., 2012 and Tai et al., 2012). Another important key regulator participating in the 
acquired resistance to sorafenib in HCC is the EMT, one of the most important steps in the 
development of metastasis: the transition of epithelial cells into a mesenchymal phenotype of 
cells (Wang et al., 2010; van Malenstein et al., 2013 and Dazert et al., 2016). The process of 
EMT leads to the loss of cell polarity and the loss of cell-to-cell contacts as well as to an 
enhancement of tumor cell migration and invasion (Kalluri & Neilson, 2003; 
Kalluri & Weinberg, 2009 and Maheswaran & Rushbrook, 2012). These newly generated 
tumor cells then become more motile and insensitive to antitumor drugs (van Malenstein et 
al., 2013). In the context of the EMT process and the emerging evidence that the occurrence 
of EMT and its mediated anticancer drug resistance may restrict the therapeutic efficacy of 
the treatment, it might be relevant to identify and analyse the trigger of EMT (Huang et al., 
2013 and van Malenstein et al., 2013). Regarding this, it is reported that the transcription 
factor serum response factor (SRF) plays a crucial role in tumor progression and also in EMT 
formation of cells (Psichari et al., 2002). In addition, Park and colleagues figured out that 
epithelial HCC cell lines exhibited only a minimal expression of SRF, while the cell lines 
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having undergone EMT show a high expression of SRF and of the mesenchymal marker 
vimentin (Park et al., 2007). In accordance with these data, an increase in the expression of 
mesenchymal markers like vimentin as well as N-cadherin and the simultaneous loss of 
endogenous E-cadherin expression due to SRF expression is reported arguing for an 
important role for SRF in the EMT process in HCCs (Park et al., 2007 and Bae et al., 2013). 
Consequently, the recent study of Bae et al. demonstrates that the induced sorafenib 
resistance caused by EMT is a result of SRF overexpression in the cells (Bae et al., 2013). 
The authors also showed the reduced responsiveness of SRF-expressing, mesenchymal-like 
cells to sorafenib-induced cell death and the fact that the depletion of SRF enhanced the 
apoptotic effect of sorafenib again (Bae et al., 2013). Because the process of EMT elicited by 
SRF is responsible for the development of cell’s resistance to sorafenib in HCC and the 
finding that a modulation of the SRF expression can affect the sensitivity of HCC cells to 
sorafenib, the combinational administration of sorafenib and the reduction of SRF expression 
might be a potential therapeutic approach for a more efficient treatment of HCC. Results from 
our group also revealed a strong effect of MYOF on the cell proliferation and invasion of HCC 
cells comparable to those shown for SRF. Since MYOF is described as a direct SRF/MKL1/2 
target gene it might be possible that the tumorigenic effects are mediated by MYOF and that 
the knockdown of MYOF may also increase the therapeutic potential of sorafenib in HCC 
patients during a combinatorial therapeutic approach. In this regard, there is recent evidence 
that MYOF has an effect on the malignant transformation of epithelial cells because Volakis 
and colleagues found out that the knockdown of MYOF can reverse the EMT and thus leads 
to a mesenchymal-epithelial transition (MET) of breast cancer cell lines (Volakis et al., 2014). 
This way, the decrease of MYOF expression in combination with sorafenib administration to 
HCC patients represents a very promising strategy to overcome the chemoresistance of 
sorafenib and other drugs in therapeutical approaches. 
The described data of the low efficacy of chemo drugs such as sorafenib treatment suggest 
that more effective strategies for conquering the sorafenib resistance of cells and patients 
with advanced HCC are needed. In this regard, there are recently several ongoing clinical 
trials of two categories, whereas the first option is a combinatorial therapy combining 
sorafenib with other anticancer drugs like tegafur/uracil or octreotide (Hsu et al., 2010 and 
Prete et al., 2010). The second option is the use of other drugs as second line therapy in 
consequence of the failure of sorafenib treatment like sunitinib and tivantinib (Worns et al., 
2010 and Santoro et al., 2013). Both variants are in the phase II clinical trial with good effects 
and promising results for the patients and this way let expect a better prognosis for patients 
with advanced HCC. 
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Because of the limited number of therapeutic approaches and the high significance of an 
effective HCC treatment it remains an important research goal to find new drugs for HCC 
therapy that do not underlie a resistance mechanism of the cell and that prevents the 
patients from recurrence of tumor development. Our research and the results of this thesis 
strongly accounts for a very promising role for MYOF in the context of HCC therapy and 
restriction of hepatocarcinogenesis. We could impressingly show that MYOF depletion 
resulted in reduced tumorigenic properties, like proliferation and invasion, and in the 
induction of oncogene-induced senescence of HCC cells in vitro as well as in liver tumor 
cells ex vivo. The particular relevance of MYOF in tumor regression is additionally 
substantiated by a very recent study of Blomme and colleagues indicating a prominent role 
for MYOF also in triple-negative breast cancer (TNBC) exhibiting poor prognosis for the 
patients (Blomme et al., 2017). The authors describe that MYOF depletion in TNBC cells 
reduced the tumor growth and metastatic progression due to a deregulation of the cellular 
metabolism. For the first time they pointed out a link between cancer progression, cancer cell 
metabolism and cellular vesicle traffic depending on the expression level of MYOF (Blomme 
et al., 2017). 
In summary, the novel identified MKL1/2 target gene MYOF serves as very promising target 
for cancer therapy and especially for treatment in HCC patients to reduce the tumor growth 
and to decrease the metastatic potential of mesenchymal like cells and this way, further in 
vivo studies with MYOF depletion as therapeutical approach are required. 
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II  Abbreviation index 
  
aa 
ActD 
APS  
ATP 
 
bp 
amino acids 
actinomycin D 
ammonium persulfate  
adenosine triphosphate 
 
base pairs 
BSA  
 
CaCl2 
bovine serum albumin 
 
calcium chloride 
cDNA 
CDK 
ChIP 
CNN1 
complementary DNA 
cyclin dependent kinase 
chromatin immunoprecipitation 
calponin 1 
CO2  
CTGF 
CXCL10 
CytoD 
 
DEPC 
DLC1 
carbon dioxide 
connective tissue growth factor 
C-X-C motif chemokine 10 
cytochalasin D 
 
diethyl dicarbonate 
deleted in liver cancer 1  
DMEM  
DMF 
DMSO 
Dulbecco’s modified Eagle medium  
N,N-dimethylformamide 
Dimethyl sulfoxide 
DNA  
dNTP 
deoxyribonucleic acid  
deoxynucleoside triphosphate 
DTT  
 
E.coli 
EBS 
ECL 
ECM 
dithiothreitol  
 
Escherichia coli 
Ets binding site 
enhanced chemiluminescence 
extracellular matrix 
EDTA  
EGFR 
EMT 
ethylenediaminetetraacetic acid  
epidermal growth factor receptor 
epithelial-mesenchymal transition  
ERK1/2  extracellular signal-related kinase 1/2 
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FACS fluorescence activated cell sorting  
F-actin  filamentous actin  
FBS 
FDA 
FER1L3 
FHL2 
FLNa 
fetal bovine serum  
Food and Drug Administration 
Fer-1-like protein 3 (synonym for myoferlin) 
four and a half LIM domains 2 
Filamin A 
fw  
 
forward  
 
G-actin  
GAP 
GAPDH 
GDP 
GEF 
GFP 
GLIPR1  
GRB2 
GTP 
globular actin 
GTPase activating protein 
glyceraldehyde 3-phosphate dehydrogenase 
guanosine diphosphate 
guanine nucleotide exchange factor 
green fluorescent protein 
glioma pathogenesis-related protein 1 
growth factor receptor-bound protein 2 
guanosine triphosphate 
 
h  
H2O 
HBS 
HCC 
HCl 
HEPES 
HRP 
 
hour(s) 
water 
HEPES buffered saline 
hepatocellular carcinoma  
hydrochloric acid 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
horseradish peroxidase  
HSP90  
 
IEG 
IGFR 
Itga5 
 
JAK 
JNK 
heat shock protein 90  
 
immediate early genes 
insulin growth factor receptor 
integrin alpha-5 
 
Janus kinase 
c-Jun N-terminal kinase 
 
KCl 
 
potassium chloride 
kDa  kilo Dalton  
KH2PO4  potassium dehydrogen phosphatase 
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LatB 
LiCl 
LLC 
LPA 
LT cells 
LZ 
latrunculin B 
lithium chloride 
Lewis lung carcinoma 
lysophosphatidic acid 
liver tumor cells 
leucine zipper 
 
M  
 
molar  
mA  milliampere  
MADS-Box 
MAL 
MAP 
MAP1B 
MAPK  
MCM1, Agamous, Deficiens, SRF-Box  
megakaryocytic acute leukemia  
mitogen-activated protein 
microtubule-associated protein 1B 
mitogen-activated protein kinase 
MEF 
MEM  
mouse embryonic fibroblast  
minimum essential medium  
MET  
mg  
Mig6 
mesenchymal-epithelial transition 
milligram  
mitogen-inducible gene 6 
min  minute(s)  
MKL1 
MKL2  
megakaryoblastic Leukemia 1  
megakaryoblastic Leukemia 2  
mL  
mM 
MMP 
MRTF-A 
MRTF-B 
MYH9 
MYL9  
MYOF 
milliliter  
millimolar 
matrix metalloproteinase 
myocardin-related transcription factor A  
myocardin-related transcription factor B  
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myosin light chain 9 
myoferlin 
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NPC 
 
OIS 
nasopharyngeal carcinoma 
 
oncogene-induced senescence  
 
PAGE  
 
polyacrylamide gel electrophoresis  
PBS  
PCR 
PDGFR 
pEGFR 
PEI 
pERK 
PFA 
PI 
PIPES 
PMSF 
pRb 
PTEN 
PVDF  
 
Ras 
Rb 
phosphate buffered saline  
polymerase chain reaction 
platelet derived growth factor receptor 
phosphorylated epidermal growth factor receptor 
polyethylenimine 
phosphorylated extracellular signal-related kinase 1/2 
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protease inhibitor 
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rev  reverse  
RNA  
RNAi 
ribonucleic acid  
RNA interference 
rpm  rounds per minute  
RPMI  Roswell Park Memorial Institute  
rRNA 
RT  
RTK 
ribosomal RNA 
room temperature  
receptor tyrosine kinase 
RT-PCR  
 
SA-β-Gal 
SAP 
SD 
real-time polymerase chain reaction  
 
senescence-associated β-galactosidase 
SAF-A/B, Acinus and Pias 
standard deviation 
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sec  
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second(s)  
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siRNA  small interfering ribonucleic acid  
SM22 
SMA 
SMC 
SMS 
SOS 
SRE  
SRF  
STAT 
 
TAD 
smooth muscle protein 22 
smooth muscle actin 
smooth muscle cell 
senescence-messaging secretome 
son of sevenless 
serum response element  
serum response factor  
signal transducers and activators of transcription 
 
transcription activation domain  
TAGLN 
TBS  
smooth muscle protein 22 (synonym for SM22) 
tris-buffered saline  
TBS-T  
TCF 
tris-buffered saline with Tween 20  
ternary complex factor 
TEMED  N,N,N’,N’-tetramethylethylenediamine 
TGFβ1 
TM 
TNBC 
TNFSF10 
Tris  
transforming growth factor β1 
transmembrane  
triple-negative breast cancer 
tumor necrosis factor superfamily member 10	  
tris(hydroxymethyl)aminomethane  
Tween 20  
 
polysorbate 20  
 
VEGFA 
VEGFR 
VGLL3 
VHL 
v/v  
 
wt 
 
X-Gal 
vascular endothelial growth factor A 
vascular endothelial growth factor receptor 
vestigial like 3 
von Hippel-Lindau 
volume to volume  
 
wildtype 
 
5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
 
µg  
 
microgram 
µL  microliter  
µM  micromolar  
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